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Abstract 
Investigations to identify the influence of the inhalation manoeuvre on the ex-vivo dose 
emission and the in-vitro aerodynamic dose emission characteristics of dry powder 
inhalers 
Key words: Ex-vivo, in-vitro, dose emission, aerodynamic characteristics, inhalation, 
inhalation flow, inhalation volume, dry powder inhalers  
Currently available dry powder inhalers (DPIs) for drug delivery to the lungs require 
turbulent energy to generate and disperse aerosol particles in the respirable range ≤5µm 
during inhalation. The patient's inspiratory effort together with the resistance inside the 
device creates this energy. Different inhalers provide varying degrees of resistance to 
inhalation flow and require different inhalation techniques for the generation and delivery of 
drug fine particles in respirable size range to the lungs.  
The aim of this research programme was to identify the influence of inhalation flow, 
inhalation volume and the number of inhalations per dose on the ex-vivo dose emission and 
the in-vitro aerodynamic dose emission characteristics of the salbutamol Accuhaler®, 
Easyhaler®, and Clickhaler® and the terbutaline Turbuhaler® DPIs.  
A high-performance liquid chromatography method for the assay of salbutamol sulphate and 
terbutaline sulphate in aqueous samples was modified and accordingly validated. In-vitro 
dose emission of the four different DPIs was measured using the pharmacopoeia method 
with modifications to simulate varying inhalation flows within patient and between patients. 
The ranges of the total emitted dose (% nominal dose) at the inhalation flow range of 10 - 60 
Lmin
-1
, following one and two inhalations per metered dose for 2L and 4L inhaled volumes 
were as follows: the Accuhaler (52.64- 85.11; 61.88-85.11 and 59.23-85.11; 62.81-85.11); 
the Easyhaler (68.35-91.99; 79.94-91.99 and 73.83-92.51; 80.40-92.51); the Clickhaler 
(46.55-96.49; 51.12-96.49 and 51.18-101.39; 59.71-101.39) as well as the Turbuhaler 
(46.08-88.13; 51.95-88.13 and 48.05-89.22; 48.64-89.22). The results highlight that the four 
inhalers have flow-dependent dose emission property to a varying degree using 2L and 4 L 
inhaled volumes. There was no significant difference in the total emitted dose between a 2L 
inhaled volume and a 4L inhaled volume at each inhalation flow. Furthermore, the total 
emitted dose from the Easyhaler®, Clickhaler®, and Turbuhaler® was significantly 
(p≤0.001) greater with two inhalations than one inhalation per metered dose across the range 
of inhalation flow (10 – 60) Lmin
-1
. This effect was only observed at inhalation flow less 
than 30 Lmin
-1
 with the Accuhaler®. Overall there is a significant difference in the total 
emitted dose.  
The ex-vivo dose emission of the four different DPIs has been determined using the In-
Check Dial device to train twelve non-smoking healthy adult volunteers to inhale at slow 
(30 Lmin
-1
) and fast (60 L min
-1
) inhalation flows through the device with its dial set 
corresponding to each inhaler. Subsequently each volunteer inhaled at the trained inhalation 
flows through each active inhaler. The local ethics committee approval was obtained prior to 
the study and all volunteers gave signed informed consent. The results obtained demonstrate 
that the studied inhalers have flow-dependent dose emission, thereby enhancing confidence 
in the use of the In-Check Dial® to identify a patient’s inhalation flows through a variety of 
DPIs. Also the total emitted dose determined by ex-vivo methodology was significantly 
(p≤0.05) greater with two inhalations than one inhalation per metered dose.  
The results of the in-vitro aerodynamic dose emission characteristics highlight that the fine 
particle dose (FPD) from the four studied inhalers is flow dependent. Also the minimum 
inhalation flow to generate the (FPD) with the appropriate characteristics for lung deposition 
has been identified to be 20 L min
-1 
for the Accuhaler®, Easyhaler® and Clickhaler®, while 
that for the Turbuhaler® is about 30 L min
-1
. Also the inhalation volume above 2L and the 
number of inhalations for each dose have respectively no significant (p≤0.05) influence on 
the FPD emitted from the four studied inhalers. The results support the present instructions 
to patients using these inhalers to inhale once for each dose as fast as they can. 
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1 General Introduction 
1.1 Introduction 
Asthma and chronic obstructive pulmonary disease (COPD) are common lung diseases that 
can be treated systemically or by local administration of a bronchodilator and / or a 
corticosteroid to the lungs via the inhaled route.  
 The inhaled route of administration is a preferred route for delivering bronchodilators and 
corticosteroids to patients with asthma and chronic obstructive pulmonary diseases 
(COPD). In comparison with oral or parental routes of administration, the inhaled route 
allows delivery of a small but therapeutic dose of drug directly to the airways achieving a 
high local concentration within the lung, whilst at the same time minimising side effects of 
the drug. Central to the success of inhaled treatment has been the availability of aerosol 
delivery systems or inhalers (Chrystyn 2006). 
 Current available inhalation systems are: nebulisers, pressurised metered dose inhalers 
(MDIs) and dry powder inhalers (DPIs). Administration of drugs by nebulisation is an 
effective treatment but only for stationary use and often reserved for patients needing 
urgent bronchodilator therapy (BTS 1997). MDIs are the oldest and most commonly used 
inhalation device worldwide because they are, small, portable, and deliver consistent doses 
up to labelled claim (Boyd 1995). However, side effects due to propellants  (cold “Freon” 
effect that hits the back of  throat) may occur (Fink 2000). The main drawback with the 
MDI is in coordination between the release of the dose and inhalation, necessary for 
correct dose delivery, leading to reduced effectiveness and poor compliance (Crompton 
1982). To overcome the problems with MDIs special add-on devices (spacers) and more 
recently breath-operated MDIs have been introduced (O’Callaghan, et al, 1997). Also the 
problems of coordination and formulation, arising from the recently introduced ozone-
friendly hydrofluoroalkanes propellants, can be overcome using dry powder inhalers which 
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are designed such that a patient’s inspiratory effort generates particles in the respirable 
range. 
Dry powder inhalers (DPIs) rely on the patient’s inhalation flow for drug delivery to the 
lungs. The patient’s inhalation flow interacts with the resistance inside the DPI to generate 
a turbulent energy which de-aggregates the formulation into an emitted dose containing 
particles that have the potential for lung deposition
 
(Chrystyn, 2003). The part of the 
emitted dose from an inhaler device with particles in size range (<5µm) that have the 
potential to deposit in the lungs is known as the fine particle dose. All DPIs have a 
different internal resistance (Chrystyn, 2003b) that decreases the inhalation flow generated 
by a patient.  The turbulent energy inside a DPI is represented by a pressure change ( P∆ ) 
that developed across the device during inhalation. This pressure change is directly related 
to the DPIs` internal resistance to airflow (R) and the inhalation flow (Q) and the 
relationship  is described as: P∆ = QR (Clark and Hollingworth 1993). Each type of DPI 
has its own resistance characteristics which are caused by the internal structure of the 
device and there is considerable variation in resistance between available DPIs (Steckel 
and Muller 1997). Since the turbulent energy is a product of the flow and the inhaler’s 
resistance then for a set energy level (inspiratory effort) the flow required through a low 
resistance DPI will be faster than that of a high resistance DPI. The faster the inhalation 
flow through a DPI then the greater will be the turbulent energy and therefore the better is 
the quality of the emitted dose.  Hence all DPIs have flow-dependent dose emission with 
some DPIs more prone to this than others (Chrystyn, 2003c). There is a minimum 
inhalation flow (hence threshold energy) required at which the de-aggregation is sufficient 
to provide a dose with the potential to produce particles with the required size. DPIs with 
higher resistance such as the Easyhaler, Turbuhaler  and Clickhaler would require a lower 
flow whilst for those with a lower resistance (Accuhaler and Novolizer) would require a 
faster inhalation flow (Assi and Chrystyn 2001). 
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Different inhalers due to formulations and device designs provide varying degrees of 
resistance to inhalation flow and require different inhalation technique, i.e. the way in 
which the patient uses the inhaler. Hence patient information leaflets for DPIs 
recommended that the inhalation manoeuvre should be as deep and hard as possible.  
To ensure effective drug delivery to the lung, the turbulent airstream created in any DPI 
during inhalation must be sufficient to produce an adequate aerosol cloud with respirable 
fine particles. This involves a balance between the design of the DPI, the formulation and 
the patient's generated inhalation flow. A period of breath holding after inhalation 
improves delivery of inhaled medication because it gives time for the process of 
sedimentation.  
Many patients experience problems using their devices correctly. Poor inhalation technique 
can markedly reduce the proportion of the drug that reaches the lungs. Studies suggest that 
28-68% of patients with asthma have problems using their MDI or DPI sufficiently well to 
benefit from the dose (Raul 2006). Overall, the issue of correct use of inhalers is of critical 
importance in maintaining optimal asthma control as patients who misuse their inhalers 
tend to have less stable control of their asthma than those who use their device correctly 
(Giraud and Roache 2002). 
Thus, the therapeutic efficacy of an inhaled dose depends on the characteristics of the 
emitted dose, which are a function of a combination of the formulation and the device 
resistance, intra and inter patient variability and the inhalation technique. 
For DPIs the Pharmacopoeias (USP, 2009;  EP, 2007; BP, 2008) recommended the use of 
inhalation volume of 4L at a constant flow corresponding to a pressure drop of 4 kPa 
across the device to measure both the total emitted dose and the aerodynamic 
characteristics of the emitted dose, whereas in routine practice  patients use varying flows 
and volumes due to a variety of factors such as lung size (age, gender), degree of airway 
obstruction that is present and inspiratory musculature (Stocks 1995). Furthermore, when 
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patients inhale through a DPI, the inhalation volume is less than 4L, for example, it has 
been reported that the asthmatic and COPD patients have an average inhalation volume of 
about 2L (Hawskworth et al. 2000).  
The Andersen Cascade Impactor (ACI) described in the United State Pharmacopoeia (USP, 
2009), European Pharmacopoeia (EP, 2007) and British Pharmacopoeia (2008) has been 
used in this study to measure the in-vitro characteristics of the emitted dose. Traditionally, 
the ACI has been designed to operate at flow of 28.3 Lmin
-1
. Use of different flows will 
alter the cut-off diameter of each stage of the Impactor, whereas patients will inhale at 
different flows. To overcome this problem, modifications to the stages of the ACI together 
with the use of a mixing inlet valve have recently been introduced which  enabled the 
measurement of  the characteristics of the emitted dose from DPIs at a variety of flows 
consistent with the  patient's routine use.  
Previously, Al-Fadhl (2005) used the modified in-vitro method to study the effects of 
inhalation technique on the emitted dose of tiotropium from a Handihaler (a single dose 
capsule) dry powder inhaler (DPI). The study highlighted that dose emission was 
influenced by inhalation flow and volume and that two inhalations were required for each 
dose. Simulated inhalation flows from a vacuum pump were used in the in vitro study 
which cannot be extrapolated to the patients’ inspiratory flows. 
 In this research programme, in addition to the in vitro dose emission measurements, a 
novel but simple ex vivo approach with the aid of the In-Check Dial® to measure the 
effects of inhalation technique on dose emission from a variety of DPIs has been conceived. 
The In-Check Dial is a device designed and tested to accurately identify patients` 
inhalation flows through currently available DPIs (Tarsin, 2000). 
 Using the in vitro and the ex vivo methods, the flow dependent dose emissions of DPIs 
have been determined and whether instructions should direct the patient to use one or two 
inhalations per dose has also been investigated. At present the instructions (manufacturer’s 
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patient information leaflet) for using available multi-dose DPIs state only one inhalation 
per dose and patients should inhale as fast as they can. 
This research programme has focused mainly on four different multi-dose (strips/reservoir 
type) dry powder inhalers (DPIs) namely-the Ventolin® Accuhaler®, the Asmasal 
Clickhaler® and  the Easyhaler® all containing salbutamol sulphate and the Bricanyl 
Turbuhaler® containing terbutaline sulphate. Both salbutamol and terbutaline (relievers) 
are rapid and short acting β2-agonists widely used as the initial drugs of choice for acute 
bronchospasm in the treatment of asthma and chronic obstructive pulmonary disease 
(COPD). The British Thoracic Society (BTS) / Scottish Intercollegiate Guidelines Network 
(SIGN) guidelines recommended short acting β2 agonists as a first line treatment for the 
management of asthma, while the National Institute for Health and Clinical Excellence 
(NICE) guidelines recommended these drugs as a first line option for the management of 
COPD. 
1.2 Hypothesis 
According to the Pharmacopoeias, it is recommended that DPIs should be tested using a 
dose sampling unit and an impactor, using inhalation volume of 4L at a constant flow rate 
corresponding to a pressure drop of 4 kPa across the device. However, in routine practice  
patients use varying flows  and volumes due to a variety of factors such as lung size (age, 
gender), degree of airway obstruction that is present and inspiratory musculature (Stocks 
1995). It is important to assess the effects of different airflow using different inhalation 
flows and volumes on the performance of DPIs consistent with routine use by patients. 
Also studies have shown that some DPIs operate effectively at peak inhalation flows >30 
Lmin
-1
 and that the optimum flows for some  DPIs in terms of the total emitted dose and 
the fine particle dose is >60 Lmin
-1
 (Bisgaard et al. 1998; Nielsen et al. 1998). Other 
studies have shown that some patients, especially those with COPD (Broeders et al. 2003) 
and children with severe asthma (Pedersen et al., 1999) were not able to generate the 
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minimum flows through a DPI that is required to generate an emitted dose with  the 
appropriate characteristics for lung deposition. This means that for these patients, inhaling 
once from a DPI would result in leaving a portion of the dose in the device and if they 
inhale twice, they should be able to generate more aerosolised drug particles in the optimal 
size range to reach the target sites in the lungs irrespective of inhalation flows used.  At 
present there have been no published reports of investigations on the influence of two 
inhalations per metered dose on the dose emission of multi-dose (strips/reservoir type) 
DPIs.  
The research project was designed to investigate, under the conditions that simulate the 
patients’ routine use of DPIs, the ex vivo flow dependent dose emission properties and the 
in-vitro emitted dose characterisation from four different multi-dose DPIs (the 
Ventolin®Accuhaler®, the Asmasal Clickhaler®, the Easyhaler® and Bricanyl 
Turbuhaler®) and whether instructions should direct the patients to use one or two 
inhalations per dose. Hence, variable inhalation flows (10 to 60) Lmin
-1
 and inhalation 
volumes of 2L and 4L respectively, have been used. 
1.3 Aims and objectives 
The aims of this study were to:  
• Assess by in-vitro methods the effects of different inhalation flows and inhalation 
volume on the emitted dose and the aerodynamic characteristics of the emitted dose 
from the Accuhaler®, the Easyhaler®, the Clickhaler® and the Turbuhaler®.  
• Evaluate by in-vitro methods whether there is difference in the emitted dose and the 
aerodynamic characteristics of the emitted dose from the above mentioned inhalers, 
when inhaling once or twice per dose. 
• Measure using ex-vivo methodology, the effects of inhalation flow on the total dose 
emission and whether there is a difference in the emitted dose from the above 
mentioned inhalers, when inhaling once or twice per dose. 
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The objectives were to: 
• Validate a high performance liquid chromatography (HPLC) method for the assay 
of salbutamol sulphate in aqueous samples. 
• Validate a high performance liquid chromatography (HPLC) method for the assay 
of terbutaline sulphate in aqueous samples. 
• Determine the in-vitro emitted dose of salbutamol sulphate from (the 
Ventolin®Accuhaler®, the Asmasal® Clickhaler®, and the Easyhaler®) as well as 
terbutaline sulphate from Bricanyl® Turbuhaler®  following one and two 
inhalations per dose at varying inhalation flows (10 to 60) Lmin
-1
 for inhaled 
volume of 2 and 4L respectively. 
• Determine the in-vitro characteristics of the emitted dose of salbutamol sulphate 
from (Ventolin®Accuhaler®, Asmasal® Clickhaler®, and Easyhaler®) as well as 
terbutaline sulphate from Bricanyl® Turbuhaler®  following one and two 
inhalations per dose at varying inhalation flows (10 to 60) Lmin
-1
 for inhaled 
volume of 2 and 4L respectively. 
• Determine with the aid of the In-Check Dial® the ex-vivo emitted dose of 
salbutamol sulphate from (Ventolin®Accuhaler®, Asmasal® Clickhaler®, as well 
as Easyhaler®) and terbutaline sulphate from Bricanyl® Turbuhaler®  following 
one and two inhalations at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) inhalation flows 
respectively, performed by healthy volunteers. 
1.4 Thesis structure 
The thesis consists of seven chapters: 
Chapter 1 is a general introduction highlighting the principles governing the operation of 
aerosol delivery devices, especially dry powder inhalers and the factors that affect the 
delivery and deposition of aerosolised drug particles to the target site in the lungs. Previous 
studies on the effects of inhalation flows, inhalation volume and two inhalations on dose 
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emission of (a single dose capsule type) have been highlighted. This provides the rational 
for this research work. Also the aims and objectives of the research have been included. 
Chapter 2 provides an overview of the issues related to this research work which includes: 
• Respiratory system-including brief physiology and anatomy.  
• Asthma and chronic obstructive airways pulmonary disease (COPD) and their 
management. This details the use of various type of bronchodilators (ß-agonists 
and anticholinergics) and corticoid steroids used in the prevention and 
management of these diseases. 
• Inhalation therapies: introduction to the importance of inhalation therapies, drug 
delivery system, mechanism of particle deposition, factors influencing deposition 
of particles, use of the In-Check Dial to identify inhalation rates, and the methods 
to determine bioequivalence. 
Chapter 3 details the HPLC method for the assay of salbutamol sulphate and terbutaline 
sulphate in aqueous samples. 
Chapter 4 focuses on the in-vitro dose emission of salbutamol sulphate from the 
Accuhaler®, the Clickhaler® and the Easyhaler® respectively and terbutaline sulphate 
from the Turbuhaler®. 
Chapter 5 describes the determination of the in-vitro aerodynamic particle size distribution 
of salbutamol sulphate from the Accuhaler®, the Clickhaler® and the Easyhaler® and 
terbutaline sulphate from the Turbuhaler® at varying inhalation flows (10 to 60 Lmin
-1
), 
following one and two inhalations for each dose using inhalation volumes of  2L and 4L 
respectively.  
Chapter 6 describes the measurement of the ex-vivo dose emission of the four different 
DPIs with the aid of the In-Check Dial® using healthy volunteers at slow (30 Lmin
-1
) and 
fast (60 Lmin
-1
) inhalation flows following one and two inhalations. 
Chapter 7 provides a general discussion and conclusion. 
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2 Literature review 
2.1 Respiratory system  
 
The efficacy of aerosol therapy depends on the ability of an inhaler to deliver sufficient 
drug of suitable-particles to appropriate sites in the lungs with minimal side effects 
(Pauwels R et al. 1997). This is, in turn, depends on aspects of airway anatomy and 
physiology, which will alter with age and disease status (Martin et al. 1988; Stocks 1995; 
Wohl 1998) and therefore need to be understood in considering both delivery and 
deposition.  
The human respiratory tract is a branching system of air channels with more than 23 
bifurcations from the mouth to the alveoli that looks like an inverted tree with a single 
trunk (Figure 2.1). The most widely used morphologic model for describing the structures 
(Table 2.1) within the lung was initially given by (Weibel 1963; Hickey 1992). The first 
region is the upper respiratory tract, which includes the nose, mouth and pharynx. The 
main function of this region is heating and moistening of air as well as acting as a filter. 
Normal atmospheric air contains around 40 - 60% moisture and usually has a temperature 
of 20 °C. In the mouth, nose and throat the air is heated to 37 °C and moistened to 99% 
relative humidity. The pharynx is the common opening of both the digestive system and 
the respiratory system. It receives air from the nasal cavity and air, food and water from the 
mouth. Inferiorly the pharynx connects the respiratory system at the larynx and the 
digestive system at the oesophagus. The larynx consists of an outer casing of nine 
cartilages that are connected to each other by muscles and two pairs of ligaments. The 
epiglottis prevents food and liquid from entering the larynx and air from leaving the lung. 
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Figure  2.1 Physiology of lungs (adapted from Massachusetts General Hospital Cancer 
Resource Room, Boston, USA). 
The second region is the conduction zone. This region consists of the first 16 generations 
of branching. The airways of the conducting zone are described as rigid tubes that initially 
consist primarily of cartilage in the walls. These airways symmetrically divide or bifurcate 
beginning with the trachea and ending with the terminal bronchioles (Figure 2.1). The third 
region is the transitional zone. This region consists of generations 17 through to 19 of the 
branching (Figure 2.1). The respiratory bronchioles each consist of a few alveoli in which 
limited gas exchange occurs. The fourth region is the respiratory zone. This region consists 
of generations 20 to 23 of the branching, ending in the alveoli. In the highly vascularised 
respiratory zone gas exchange occurs by adding oxygen to, and removing carbon dioxide 
from the blood passing the pulmonary capillary bed. With increasing generation number, 
the number of branches rapidly increases, while the distance between the branches and the 
airway diameter decrease. The summed cross sectional area from the mouth to the alveolar 
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sacs rapidly increases and results in a trumpet shaped lung model, with a total absorptive 
surface area of up to 100 m
2
 (Hickey 1996) 
Table  2.1 Morphorlogic model for describing the respiratory tract   
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2.1.1 Pulmonary volumes, capacity and indices: 
The inhaled air volume depends on the extent (Kresch 1996) of chest enlargement. During 
normal breathing, the inhaled and exhaled volumes (tidal volume) are only a part of the 
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total lung volume. The different parameters describing pulmonary ventilation are shown in 
Figure 2.2. Definitions of the different parameters are given in Table 2.2. 
 
Figure  2.2 Spirometric tracing for lung volumes and capacities (Hickey 1996).  
Determination of lung volumes and capacities can provide important information on the 
pathophysiological status of the lung. The amount of air moving in and out of the lungs 
(characterised by VT, IRV, ERV, VC and IC) can be measured through spirometry. 
Definitions for the abbreviation used and described below in Table 2.2. Estimates for the 
volume of air remaining in the lungs after expiration (RV and FRC) are made by gas 
dilution methods and by body plethysomography. The respiratory system of a normal adult 
processes 10-20 m
3
 of air per day. Furthermore performing a vital capacity manoeuvre 
with as much force as possible provides useful data. These spirometric measurements are 
the Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and the 
Peak Expiratory Flow Rate (PEFR). The gas-exchange area of the lungs is about 120 - 160 
m
2
 and is perfused with over 2000 km of capillaries (Hickey 1996). At rest, about 500 ml 
of tidal air is inhaled and exhaled with each breath (Hinds 1982). During heavy work, tidal 
volume may be three times as much. A resting adult breathes about 12 times per minute 
and this rate will triple during heavy work. 
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 Table  2.2 Definitions of lung volumes and capacities describing pulmonary ventilation 
 
Parameter Definition 
Tidal volume (VT) 
The volume of air inspired or expired 
during a normal breath 
Inspiratory reserve volume (IRV) 
The maximal volume of air that can be 
inspired after a normal tidal inspiration 
Expiratory reserve volume (ERV) 
The maximal volume of air that can be 
expired after a normal tidal expiration 
Residual volume (RV) 
The volume of air remaining in the 
lungs after a maximal expiratory effort 
Inspiratory capacity (IC) 
The maximal volume of air that can be 
inspired after a normal tidal expiration 
(IC = VT + IRV)  
Functional residual capacity 
(FRC) 
The volume of air remaining in the 
lungs after a normal tidal expiration 
(FRC = ERV + RV) 
Vital capacity (VC) 
The maximal volume of air that can be 
expired from the lungs after a maximal 
inspiration (VC = IRV + VT + ERV)  
Total lung capacity (TLC) 
The volume of air in the lungs after a 
maximal inspiratory effort (TLC = IRV 
+ VT + ERV + RV) ml 
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2.1.2 Pulmonary mechanics 
The ventilatory apparatus consists of the lungs and surrounding chest wall. The chest wall 
includes not only the rib cages but also the diaphragm and abdominal wall (Figure 2.3). 
  
 
Figure  2.3 Forces and pressures during inspiration (Illustration from CIB collection of 
Medical Illustrated by F.H Netter, M.D. 1979) 
Movement of air into and out of the lungs is driven by pressure differentials or gradients 
across the lungs. When inspiratory muscles (diaphragm and intercostal muscles) contract to 
expand the thoracic cavity, a force is applied to the lung surface, which causes expansion 
of the lungs. Lung expansion occurs because the lungs are compliant and distensible. By 
expanding, a negative pressure is created within the lungs, specifically in the airways and 
alveoli. This results in airflow in the direction from high to low pressure, which is in the 
direction of the alveoli. Changes in lung pressures relative to atmospheric pressure can be 
summarised as follows. At the start of inspiration, the alveolar pressure equals atmospheric 
pressure. There is no pressure difference and thus, no driving force for airflow. In this 
situation, the relative alveolar pressure is referred to as zero (Figure 2.4). Interpleural 
Interpleural 
pressure 
(increasingly 
subatmospheric) 
Elastic recoil of chest wall 
(interpleural pressure minus 
pressure at surface of chest) 
Elastic recoil of lung 
(alveolar pressure minus 
interpleural pressure) 
Alveolar pressure 
(subatmospheric) 
Force of muscular 
contraction (diaphragm) 
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pressure is about –500 Pa because elastic recoil of the lungs counteracts the forces of the 
chest wall to recoil outwards. Thus, a negative pressure is generated in the interpleural 
space between the lungs and the chest wall. Upon inspiration, a greater negative 
intrapleural pressure is generated as the chest wall moves outward against the elastic recoil 
of the lungs, reaching a maximal value of about –700 to –800 Pa under normal conditions. 
The expansion of the lungs by the greater negative intrapleural pressure causes alveolar 
pressure to decrease (become negative relative to atmospheric pressure) until it reaches a 
maximum value of about –100 Pa under normal conditions, providing the pressure gradient 
for air to flow into the airways and alveoli (depicted as negative flow in Figure 2.4). 
 
 
Figure  2.4 Ventilatory parameters during tidal breathing (single breath) (Hickey 1996). 
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The rate of airflow does not depend on the pressure gradient alone but also on the internal 
resistance to airflow of the airway system, which is mainly a function of the airway 
diameters and the existence of obstruction. The obstructions reduce the airway diameters 
locally, thereby increasing the resistance to airflow. 
Patients suffering from obstructive diseases have to generate higher pressure differences to 
create the same airflow rate, compared to patients without lung obstructions. Consequently, 
alveolar pressures have to be much lower. During inhalation, the airflow gradually 
decreases as the alveoli are filled with air and the relative alveolar pressure returns to zero. 
The difference between intrapleural pressure and alveolar pressure is the transpulmonary 
pressure, which provides a measure of the elastic lung recoil at each point of lung 
expansion. When inspiration is complete and the lungs are inflated, respiratory muscles 
relax and the elastic recoil properties of the lung cause it to return to its original state prior 
to inflation, thereby expelling the inspired air. Intrapleural pressure returns to –500 Pa and 
alveolar pressure increases to about +100 Pa, thereby creating the pressure gradient to 
allow air to flow out of the lungs to the external environment (depicted as positive flow in 
Figure 2.4). Throughout this cycle of normal inspiration and expiration, airways remain 
open in order to allow air to flow in and out of the lungs with relative ease.  
2.1.3 Inspiratory muscle strength 
The maximal inspiratory mouth pressure is a measure for the inspiratory muscle strength. 
In this measurement, maximal inspiratory manoeuvres from residual volume (RV) are 
performed against a closed shutter. An oval flanged mouthpiece with a small leak is used 
to prevent the use of the buccinator muscles (Black and Hyatt 1969; Koulouris et al. 1988; 
Mayos et al. 1991). Conventionally, inspiratory muscle strength has been assessed by 
maximal inspiratory mouth pressure sustained for one second (PImax or MIP) during a 
maximal static manoeuvre against a closed shutter (Black and Hyatt 1969; Leech et al. 
1983; Wilson et al. 1984; Newell et al. 1989; Bruschi et al. 1992; Nava et al. 1993). 
 19
However, PImax is poorly reproducible (Fiz et al. 1989; Wen et al. 1997). The peak 
maximal inspiratory pressure (P-MIP) during a maximal static manoeuvre is a more valid 
assessment of inspiratory muscle strength. This measurement is considered to be less 
influenced by the learning effect and has a high reproducibility (Larson et al. 1993; 
Wijkstra et al. 1995). Figure 2.5 shows a typical pressure recording during fast maximal 
inhalation obtained from a maximal inspiratory pressure measurement. The peak value is 
referred to as the peak maximal inspiratory pressure (P-MIP) or P-PImax (Larson et al. 1993; 
Wijkstra et al. 1995). The plateau value, which has to be maintained for at least one second, 
is referred to as the maximal inspiratory pressure (MIP). As shown in Figure 2.5 the flow 
profile in the mouth follows the alveolar pressure profile during ventilation without time 
delay. The commonly used inhalation-instruction for dry powder inhalers is to inhale 
forcefully and deeply. Because the airflow through breath controlled dry powder inhalers 
depends on the patient-generated inspiratory pressure, the P-MIP might be a useful 
measure for the peak inspiratory flow through a dry powder inhaler. 
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Figure  2.5 Diagram with definitions of peak maximal inspiratory pressure (P-MIP) and 
maximal inspiratory pressure (MIP). 
1 Second 
MIP 
P-MIP 
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In some studies an indication is given that the inspiratory muscle strength might be a 
determinant for the peak inspiratory flow through breath-controlled DPI's, or a resistance 
to airflow (Rainer et al. 1992; Clark and Bailey 1996; Sarinas et al. 1998). Moreover, the 
respiratory muscles are striated skeletal muscles, which can be trained like other striated 
muscles in order to increase their strength and endurance. This is demonstrated in healthy 
volunteers (Leith and Bradley 1976; O'Kroy and Coast 1993) as well as in patients 
(Dekhuizen et al. 1991; Reid and Dechman 1995; Villafranca et al. 1998) training with 
high force contractions increases maximal force, whereas training with high velocity, low 
force contractions, increases maximal shortening velocity (Reid and Samrai 1995; Tzelepis 
et al. 1999). 
2.2 Asthma 
Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular 
elements play a role, in particular, mast cells, eosinophils, T-lymphocytes, macrophages, 
neutrophils, and epithelial cells. In susceptible individuals, this inflammation causes 
recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly 
at night or early morning. These episodes are associated with widespread and variable 
degrees of airflow obstruction that is often reversible either spontaneously or with 
treatment. The inflammation causes an associated increase in the existing bronchial hyper 
responsiveness (BHR) to a variety of stimuli (NHLBI 1997). 
Asthma has become one of the commonest chronic diseases in the industrialised countries. 
Its prevalence has increased over the past 20 years with a dramatic increase in hospital 
admission rates and general practitioner consultations, for both adults and children (Hill 
and Thomason 1998). Children have the highest prevalence (Akinbami and Schoendorf 
2002). A report indicates that there are 5.2 million people in the UK with asthma, with 1.1 
million of these being children, making it the most common long-term medical condition 
with 1 in 10 children being affected. 70,000 people are admitted to hospital in England 
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with asthma attacks and there is one death every 7 hours from asthma. Asthma is estimated 
to cost the UK over £2.3 billion per year, which includes both the cost to the NHS and lost 
productivity due to absence from work (Asthma UK, 2004). 
2.2.1 Causes of asthma 
Although genetic disposition to atopy (tendency to form immunoglubin IgE antibodies 
against common materials present in environments) is a significant risk factor for 
developing asthma, the underlying causes of the disease are not known. What is known is 
that an individual’s environment appears to be important in determining whether the 
individual becomes asthmatic or not. The environmental risk factors for the development 
of asthma include exposure to maternal smoking during pregnancy and infancy, exposure 
to concentration of allergens (air bone pollen, house-dust-mites, animal dander), viral 
infection during infancy, air pollution, food preservatives and drugs (von Matius 2000) . 
2.2.2 Pathophysiology 
 Airways inflammation, as seen in asthma, is a complex and dynamic process with acute 
and chronic events occurring simultaneously. Inhaled allergen challenge models, as 
demonstrated in extrinsic asthma, contribute to the understanding of acute inflammation in 
asthma (Kay 2001). 
Patients with extrinsic asthma tend to be atopic, that is, they have high level of circulating 
immunoglobulin IgE antibodies against allergens, produced by T-lymphocytes due to 
previous/chronic priming of the immune system (Davies 1998). These immunoglobulin 
bind to the mast cells present in the epithelial layer of the airways. Inhalation of allergens 
further stimulates lymphocytes to produce more IgE. Also the allergen binds to the mast 
cell-bound IgE and induces de-granulation of the cell. De-granulation causes the release of 
histamine and other mediators such as prostaglandins, neutrophils, chemotactic factors and 
leukotriene which cause a sudden bronchoconstriction of the airways (immediate asthma 
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response). The other consequence of the release of these mediators is an action on the 
microvasculature causing oedema and airways narrowing (Kays, 2001). Activation of 
lymphocytes also causes the release of cytokines such as interleukin-5 and granulocyte-
macrophage colony-stimulating factors (GM-CSF) that are involved in inflammatory cell 
recruitment and activation. Some cytokines enhance production of IgE while others such as 
interleukin-5 are involved with recruitment of eosinophil and macrophages from the 
circulation into the airways (Busse and Lemanske 2001). Eosinophil secrets toxic 
substances such as eicosanoids, super oxides and eosinophil cationic protein (ECP) that 
destroy allergens, while causing damage to epithelial and endothelial tissues of the airways. 
The release of mediators from the eosinophil stimulates mucus production from the goblet 
cells and from the deeper ducts in the airways. All these later processes are characterised 
by the late asthmatic responses (LAR). Continued stimulation of the inflammatory process 
by allergens either as symptoms or acute exacerbation leads to an initiation of the chronic 
inflammatory processes where damage to the airway tissues exceeds repair and airways re-
modelling occurs. Also exposure of nerve endings which leads to twitching airways, causes 
further bronchoconstriction (hyperresponsiveness). Extrinsic asthma also known as allergic, 
episodic or early-onset asthma is commonly seen in children. 
Intrinsic asthma, which involves late-onset, is characterised by unknown or poorly defined 
agents, circumstances, or conditions responsible for attacks. Patients are not atopic and the 
condition is usually found in adulthood (Green and Harris 2000). Aspirin and non-steroids 
anti- inflammatory drugs (NSAID) may precipitate potentially fatal asthmatic attacks in 8-
20% of patients with asthma (Sturevany 1999). This syndrome known as aspirin-induced 
asthma can include bronchospasm, rhinorhea, dyspnoea, cough and angiodema. It usually 
develops over a period of 20 minutes to three hours after ingestion of the causative agent. 
Exercise- induced bronchospasm following either drying or cooling of the airways occurs 
in most patients with asthma (Busse and Lemanske 2001). 
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2.2.3  Diagnosis 
A detailed medical history and spirometry,  are usual to establish the presence of episodic 
symptoms of airway obstruction (Davies 1998). Methods used to obtain objective 
measurement of lung function include peak expiratory flow rate (PEFR) and forced 
expiratory volume during the first second of a forced expiratory vital capacity test (FEV1). 
Ideally, people who have not smoked or do not have asthma should be able to blow out at 
least 70-75% or more of their total lung capacity within the first second of a forced 
exhalation (FEV1). Reduction in the FEV1 (less than 80% of the total forced volume) 
indicates an obstructive lung disease (Hughes and Pride 2000). 
Traditionally, the diagnosis of asthma is based on the demonstration of greater than 15% 
improvement in the FEV1 or peak expiratory flow rate (PEFR) following the inhalation of 
a bronchodilator. Measurements of PEFR on waking, in the middle of the day, and before 
bed are also useful in demonstrating the variable airflow obstruction that characterise 
asthma. A drop of 20% in the FEV1 which occurs after the inhalation of a small amount of 
methacholine or histamine indicates the presence of bronchial hyper-reactivity.  
2.2.4 Management of asthma 
The British Thoracic Society (BTS 2007) has recommended a 5-step approach for the 
management of asthma as shown in the Figure 2.6. The stepwise approach to treatment is 
based on the use of inhaled short-acting β2-agonists (SABA) such as salbutamol and 
terbutaline (relievers) as the first line of treatment followed by inhaled corticosteroids 
(preventers). The treatment gradually increases to the addition of a long acting β2-agonist 
(LABA) until the final step where oral corticosteroids are used for more severe cases and 
during exacerbation as a short course. 
Step 1 Relievers such as salbutamol, terbutaline are short acting beta2 agonists (SABA), 
quick-onset drugs which produce rapid relief from the symptoms of asthma. These are 
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inhaled as required. Using two or more canisters of beta2 agonists per month or >10-12 
puffs per day is a marker of poorly controlled asthma (SIGN 2002). If the patient is using a 
SABA on a regular basis anti-inflammatory therapy is recommended. 
 
 
Figure  2.6 Proposed BTS / SIGN stepwise approach for the management of asthma 
(www.brit-thoracic.org.uk). 
Step 2 has been judged on the ability to improve symptoms, improve lung function, and 
prevent exacerbations, with an acceptable safety profile. Inhaled steroids are the most 
effective preventer drugs for asthmatic patients for achieving overall treatment goals 
(Adams et al. 2001; SIGN 2002). Two recent studies have shown benefit from regular use 
of inhaled steroids in patients with mild asthma (O'Byrne et al. 2001; Pauwels 2003). 
Inhaled steroids should be considered for patients with any of the following: 
• Exacerbations of asthma in the last two years 
• Using inhaled beta2 agonists three times a week or more 
• Symptomatic three times a week or more, or waking one night a week. 
STEP 1 
Inhaled short-acting β2-agonist (or other bronchodilator)  
 
STEP 2  
Add inhaled corticosteroid: ≤ 800 µg/day adult ≤ 400 µg/day children 
 
STEP 3  
Add long-acting β2-agonist from 200µg per day  
STEP 4  
Add any or all of the following as determined by 
empirical trial: increase inhaled corticosteroid up  
to ≤ 2000 µg/day, oral β2-agonist, leukotriene 
receptor antagonist, theophylline, cromone 
STEP 5  
Add daily oral steroid or regular 
booster courses of oral steroid 
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Literatures also suggest the use of twice daily dosing is more effective than single dose 
(CHSR 1999; SIGN 2002). 
Step 3 focuses on add on therapy along with steroids. The use of high doses of steroids can 
cause side effects in patients. The BTS (2007) guidelines recommend a trial with add on 
medications before stepping up the dose of steroids.  
The first recommended choice is the use of long acting beta2 agonists (LABA) like 
formoterol or salmeterol to improve lung function and symptoms, and decrease 
exacerbations (Becker and Simons 1989; Kips and Pauwels 2001; SIGN 2002).  
Step 4 advises an increase in the dose of steroids if there is poor control when prescribed a 
moderate dose of inhaled steroid from MDI with spacer. If there is a response to LABA, 
but control remains poor, LABA should be continued and the dose of the inhaled steroid 
should be increased. If the addition of add on still remains inadequate, the use of 
leukotriene receptor antagonists, theophyllines, slow release beta2 agonist tablets are 
recommended in step 4 (Ducharme and Hicks 2002; SIGN 2002). LABA should always be 
used with an inhaled steroid and not alone in the management of asthma. 
There is also a recommendation to add leukotriene receptor antagonists and theophyllines, 
however the side effects are considered to be high. The maximum inhaled steroid dose that 
is recommended is equivalent to beclomethasone 2000 µg / day. 
Step 5 recommends the use of oral steroids using the lowest dose that provides adequate 
control. A high dose of inhaled steroid at 2000 mcg/day is advised. 
The treatment of asthma in children is similar to the treatment in adults with some 
modifications. It is more essential that airway inflammation be minimised or prevented in 
younger patients, because years of persistent inflammation can increase the potential for 
the chronic effect of inflammation, which causes airway re-modelling and the development 
of irreversible chronic obstructive airway disease at an early stage (Gershwin and 
Albertson, 2001). 
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Central to the management of asthma is careful and continual monitoring. Patients should 
receive regular clinic review, be encouraged to participate in the monitoring of their 
condition by means of PEFR recordings and be able to tailor their therapy to their level of 
symptoms. As an important prophylactic measure, patients with asthma should avoid 
triggers such as aero-allergen sources (e.g. pollen, house dust mites). It is recommended in 
the guidelines that compliance and inhalation technique are checked before making 
changes to a patient’s therapeutic management. 
2.3  Chronic obstructive pulmonary disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is a disease state characterised by airflow 
limitation that is not fully reversible. The airflow limitation is usually both progressive and 
associated with an abnormal inflammatory response of the lungs to noxious particles or 
gases. The disease is predominantly caused by smoking [(National Institute for Health and 
Clinical Excellence (NICE) 2004; Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) 2007; NICE 2004)]. The most common conditions comprising COPD are chronic 
bronchitis and emphysema. Chronic bronchitis is defined as a condition with presence of 
cough and sputum production for at least 3 months in each of 2 consecutive years, is not 
necessarily associated with airflow limitation (NICE, 2004b). 
2.3.1  Causes  
Irritants like cigarette smoke, air pollution, or infection can produce a chronic 
inflammation of the bronchi (Jensen et al. 2000). If the irritant persist then the diameter of 
the bronchi decreases and ventilation is impaired causing bronchitis. There is an increase in 
mucus production in some patients that leads to chronic bronchitis. Also emphysema 
results in the destruction of the alveolar walls. Loss of the alveolar walls decreases the 
respiratory membrane surface area, decreasing the gas exchange and loss of elastic fibers 
that decrease the ability of the lung to expel air out. Figure 2.7 reproduces classic data from 
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a study by Fletcher et al (1977) showing the different rates of decline in  the FEV1 with age 
for non-smokers and smokers who either do or do not develop COPD. The horizontal lines 
have been added to show the boundaries of COPD severity recommended by the  global 
initiative on obstructive lung disease (GOLD) (Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) 2007). These investigators also showed that in a susceptible 
minority of tobacco smokers (estimated at 15–20% of the total), lung function declines 
rapidly to levels consistent with moderate (GOLD 2), severe (GOLD 3), and very severe 
(GOLD 4) COPD. Their data also showed that stopping smoking had a beneficial effect on 
stopping the fast rate of decline in the FEV1 at any age.  
 
Figure  2.7 Natural history of chronic obstructive pulmonary disease at varying age 
population [Reproduced from (Fletcher and Peto 1977)]. 
Although this shows rate of loss of FEV1 for one particular susceptible smoker, other 
susceptible smokers will have different rates of loss, thus reaching disability at different 
ages (Fletcher and Peto 1977) as lung inflammation is present in everyone with a tobacco 
smoking habit (Hogg 2004). The reason why only a minority of smokers experience an 
excessive decline in FEV1 is unknown, but preliminary evidence suggests that the lung 
inflammatory response is amplified in the susceptible group (Retamales et al. 2001). Figure 
2.7 highlights why smoking cessation is the first intervention for COPD patients as 
recommended by the NICE guidelines, whereas long-term oxygen therapy is able only to 
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prolong survival in severe COPD patients (Gorecka et al. 1997). Associated risk factors for 
COPD include: 
 Tobacco exposure. 
 Alpha-1 antitrypsin deficiency. 
 Occupational exposure eg cadium, silica or dusty environments. 
 Low social class. 
 Diet deficient in vitamin C. 
 Pre-existing bronchial hyper-responsiveness. 
 Low birth weight. 
 Childhood respiratory infections. 
However, there are some smokers that are not at risk, for reasons that are not fully 
understood. This may be related to an individual’s genetic profile that gives rise to α1 
antitrypsin deficiency with resultant low levels of protease inhibitors in those smokers who 
develop COPD (Figure 2.9). Non-smokers that develop COPD usually have a deficiency of 
alpha-antitrypsin. 
COPD affects 600 million people worldwide and is, at present, the sixth leading 
commonest cause of death worldwide and the fourth leading cause of death in developed 
countries. In the UK nearly 900,000 people are diagnosed as having COPD, and it was the 
fifth common cause of mortality after coronary heart disease, pneumonia, stroke and caner 
(BTS, 2001). A progressive increase in COPD has occurred between 1990 and 1997 with a 
sharp increase in number of hospital admissions due to COPD from 1995 to 1999 as shown 
in Figure 2.8. The trend in the number of hospital admissions due to COPD might not have 
been overcome to date. It is the only common chronic disease that has an annual mortality 
rate that is still increasing. In 1999 there were approximately 30,000 deaths due to COPD 
in the UK. This represented 5.1% of all deaths, with approximately 20 times as many 
deaths compared to asthma. 
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Figure  2.8 Hospital admissions due to chronic obstructive pulmonary disease 1990-99 
(Adapted from Lung and Asthma Information Agency, Fact sheet 2001/4). 
2.3.2 Pathophysiology 
The major players in the inflammatory changes in COPD are: neutrophils, macrophages 
and CD8+ lymphocytes. The actions of these cells and mediators are complimentary, 
leading to widespread destructive changes (NHLBI, 2001). The stimulus for the activation 
of inflammatory cells and mediators is an exposure to noxious particles and gas through 
inhalation. Other processes involved in the pathogenesis of COPD include oxidative stress 
and an imbalance between aggressive and protective defence system in the lung (protease 
and anti proteases). The increased oxidants generated by cigarette smoke react with and 
damage various proteins and lipids, leading to cell and tissue damage. Oxidants also 
exacerbate the protease-anti proteases imbalance by inhibiting antiproteases, that is, α1 
antitrypsin (AAT) (Figure 2.9). 
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Figure  2.9 Disease processes in chronic obstructive pulmonary disease (Barnes 2000) 
2.3.3  Diagnosis and assessment 
A diagnosis of COPD should be considered in any individual presents with symptoms of 
chronic bronchitis, especially cigarette smoking together with confirmation of presence of 
airflow obstruction using spirometry. The hallmark of COPD is a reduction in the ratio of 
forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) to less than 
70%. The degree of spirometry abnormality generally reflects the severity of COPD 
(NHLBI, 2004; GOLD, 2007). Although by definition COPD is an irreversible disease, 
reversibility testing is important in assessing both diagnosis, prognosis of COPD and 
determining treatment choice. Patients with an element of reversibility are those that 
respond to inhaled corticosteroids. 
Classification of COPD by severity is as shown in Table 2.3. 
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Table  2.3 Classification of COPD by severity (Adapted from BTS, 2004)  
Disease 
Severity 
FEV1                  % 
predicted 
Symptoms and signs 
Mild 60 
No abnormal signs 
Smoker's cough 
Little or no breathlessness 
Moderate 40–59 
Breathlessness (± wheeze) on moderate 
exertion. Cough (± sputum). Variable abnormal 
signs (general reduction in breath sounds, 
presence of wheezes) 
Severe <40 
Breathlessness on any exertion/at rest 
Wheeze and cough often prominent 
Lung hyperinflation usually with cyanosis, 
peripheral oedema and polycythaemia in 
advanced disease, especially during acute 
exacerbations 
 
2.3.4 Difference between asthma and COPD  
Although asthma and COPD have similar characteristics such as the signs of coughing and 
wheezing, they are two distinct conditions in terms of disease onset, frequency of 
symptoms and reversibility of airway obstruction.  
1. The onset of asthma typically occurs during childhood or adolescence (British Thoracic 
Society 2007). COPD most often develops in smokers and former smokers who are in their 
mid-50s (Petty 1995; Hogg 2004). 
2. Exacerbations of asthma - characterized by recurrent wheezing, shortness of breath, 
chest tightness and cough - often have identifiable triggers such as allergens, cold air, 
exercise, viral infection or bacterial infection (British Thoracic Society 2007). However, 
exacerbations in COPD patients are commonly caused by respiratory tract infections 
(Pauwels et al. 2001).  
3. With treatment the aim is for asthma patients to have near-normal lung function and be 
symptom-free between exacerbations (British Thoracic Society 2007). COPD patients 
rarely experience a day without symptoms. Airflow obstruction in COPD sufferers is only 
partially reversible (National Institute for Health and Clinical Excellence (NICE) 2004).  
 32
4. In COPD patients there are more neutrophils compared to patients suffering from 
asthma. In asthmatic patients the percentage of eosinophils is more compared to patients 
suffering from COPD. Since glucocorticoids are effective against inflammation caused by 
eosinophils (Altman et al. 1981) then these agents are useful in asthma. Inflammation that 
is mediated by the neutrophils is more resistant to the effect of glucocorticoids agents. 
Smoking cessation decreases the accelerated downward progression of lung function and 
breathlessness whilst bronchodilator use provides symptom relief (British Thoracic Society 
2007).  
The maintenance therapy for most patients with asthma is an inhaled corticosteroid to 
control inflammation, with the addition of a bronchodilator, when required to control 
symptoms (British Thoracic Society 2007). However, the reverse is true for the treatment 
of COPD. Bronchodilators are the first line maintenance treatment for COPD. Treatment 
with inhaled corticosteroids is reserved only for selected patients whose COPD is not 
adequately managed with bronchodilators (British Thoracic Society 2007) that have 
moderate or severe COPD (FEV1 50% predicted) and have frequent exacerbations 
(National Institute for Health and Clinical Excellence (NICE) 2004) A summary of the 
differences between COPD and asthma are shown in Table 2.4. 
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Table  2.4 Differential diagnosis for chronic obstructive pulmonary disease and asthma. 
 
History COPD Asthma 
Smoker or ex-smoker Nearly all Possibly 
Symptoms under age 45 Rare Often 
Chronic productive cough Common Uncommon 
Breathlessness Persistent and progressive Variable 
Night wakening with 
 breathlessness and or wheeze 
Uncommon Common 
Significant diurnal variation or day to day Uncommon Common 
 
2.3.5  Management of stable COPD 
The goals of management of COPD are to: 
• Enable early and accurate diagnosis 
• Control symptoms 
• Prevent deterioration 
• Prevent complications 
• Improve quality of life 
Although by definition COPD is an irreversible disease, reversibility testing is important in 
assessing diagnosis, prognosis of COPD and determining treatment choice. Hence the 
results of reversibility tests are important for future management, they should be clearly 
documented and be easily available for future reference. A summary of National Institute 
for Clinical Excellence (NICE) recommendation gives a broad outline to treat and stabilise 
COPD. A schematic design of the NICE guidelines recommendation for the therapeutic 
management of patients with stable COPD is described in Table 2.5. 
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Table  2.5 Summary of the recommended managements of stable COPD [reproduced from (NICE 2004)] 
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2.3.5.1 Smoking cessation 
All COPD patients should be encouraged to stop smoking as this is the most effective way 
to improve outcomes and prevent further accelerated airway obstruction (Fletcher and Peto 
1977; National Institute for Health and Clinical Excellence (NICE) 2004). 
Table 2.5 Summary of the recommended managements of stable COPD [reproduced from 
(NICE 2004)].  
2.3.5.2 Bronchodilators 
All COPD patients should be given an inhaled bronchodilator to provide relief of 
symptoms (Celli et al. 2004). If they help the patient to perform normal daily activities or 
to improve exercise tolerance, it is worthwhile continuing this treatment (National Institute 
for Health and Clinical Excellence (NICE) 2004). 
Inhaled short-acting β2-agonists (e.g. salbutamol, terbutaline) have a relatively rapid onset 
of action and are often used as required to relieve symptoms (National Institute for Health 
and Clinical Excellence (NICE) 2004). Inhaled antimuscarinics (e.g. ipratropium bromide) 
are as efficacious as short-acting β2-agonists in COPD and may provide a greater and 
longer bronchodilator response. However, due to their slower onset of action, 
antimuscarinics may be less suitable for symptom relief than β2-agonists. 
Clinical trial evidence also recommends the use of long-acting β2-agonists (e.g. salmeterol 
and formoterol) in COPD. Long-acting β2-agonists have a prolonged duration of action 
from 12-14 hours. In addition to their bronchodilator action, long-acting β2-agonists
 
also 
inhibit mast cell mediator release, plasma exudation and
 
may reduce sensory nerve 
activation (Nials et al. 1994). Long-acting antimuscarinic bronchodilators show muscarinic 
M1 and M3
 
receptor subtype selectivity. Tiotropium bromide, the first of a new class of 
selective
 
and long-acting antimuscarinic agents was introduced for once daily
 
maintenance 
treatment of COPD patients. The combination of long-acting β2-agonists and tiotropium 
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bromide exhibited additive effects in terms of daytime lung function improvements and 
sustained improvements during the night compared with the single components, despite the 
once daily dosing (Cazzola et al. 2004; Cazzola et al. 2005; van Noord et al. 2005). The 
NICE / BTS guidelines recommend that the combination of two long-acting 
bronchodilators with different pharmacological mechanisms of action should be considered 
in all patients with moderate to severe chronic obstructive pulmonary disease. The rational 
for using both of the anticholinergics and the β2-agonist is that the anticholinergics will 
inhibit the vagal tone that exists in COPD. This will help the airways to relax so when the 
β2-receptors are stimulated the bronchodilatation should be enhanced. A combination 
treatment of tiotropium and formetrol was more effective than the single agents with 
respect to bronchodilation in COPD patients (Cazzola et al. 2004; Cazzola et al. 2005; van 
Noord et al. 2005). These two studies highlighted the value of using a long acting β2-
agonist together with a long acting anticholinergic agent.  
There is limited evidence showing the benefit of theophylline in COPD. Theophylline may, 
however, cause serious side effects which may occur within the normal dosage range. The 
use of theophylline is therefore not strongly recommended and limited to those in whom 
other treatments have failed to control symptoms. Mucolytic therapies have recently had a 
lot of interest and should be considered in patients with a chronic productive cough. The 
aim of treatment is to reduce the frequency of cough and sputum production. A meta- 
analysis of such agents revealed that when used for more than two months there is a 
reduction in exacerbations by 29% correspond to placebo (Poole and Black 2001). 
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2.3.5.3 Corticosteroids 
The pathogenesis of airway obstruction in
 
COPD is multifactorial, involving neutrophilic 
airway inflammation (Stanescu et al. 1996), protease-antiprotease imbalance (Tetley 1993), 
oxidative
 
stress (Repine et al. 1997), and recurrent infection. These mechanisms are 
interrelated
 
such that reducing one factor may also reduce the stimulus to
 
others.  
An increased number of neutrophils are present in the lungs of cigarette smokers compared 
with that in non-smokers. Cigarette smoke may attract neutrophils to the lung by 
stimulating alveolar macrophages to release a potent chemotactic factor for neutrophils 
(Hunninghake and Crystal 1983). These increased neutrophils are associated with a rapid
 
decline in the FEV1 (Stanescu et al. 1996). Furthermore, neutrophils activation markers
 
are 
elevated in the sputum supernatants of subjects with COPD (Keatings and Barnes 1997), 
suggesting that neutrophils are active participants in
 
airway inflammation. There is still an 
ongoing debate about the benefit of inhaled or oral corticosteroids in patients with stable 
COPD. While corticosteroids have no effect on inflammation caused by neutrophils,  they 
may also influence the cyctokine level (Keatings et al. 1996). 
Inhaled budesonide was found to be of no clinical benefit in COPD patients recruited from 
the general population by screening (Vestbo et al. 1999). Although the ISOLDE study 
(Burge et al. 2000) showed benefits from inhaled fluticasone,  the TORCH (Towards a 
revolution in COPD Health) study (Calverley et al. 2003) did not. Only those COPD 
patients with a positive response to a corticosteroid reversibility test should be considered 
for inhaled steroid therapy without long-acting β2-agonists. It has also been noted that the 
combination of corticosteroid and long-acting β2-agonist in a single inhaler improved lung 
function and decreased severity of dyspnoea in patients with COPD (Cazzola and Dahl 
2004). The TORCH study has also published and consolidated these findings (Calverley et 
al. 2003). A similar study by Szafranski, et al., (2003) has shown the benefit of budesonide 
in combination with formoterol. The NICE guidelines suggest that if a patient is prescribed 
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a long-acting β2-agonist and has a FEV1 <50% with two or more exacerbations per year 
then a high dose of inhaled corticosteroid with a long-acting β2-agonist should be 
considered. Recently, from the results of the TORCH study, the prescription licence for 
Seretide (Fluticasone and Salmeterol) has been changed to allow those with a FEV1 <60% 
to be prescribed this inhaled combination. 
Also the benefit of the combination of a long acting β2-agonist and an inhaled 
corticosteroid in a MDI was demonstrated in a study by Theophilus, et al., (2006). They 
demonstrated that there is a significant co-association of salmeterol and fluticasone 
propionate particles, leading to increased co-deposition when they are administered from 
the same inhaler. This provides a greater opportunity for a synergistic interaction between 
the two drugs to occur in the airways (Barnes et al. 2006) and may possibly be a significant 
factor contributing to the enhanced clinical effect seen in comparison with that observed 
when the drugs are administered separately from two inhalers (Theophilus et al. 2006). 
COPD patients may develop Cor Pulmonale (a secondary heart disease) with pulmonary 
hypertension, right ventricular hypertrophy and right heart failure. Patients with COPD 
frequently suffer acute exacerbations of their symptoms, and may require hospitalization 
(Vestbo et al. 1999). Treatment options include antibacterial agents and oxygen as 
necessary, together with appropriate managements of any associated cardiovascular 
disorder (Vestbo et al. 1999; Martindale 2002; Hogg 2004). 
2.3.5.4  Supplemental long-term oxygen therapy (LTOT) 
Supplemental long-term oxygen therapy (LTOT) improves survival, exercise, sleep and 
cognitive performance in hypoxaemic patients (Eaton et al. 2004; Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) 2007). Arterial blood gas (ABG) assessment is 
the preferred method to determine oxygen need because it includes acid-base information. 
Arterial oxygen saturation as measured by pulse oximetry (SpO2) is used as well in 
determining oxygen need. Physiological indications for oxygen include an arterial oxygen 
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tension (PaO2) <7.3 kPa (55 mmHg). The therapeutic goal is to maintain SpO2>90% 
during rest, sleep and exertion to prevent tissue hypoxia. If CO2 retention occurs, it is 
suggested to monitor for acidemia. If acidemia occurs, mechanical ventilation is essential 
for the survival of the patient. 
2.4 Inhaler devices 
Successful management of asthma and other lung diseases depends on achieving adequate 
delivery of inhaled drug to the lungs and it is generally  acknowledged that the inhaler 
device is a key element in determining the success (Selroos et al. 1996). Ideally, an inhaler 
device should be easy to use and able to deliver a predetermined dose of drug to the lung in 
a reproducible and cost-effective manner. The three types of inhalers are: nebulisers, 
pressurised meter dose inhalers (MDIs) and dry powder inhalers (DPIs). 
2.4.1 Nebulisers 
These are devices that convert a solution or suspension of drug into aerosol droplets 
suitable for inhalation. Although nebulisers can be used in patients who cannot master the 
correct use of a MDI or DPI (Fink 2000), there are most commonly used where the 
therapeutic dose is too large for delivery using the alternative systems (Taylor and 
McCallion 1997). Generally, nebulisers are bulky, costly and more complex. Indications 
for nebulised treatment in asthma have declined, especially in community settings (BTS in 
Thorax 1997). Concentrated solutions are used in nebulisers from which aliquots are 
withdrawn and diluted before administration. Some of these solutions contain preservatives 
and antioxidants which sometimes cause bronchospasm. The physicochemical properties, 
e.g. viscosity and surface tension, of the nebulised solution significantly affect the 
performance of nebulisers (Taylor and McCallion, 1997). Two types of nebulises are 
available: Jet nebulisers and Ultrasonic nebulisers. 
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2.4.1.1 Jet nebulisers 
These utilise compressed gas from an air or oxygen cylinder or electrical compressor to 
convert a drug solution into a spray. The compressed gas passes though a narrow venture 
orifice at a high velocity which causes the liquid from a fluid reservoir to disperse into 
droplets. Smaller droplets leave the nebuliser directly and can be inhaled. 
2.4.1.2 Ultrasonic nebulisers 
These utilise mechanical energy produced by a piezoelectric transducer that usually 
vibrates to generate the spray. 
2.4.2 Metered dose inhalers (MDIs) 
Metered dose inhalers were introduced in the 1950s and remain the most popularly used 
inhaled products (Vaswani. and Creticos 1988). MDIs consist of a canister containing the 
drugs dissolved or suspended in a propellant e.g. chlorofluorocarbons (CFC) and moe 
recently hydrofluoroalkanes (HFA) under pressure. When activated, a valve system 
releases a metered volume of drug and propellant. The propellant provides the force to 
release and de-aggregate particles. The fast release of the particles causes high 
oropharyngeal deposition and produces a cooling sensation at the back of the throat, known 
as cold Freon effect (Fink, 2000) that may stop some patients inhaling immediately after 
actuation thereby depositing the large portion of the dose in the mouth. MDIs require co-
ordination between the start of an inhalation and release of the dose from the device, which 
many patients; especially children and elderly find difficult (G.K.Crompton 1982). The ban 
on the use of chlorofluorocarbons (CFC) propellant in MDIs to protect the ozone layer 
(Montreal Protocol 2000) has led to the development of MDIs containing 
hydrofluoroalkanes (HFAs), non-ozone depleting propellants that replaced CFC-MDIs. 
The change to HFAs propellants has generated formulation issues with changes in the size 
and the velocity of the emitted droplets. 
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2.4.3 Spaces and valved holding chambers 
These are add -on devices, which used properly, reduce oropharyngeal deposition of drug, 
increase the lung deposition, eliminate the cold Freon effect and in case of valved holding 
chamber, reduce drug loss associated with poor patient coordination (Vaswani.S.K. and 
Creticos 1988; Fink 2000; Aswania and Chrystyn 2001; Terzano 2001). However, spacers 
have the disadvantage of being bulky to carry and patient compliance with therapy could 
be decreased (Keller.M. 1999). 
2.4.4 Dry powder inhalers (DPIs) 
Dry powder inhalers basically contain four functional elements: the powder container, the 
metering system, the disintegration principle and a mouthpiece. Based on these functional 
elements, dry powder inhalers can be divided into two major groups, single dose and multi-
dose inhalers (Table 2.6). 
Table  2.6 Dry powder inhalers available in the market 
 
Inhaler device (manufacturer) 
Single dose inhalers 
Spinhaler (Aventis) 
Cyclohaler (Pharmachemie) 
Rotahaler (GlaxoWellcome) 
Aerolizer (Novartis Pharma) 
Inhalator (Boehringer Ingelheim) 
Handihaler (Boehringer Ingelheim) 
Multi-dose inhalers 
Multiple unit-dose inhalers 
Diskhaler (GlaxoWellcome) 
Aerohaler (Boehringer Ingelheim) 
Diskus / Accuhaler (GlaxoWellcome) 
Reservoir systems 
Turbuhaler (AstraZeneca) 
Clickhaler (Innovata Biomed/ML labs celltech) 
Easyhaler (Orion Pharma) 
Pulvinal (Chiesi) 
Novolizer (Viatris) 
  For the marketed dry powder inhalers, only two different types of powder formulations 
are currently used: spherical pellets and adhesive mixture. Spherical pellets are used in the 
Turbuhaler. In this type of formulation, the micronized drug particles are agglomerated 
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into much larger spherical units without a binding agent, behaving as a free flowing 
powder. Some micronized diluents such as lactose or glucose may be added to the active 
component when the dose is low (e.g. Formoterol 6 and 12µg), but the formulation does 
not contain coarser carrier crystals. Spherical pellets have to disintegrate nearly completely 
during inhalation into much smaller agglomerates or even primary particles that have the 
required size-range for deep penetration into the respiratory tract. 
All other DPIs are filled with adhesive mixtures. This type of formulation consists of 
relatively large carrier crystals, mostly α-lactose monohydrate, carrying the micronized 
drug particles distributed over their surface. During inhalation, the drug particles have to 
be released from the carrier crystals to generate the aerosol with particles of the desired 
particle size, which are able to enter the lower respiratory tract.  
The principle of operation for a DPI is to use the patient generated inspiratory flow as an 
energy source for the release of the dose and the delivery of fine drug particles into the 
respiratory tract. The particle size of the adhesive mixtures or the spherical pellets is far too 
large for lung deposition. Therefore, the pellet or mixture has to be disintegrated to make 
an aerosol cloud, which contains a high fraction of non-agglomerated drug particles with 
the desired particle size (<5 µm). Many different disintegration principles exist. They may 
vary from a simple screen (Rotahaler, Diskhaler), to twisted powder channels (Turbuhaler). 
The applied disintegration concept in the design of a dry powder inhaler largely determines 
the resistance to airflow of the inhaler device.  
Inhalers without a recognisable disintegration principle (Figure 2.10) such as Diskhaler and 
Accuhaler, often have a low (medium) resistance to airflow.  
Inhalers with specific disintegration systems like the Turbuhaler use inspiratory flow more 
optimally as the energy source for disintegration and delivery of fine particles into the 
airflow (Figure 2.11). This usually results in an increased resistance to airflow through the 
inhaler.  
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Figure  2.10 Schematic diagram of the disintegration of micronized drug particles from 
carrier crystals through a non-specific disintegration system. 
The peak inspiratory flow achieved by a patient through a powder inhaler depends upon 
the specific resistance to flow of the device and the patient inspiratory capability for a set 
of inspiratory effort. The pressure change that occurs across the mouthpiece on inhaler 
during an inhalation represents the turbulent energy inside the inhaler device that uplifts 
and de-aggregates powder formulation into fine particles with the required size <5µm. This 
turbulent energy is related to inhalation flow and airflow resistance in the device as 
described in section 2.5.2.2 of this thesis. The lower the specific resistance in the DPI the 
higher will be the peak inspiratory flow (Clark and Hollingworth 1993). Therefore, 
resistance to airflow is one of the design parameters for DPIs that could be used to control 
the inspiratory flow profile and optimize particle deposition in the airways (de Koning et al. 
2002). Thus the more resistance there is inside the inhaler then the lower will be the 
inhalation flow for a set inspiratory effort. The high resistance to airflow limits the range of 
possible inhalation flows. However, due to the higher disintegration efficiency, the fine 
particle output is higher compared to the non-specific disintegration systems (Srichana et al. 
1998; Hawksworth et al. 2000; de Koning et al. 2002; Srichana et al. 1998). The 
mouthpiece may be used to control the resistance to airflow of the inhaler and the direction 
Carrier / drug 
powder bed 
Carrier / drug 
aerosol 
Disintegration 
mechanism 
Airflow 
Carrier and drug 
aerosol after 
disintegration 
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of the aerosol cloud in the mouth and throat, in order to reduce drug deposition in the 
oropharyngeal cavities (de Boer et al. 1997). 
 
 
Figure  2.11 Schematic diagram of the disintegration of spherical pellets through a specific 
disintegration mechanism [Reproduced from (Chrystyn 2003)]. 
Some advantages and disadvantages of dry powder inhalers are summarised in Table 2.7. 
Table  2.7 Advantages and disadvantages for dry powder inhalers versus metered dose 
inhalers (Ashurst et al. 2000). 
Advantages of dry powder inhalers 
Disadvantages of dry powder 
inhalers 
• Propellant free 
• Performance depends on the 
patients inspiratory flow profile 
• Less need for patient co-ordination 
• Resistance to airflow of the 
device 
• Less potential for formulation 
problems 
• Potential difficulties to obtain 
dose uniformity 
• Less potential problems with drug 
stability 
• Less protection from 
environmental effects and patient 
abuse 
• Less potential for extractable from 
device components 
• More expensive 
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2.4.4.1  Single unit dose dispensing system 
The early DPIs were all unit dose systems such as the Spinhaler® which was introduced in 
1969 and the Rotahaler® in 1977. As single dose inhalers, both utilize pre-metered doses 
dispensed into hard gelatine capsules with a different mechanism of powder delivery. The 
capsule cap and body must be separated before inhalation (Rotacaps® for Rotahaler®) or 
the capsule has to be pierced at both ends; as for the capsules for the Aerolizer®, the 
Spincaps ®for the Spinhaler®, and the Spiriva® Handihaler.  
Other devices in this category are the Handihaler®, Berotect® (Bohringer) and Forodil 
Aeroliser®. The main disadvantages of these devices are the loading procedure which may 
be difficult to achieve by a patient with an asthma attack and possible requirement to make 
two inhalations for each dose. 
2.4.4.2 Multiple unit dose dispensing system 
The multi-dose inhalers are divided in two different types of design: the reservoir systems 
and the multiple unit-dose inhalers. The reservoir-system of DPI includes the Turbuhaler, 
the Clickhaler®, the Pulvinal®, the Novolizer® and the Easyhaler®. In this type of inhaler, 
the powder formulation is stored in a reservoir from which single doses are measured 
volumetrically and dispensed with a special dose metering unit. Accurate dose metering for 
this type of inhaler requires careful manipulation of the device by the patient. In the 
multiple unit-dose inhalers, single doses are filled by the manufacturer into suitable dose 
compartments, such as blisters. Examples are Diskhaler®, having the blisters on a disk 
(Rotadisk), and  Accuhaler® in UK) with the blisters on a long strip. 
 (a) Diskhaler®  
This device has individual doses contained within a blister on a disk. On priming the 
device, the blister is pieced on both side and the powder is ready to join the inhalation 
stream. 
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(b) Accuhaler® (Diskus®)  
The Accuhaler® (Diskus®) as shown in Figure 2.12 contains sixty factory dispensed doses 
each in a blister and sealed. The formulation is not exposed to the environment. The seal is 
opened immediately before use by sliding back the lever. The mouthpiece opens once the 
blister is unsealed, and the dose is ready to be inhaled. If the dose is not inhaled at this 
point, closure of the device will empty the dose into a collecting chamber within the device 
and stored away from the inhalation channels. Most inhaled drugs for management of 
asthma and chronic obstructive pulmonary disease (COPD) are available in the Accuhaler 
dry powder inhaler. These are the short and long acting ß2-agonists (salbutamol and 
salmeterol), a corticosteroid (fluticasone) and a combination of a long acting ß2-agonist 
and corticosteroid salmeterol and fluticasone (Seretide). The Accuhaler has a dose counter 
that shows the number of doses left in the device after each actuation, which prevents 
inadvertent double dosing. 
 
 
. 
  
 
 
 
 
 
 
 
Figure  2.12 Accuhaler® from (Boulet et al. 1995) 
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2.4.4.3 Multiples doses dispensing system 
(a) Turbuhaler® 
The Turbuhaler is a reservoir multidose dry powder inhaler containing 200 doses.  The 
device has been designed to deliver small quantities of the pure drug as spherical 
pellets/beads, which shatter during inhalation. It consists of the following parts: 
(1) Mouthpiece with insert (2) Bypass air inlet (3) Inhalation channel (4) Air inlet (5) 
Desiccant store (6) Window for dose indicator (7) Dose indicator (8) Storage unit 
for drug compound (9) Dosing unit (10) Operating unit (11) Turning grip.  
A simple twist (back and forth) of the base with the device held upright meters each single 
dose. During inhalation the air enters through the inlets and passes through the unit to 
release the dose that has been loaded in the conical holes within the inhalation channels. 
De-aggregation of the drug particles takes place in this channel due to the air turbulence 
that is created during the inhalation process. The Turbuhaler has a dose indicator, which 
shows red in the window of the dose indicator when there are 20 doses left.  
The device delivers carrier free particles of either the β-agonist terbutaline sulphate or 
salbutamol sulphate (not available in the UK) and corticosteroid budesonide. It is also 
available as Symbicort containing budesonide and formoterol. More recently the Mark3 
version of the Turbuhaler Polmucult (containing the combination of budesonide and 
eformoterol has a dose counter).  The Turbuhaler has been designed to create turbulent 
energy  by using a long flow path with spiral channels to generate shear forces that 
disperse the drug aggregate and produce the required fine particle dose (K.Wetterlin 1998). 
However, due to this long flow path, the resistance within the device is high and the device 
typically delivers only 60% of the metered dose as result of the greater losses within the 
device (Byron 1990). Patients using the Turbuhaler have to use a significantly higher 
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inspiratory effort compared to other DPIs in order to achieve the same inspiratory flow 
inside the device (Celga 2004). 
 
 
Figure  2.13 Turbuhaler (adapted from Watterlin, 1998) 
(b) Easyhaler® 
The Easyhaler® (Figure 2.14) is a multiple dose dispensing system that contains 200 doses. 
It is a high resistance device containing a mixture of a drug and lactose. The mixture is 
stored in a hopper at the bottom of the device; a dosing cup on a rotating drum is filled 
with drug powder. Shaking the inhaler ensures an even dispersion prior to dose metering. 
While the device is upright, and by pressing the top of the device dosing cup deposits the 
drug and carrier into the inhalation channel where turbulent airflow breaks up the mixture 
into fine particle dose, which is then deposited into the patient’s lungs during inhalation. 
Double dosing cannot occur with the Easyhaler because the mechanism and counter allow 
patients to see if they loaded a dose to prevent the use of empty device. Also if a dose is 
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not inhaled and another is metered the unused dose is deposited inside the inhaler away 
from an inhalation airstream. 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.14 Easyhaler-a multidose device containing pre-loaded drug doses within a 
powder reservoir 
(c) Clickhaler® 
The Clickhaler® is a reservoir device that delivers 200 doses. The device is primed by 
clicking the button on the top of it with the inhaler in an upright position (Figure 2.15). 
This causes the metering cone on a rotating wheel to take a single dose from the drug 
hopper and eventually the loaded dose reaches the inhalation passage and the dose is ready 
to be inhaled. The safety of the device include the prevention of inadvertent double dosing, 
a dose counter on the back of the device and a lock-out after 200 doses. 
 
 50
 
  Figure  2.15 Clickhaler (adapted from www.vectura.com/vec/images/clickhaler 
  
2.5 Pulmonary drug delivery 
The success of inhaled therapy depends on the ability to deliver adequate aerosolised drug 
in optimal size range to appropriate sites in the lungs with minimal side-effects.  The 
advantages of inhaled therapy compared with other forms of therapy include ease of 
administration, topical delivery of minute  but effective doses to therapeutic active sites, 
rapid action, avoidance of the gastrointestinal upset from oral therapy and the first pass 
effects in the intestine and liver (Barnes, 2004; Chrystyn, 2006b). The surface area of 
bronchioles and alveoli facilitates the rapid absorption of the inhaled medicament and this 
may additionally be employed as a route for delivery of drugs into the systemic circulation. 
The type of drug formulation and device as well as the intra and inter patient variability 
and inhalation technique are important factors in considering drug delivery and deposition 
to the respiratory system.  
2.5.1  Mechanism of particle deposition in the lungs 
Deposition of aerosolised drug in the respiratory tract is a complex interplay of 
aerodynamic behaviour of aerosol particles and the anatomy and physiology of the lungs. It 
occurs as a result of three principal mechanisms: inertial impaction, gravitational 
sedimentation, and Brownian motion (Lippman et al., 1980). 
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 The first mechanism is inertial impaction which is the dominant deposition mechanism 
for particles in the upper respiratory tract (mouth, pharynx, larynx, and tracheobronchial 
region). A particle with a large momentum (the product of velocity and mass) carried in 
inspired air is unable to follow the changing direction of the inspired air as it passes the 
bending and branching of the upper respiratory tract. This large momentum leads to 
impaction on the airway walls. The probability of impaction is dependent upon the 
momentum, thus a particle with a large diameter or high density travelling in the airstreams 
at higher velocity will show greater impaction. The airflow velocity in the main bronchi is 
estimated to be 100-fold higher than that in the terminal bronchioles, and 1,000 fold higher 
than in the alveolar region (Hillery et al. 2001). Large particles with aerodynamic diameter 
greater than 5µm, will deposit in the mouth and oropharyngeal region and are swallowed 
(Svartengren et al. 1991). 
The second mechanism of deposition is sedimentation. The smaller particles do not 
impact and are carried by the inspired air into the conducting airways. As the pulmonary 
tree branches into smaller diameter conducting airways, particles between 2 and 5µm 
deposit in these airways (tracheobronchial region) by impaction and sedimentation. 
 As the inspired air containing particles moves further down the bronchial tree the velocity 
of air stream becomes slower and slower. Particles between 0.5 and 2µm are suspended in 
slow moving air of lower airways and deposited by gravitational sedimentation. This 
occurs in the bronchioles and the alveolar region where the airflow is low. The fraction of 
particles deposited by this mechanism will be dependent upon the time the particles spend 
in these regions. Holding the breath after an inhalation increases the time the particles 
spend in these regions thus increases deposition by this mechanism (Hyder 1982; Newman 
and Clarke 1983; Hillery et al. 2001). 
The third principle mechanism of deposition is Brownian diffusion. This usually occurs 
for particles with a particle size lower than 1µm, as particles below this size are displaced 
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by random bombardment of gas molecules, which results in particle collision with the 
airway walls. The probability of particle deposition by diffusion increases as the particle 
size deceases and it is also more prevalent in regions where airflow is very low or absent, 
e.g. in the alveoli. Holding the breath after an inhalation increases deposition by this 
mechanism. Figure 2.16 shows a diagram of the above mentioned three mechanisms 
(Hillery et al. 2001). The majority of these very small sized particles do not deposit in the 
lungs (Lippmann et al. 1980). 
 
Figure  2.16 Particle deposition mechanisms at airway branching site. 
2.5.2 Factors affecting deposition of aerosol particles 
2.5.2.1 Aerosol particle characteristics 
The aerodynamic particle size is potentially the most important factor determining the site 
of aerosol deposition. Deposition throughout the conducting airways of the lungs is 
necessary for effective response following inhalation of ß2-agonists and corticosteroids. 
This is achieved by using particles of an aerodynamic diameter between 2 and 5µm 
(Chrystyn, 1999), during an inhalation. Particles greater than 5µm in aerodynamic 
diameter most likely to be deposited in the upper including the mouth, nose and pharynx 
thus eventually swallowed. For particle size 0.5-2 µm in diameter, most of the aerosol is 
deposited in the alveoli by Brownian motion with gravitational sedimentation as previously 
described. Anti inflammatory agents that deposit in this area may exert some therapeutic 
effect.  Studies by  (Cartairs et al. 1989) and (Barnes 1995) have demonstrated that 
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receptors of ß2-agonists are situated from the trachea down to the terminal bronchioles. ß2-
agonists dilate airways by their action on smooth muscles ß2-receptors but there is doubt 
about their effects on alveolar sacs.  A study in which 10 asthmatic patients inhaled 
terbutaline, there was little bronchodilation when the formulation containing drug particles 
of >5 µm diameter were inhaled. Particles above 5 µm in diameter have most likely been 
deposited in the mouth and throat (Rees et al. 1982). Another  study on ten asthmatic 
patients using 20 µg of salbutamol from specially prepared MDI consisting monodispersed 
particles with mass median aerodynamic (MMAD) of 1.2, 2.8 or 5 µm has shown that the 
bronchodilator responses with particles of 2.8 µm was the best. These responses were 
slightly better for the 5 µm particles compared to 1.5µm (Zanen et al. 1996). This implies 
greater peripheral deposition in the alveoli with the smaller particles and because there are 
no smooth muscles in this area, these airways are less liable to dilate. These suggest that, in 
mild asthma, the particle size of choice for a ß2-aerosl should be close to 2.8 µm. It has 
been  suggested particularly for patients with obstructive lung diseases, all particles should 
ideally be within the 2-3µm range (Terzano 2001). 
All currently available DPIs rely on the inspiratory effort of the patient to lift the powder 
formulation from the drug reservoir, the dosing disk, the blister or capsule. The inspiratory 
effort generated by the patient also disaggregates the powder into particles small enough 
with the greatest potential to reach the therapeutic sites in the lungs as previously described 
in Figure 2.11. A more forceful inhalation through a powder inhaler will result in better 
disaggregation, finer particles and a higher amount of drug reaching the lungs which may 
be beneficial in the management of asthma or chronic obstructive pulmonary disease 
(Borgstrom et al., 1994). 
Therefore, it is important that patient have sufficient inspiratory capacity and can use their 
inhaled medication according to the instructions provided by the manufacturer. 
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2.5.2.2 Inhalation technique 
The site of aerosol deposition in the lung is dependent on the patient’s inhalation technique, 
i.e. the way in which the patient uses an inhaler. This entails an interaction between the 
inhaler-formulation and the patients inhalation manoeuvre which include the volume of air 
inhaled, the inhalation flow, the breath holding period after inhalation and the volume of 
the lungs at the initiation of the inhalation that contribute to successful delivery and 
deposition of aerosol to the lungs of patients, and thus enhancing efficacy of inhaled 
therapy (Timsina et al. 1994). Figure 2.17 describes how the relationship between the 
patient and the inhaled product provides effective asthma/COPD management.  
 
Figure  2.17 The relationship between the patient and the inhaled product (adapted from 
Chrystyn not published) 
Generally, for particles that deposit in the airways by sedimentation mechanism (i.e., 
particles > 0.5 and < 3.0 µm), an increase in inhalation volume and the use of breath-hold 
will enhance deposition in the peripheral airways as a result of increasing residence time, 
therefore, subjects using inhaler devices are instructed to take deep breath, in order to 
distribute particles to the periphery of the lungs (Newman and Clarke 1983).  
Although a large volume of inhalation is desirable, a fast inspiratory flow is not for MDIs 
as more deposition occurred in the mouth and throat (Newman et al. 1981.). The lung 
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volume at which an aerosol is actuated is also important. (Newman et al. 1982) found that 
deposition is enhanced if the aerosol is released during the early stages of a slow inhalation. 
This means that for an MDI, a slow and deep inhalation. This study showed that co-
ordination is not important as long as the patient uses a slow inhalation and actuation after 
the start of the inhalation. 
For dry powder inhalers (DPIs), the most important factors affecting the dose delivery are 
the peak inspiratory flow of the patient, acceleration rate, inspiration time, resistant to flow 
of the device, and formulation in the inhaler (de Boer et al. 1996).   Dry powder inhalers 
(DPIs) rely on the patient’s inhalation flow (especially the initial acceleration of the 
inhalation flow within the device) for drug delivery to the lungs. The patient’s inhalation 
flow interacts with the resistance inside the DPI to generate a turbulent energy which de-
aggregates the formulation into an emitted dose containing particles that have the potential 
for lung deposition
 
(Chrystyn, 2003). The part of the emitted dose from an inhaler device 
with particles in size range (<5µm) that have the greatest potential to deposit in the lungs is 
known as fine particle dose. Since the dose leaves its metering cup, inside the DPI, during 
the first few milliseconds of the inhalation manoeuvre then the fast inhalation should occur 
immediately.  Failure to achieve a fast inhalation at the beginning (acceleration rate) results 
in the emission of particles that are too big to be deposited into the lungs and so these are 
only deposited in the mouth (Everard et al. 1997). A DPI should be inhaled with a fast suck 
that is as deep and hard as possible. 
All DPIs have a different internal resistance (Chrystyn, 2003b) that decreases the 
inhalation flow used by a patient.  The turbulent energy inside a DPI is represented by a 
pressure change ( P∆ ) that developed across the device during inhalation. This pressure 
change is directly related to the DPIs` internal resistance to airflow (R) and the inhalation 
flow (Q) and the relationship  is described as: P∆ = QR (Clark and Hollingworth 1993). 
Since the turbulent energy is a product of the flow and the inhaler’s resistance then for a 
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set energy level (inspiratory effort) the flow required through a low resistance DPI will be 
faster than that of a high resistance DPI. The faster the inhalation flow through a DPI then 
the greater will be the turbulent energy and therefore the better is the quality of the emitted 
dose, i.e. aerosol with finer particles.  Hence all DPIs have flow-dependent dose emission 
with some DPIs more prone to this than others (Chrystyn, 2003c). There is a minimum 
threshold energy required at which the de-aggregation is sufficient to provide a dose with 
the potential to produce particles with the required size.  It is generally accepted that this 
minimum threshold energy is equivalent to an initial inhalation flow of 30 Lmin
-1
 through 
a DPI. This minimum threshold comes from Turbuhaler® studies (Bisgaard, et al., 1998; 
Newman, et al., 1991).  Therefore, similar values would apply for DPIs with a similar 
resistance to the Turbuhaler® such as a Clickhaler®.  DPIs with a higher resistance 
(Easyhaler®) would require a lower flow whilst for those with a lower resistance 
(Accuhaler® and Novolizer®) would require a faster inhalation flow (Assi and Chrystyn 
2001). 
Studies have highlighted that some patients have problems achieving a fast rate during 
routine use with a DPI (Chrystyn, 2003;  Pedersen et al. 1986; Pedersen and Steffensen 
1986). These studies have revealed that young children and those with severe obstruction 
are most likely to have problems using a fast inhalation flow.  Since DPIs are very much 
dependent on achievement of a certain inspiratory flow, then there is a risk of reduced 
effects during episodes of acute wheeze or in patients with low pulmonary function 
(Pedersen 1987). Since patients will inhale at a different flow then the design and 
formulation of each inhaler should be such that the most desirable range of inhalation flow 
required is achievable by all patients, of all ages and at all times.   
The literature highlighted a link between inhalation flow, emitted dose (fine particle dose), 
lung deposition, and clinical response. 
(a)   In-vivo flow dependent dose emission.  
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Many studies have used gamma scintigraphy to highlight that lung deposition for some dry 
powder inhaler is related to flow. Radiolabelled budesonide inhaled from a Turbuhaler® 
by 10 healthy volunteers revealed that the mean (SD) total lung dose was 14.8% (3.3) of 
nominal dose when using a slow inhalation flow (36 L min
-1
) and 27.7% (9.5) for a fast 
flow (58 L min
-1
). Hence the inhalation of budesonide at the fast flow resulted in a 
significant increase in lung deposition compared with the slower flow which was matched 
by a decrease in deposition in the oropharynx and mouthpiece (Borgstrom et al. 1994).  
A study has shown that when 10 asthmatic patients inhaled terbutaline from a Turbuhaler® 
at slow (28 L min
-1
) and fast (60 L min
-1
)  rates, significantly more drug was deposited in 
the lung using the fast inhalation flow than with the slow flow. The data showed that the 
inhalation of terbutaline sulphate via the Turbuhaler® at the fast flow resulted in a 
significant increase in lung deposition (p<0.01), which was almost exactly matched by a 
significant decrease in deposition in the oropharynx (p<0.01), and the percentages of the 
dose left in the mouth piece and in the exhaled air were similar for the two inhalations 
(Newman et al. 1991). These studies highlight that the flow dependent effects are due to 
the device and the formulation rather than the drug mirror data reported by in-vitro studies 
(Ross and Schultz, 1996).  
Gamma scintigraphy was used to measure the in-vivo deposition of salbutamol in 10 
healthy volunteers. Measurements were made using a fast (46 L min-1) and a slow (28.3 L 
min
-1
) inhalation (Pitcairn et al, 1994). The data showed that the percentage of the dose 
(SD) deposited in the lungs using the fast inhalation flow was 14.1 I (3.2) %) which was 
significantly greater than the dose deposited when the slower inhaled flow was used (11.7 
(2.3) %). Deposition of labelled salbutamol in the central, intermediate and peripheral 
regions of the lung was higher at the fast flow rate than at the slow flow rate, but the ratio 
between peripheral and central deposition was similar for the fast and slow rates, and the 
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majority of the dose was deposited in the oropharynx (means 80.3 and 78.7% at fast and 
slow flow rate respectively).  
Lung deposition of 20mg sodium cromoglycate powder inhaled via the Spinhaler has been 
measured in 10 healthy volunteers at fast (120 L min
-1
) and slow (60 L min
-1
) inhalation 
flow. Optimum lung deposition was achieved when powder was inhaled at 120 L min-
1
 
(mean 17.1% of the dose) compared to the slow inhalation flow 60 L min
-1
 (mean 5.5%) 
(Newman et al, 1994), similar results were reported by Vidgren et al., (1988) where the 
mean lung deposition of labelled sodium cromoglycate inhaled via the Rotahaler at a slow 
inhalation flow rate (60 L min
-1
) was 6.2%.  
A further study, reported by Pitcairn et al (1997), also showed flow dependent lung 
deposition when radiolabelled nedocromil was inhaled by healthy volunteers using an 
Ultrahaler at a slow (42 L min
-1
) and fast (75 L min
-1
) inspiration flow. The total lung dose 
was higher for the fast rate, a finding which is consistent with the above reports for other 
devices. The mean total lung deposition of nedocromil at the slow and fast flow was 9.8% 
and 13.3% respectively (Pitcairn et al. 1997).  
Studies with the Novolizer® have shown that a comparable or better lung deposition can 
be achieved compared with the Turbuhaler at similar or higher inspiratory flows. Newman 
et al. (2000) evaluated the lung deposition of budesonide (200 µg single radiolabelled dose) 
delivered through the Novolizer® at different targeted flows (45, 60 and 90 L min
-1
) and 
compared this with the lung deposition of budesonide delivered through the Turbuhaler at 
a high flow (60 L min
-1
), using a gamma scintigraphy technique. The study included 13 
healthy volunteers and had a randomized cross-over design. Results showed that the 
median percentage deposition of budesonide in the lungs achieved through the Novolizer 
was 32.1 %, 25% and 19.9 % for measured flows of 99, 65 and 54 L min
-1
 respectively. At 
the lowest flow of 54 L min
-1
, comparable to that for the Turbuhaler 58 L min
-1
, a similar 
percentage of the drug was delivered to the lung. However, at higher flows, the 
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Novolizer® delivered significantly more drug to the lungs and resulted in significantly less 
deposition in the mouth and oropharynx compared to the Turbuhaler. The pattern of 
regional lung deposition in the different regions of the lungs achieved through the 
Novolizer® showed good penetration of the lung periphery independent of the flow rates 
tested as shown in Table 2.8.  
Table  2.8 Mean percentage deposition of budesonide inhaled via the Novolizer® and 
Turbuhale®r at different flows (adapted from Newman et al., 2000) 
  Novolizer® Turbuhaler® 
Targeted flow (Lmin
-1
) 90 60 45 60 
Measured flow (Lmin
-1
) 99 65 54 58 
Mouthpiece % 9.5 15.6 17.3 11.6 
Exhalation filter % 0.8 0.6 0.2 0.2 
Oropharynx % 57 61.6 60.9 71.9 
Lungs % 32.1 25 19.9 21.4 
Central lung% 10.6 7.8 6.3 5.9 
Intermediate lung % 10.9 8.9 6.7 7.3 
Peripheral lung % 8.5 7.8 6.5 4.8 
Peripheral/central ratio 0.9 1 1 0.9 
 Although lung deposition with the Novolizer® increased with inhalation flow the 
penetration index (peripheral: conducting airway ratio) was the same. 
(b)  In-vitro flow dependent dose emission  
Total dose and fine particle dose emission together with the determination of the 
aerodynamic particle size distribution provide useful data to highlight the in-vivo results 
described above. Palander et al. (2000) demonstrated the property of flow dependent dose 
emission from dry powder devices. Figure 2.18 shows that for some dry powder devices 
such as the Accuhaler the effect of the inhalation flow is low whilst it is greater for the 
Turbuhaler.  
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Figure  2.18 Fine particle dose (percentage of label claim) determined for three salbutamol 
containing multidose dry powder inhalers at inhalation flows (30-60 L/min) (adapted from 
Palander et al., 2000). 
The emitted dose from three different DPIs (Spinhaler, Turbuhaler and Diskhaler) at 
different inhalation flows also showed significant sensitivity of dose delivery (Figure 2.19). 
The Diskhaler was the most sensitive to inhalation flow, emitting <30% of the claimed 
label dose at 20 L/min (de Boer et al, 1996). 
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Figure  2.19 Emitted doses of three DPI devices at different inhalation flows (adapted from 
de Boer et al, 1996). 
Furthermore, inhalation volume (which translates inspiration time) is of importance in 
parallel to inspiratory flow, when considering dose emission from a dry powder inhaler.  
 The effect of inspiration time (which translates to inhalation volume) on dose emission 
from the dose systems of Diskhaler® (blister), Turbuhaler® (reservoir) and Spinhaler® 
(hard gelatine capsule) over inhalation flow range (20-60Lmin
-1
) was studied by de Boer, 
et al, (1996). In that study it was found that the effect of inspiration time on the dose 
emission from the Turbuhaler® and the Diskhaler® over the same flow range was 
negligible for all four inspiration times (0.5, 1.5, 3.0 and 6 s) used. On the other hand, the 
effect of inspiration time was evident for the Spinhaler®. After 0.5s of inspiration time, 
only a fraction of the dose was discharged from the capsule compared to the longer time, 
thus the DPI showed dependence on both inspiration flow and inspiration time (inhaled 
volume). De Boer and colleagues attributed the difference in behaviour to different designs 
and the type of powder formulation (de Boer et al., 1996). For the Spinhaler®, dose 
emission depends on the flow properties of the drug formulation and the rotation speed of 
the capsule such that the capsule is emptied. They further reported that inhalation flows < 
 62
50-60 Lmin
-1
 seemed to be insufficient for complete emptying of the capsule, even at 
longer inspiration times of 3-6 s. A study by Hawskworth, et al. (2000) has shown that 
inhalation volume for asthmatic patients when they inhaled through a DPI was about 2L 
(which translates to inspiration time of 2s, if 60 Lmin
-1
 is used).This means that an 
asthmatic patient will require longer time to empty a single-dose capsule and this may be 
achieved using two inhalations per dose. Hence for this type of DPI inhaling twice using 
the same capsule has been recommended in order to allow emptying of the capsule as 
shown in Figure 2.20. 
Time
Patient’s Inhalation Flow 
profile through a DPI
Dose emission from the 
metering cup of DPI 
(reservoir or a blister type)
√P
Dose emission from 
a capsule
In
ha
la
tio
n 
flo
w
Time post start of inhalation
 
Figure  2.20 The relationship between a patients inhalation flow profile through a DPI and 
dose emission from two types of DPI (adapted from Chrystyn,unpublished) 
A study using the electronic lung (ex-vivo) method confirmed that the fine particle dose 
increased with inhalation flows through the Accuhaler and the Turbuhaler devices, hence 
the increase in lung deposition with flow (Tarsin et al. 2006). They also reported that the 
MMAD decrease as the inhalation flow increased (Figure 2.21). The smaller MMAD 
values would counteract the increased potential for more central deposition in the lungs 
with fast inhalation flow. Thus a higher fine particle dose and smaller MMAD explain why 
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the lung deposition for the Novolizer® increased with the flow but the penetration index 
did not change (Newman et al. 2000). 
 
 
 
 
 
 
Figure  2.21 DPI-Fine particle dose and MMAD alter with inhalation flow (adapted from 
Tarsin et al, 2006). 
Tarsin and colleagues also measured the in-vitro dosage emission and the fine particle dose 
(FPD) from 100/6 and 200/6 Symbicort Turbuhaler® (budesonide and eformoterol) at 
different flows (30, 60 and 90 Lmin
-1
). The results are as shown in Figure 2.22. The data 
show that the amounts of budesonide and eformoterol emitted from the Symbicort 100/6®  
and Symbicort 200/6®  inhalers were affected by the increased inhalation flow (Tarsin et 
al. 2004). Also the results demonstrate that the average total dose emissions at 90 L min-1 
were all greater than 100%. Each determination at 90 Lmin
-1
 was carried out after doses 
had been discharged using a flow rate of 60 Lmin
-1
. The data obtained suggest that at 60 
Lmin
-1
 the total dose emission is not 100%. Thus total dose emission of >I00% at 90 L 
min
-1
 suggests that at the higher flow, some residual dose from the previous inhalation may 
also be inhaled. This study also showed that from the Turbuhaler ® there was an intra-
inhaler variability of the dose emitted from the same inhaler and that there was also an 
inter-device variability.   
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Figure  2.22 Mean (% nominal dose) emitted from the Symbicort100/6® and the Symbicort 
200/6 Turbuhalers® for budesonide and eformoterol at different flows (adapted from 
Tarsin et al, 2004)  
Ross and Schultz (1996) compared the emitted dose delivery from a Diskhaler (Ventodisk 
200µg), Rotahaler® (Becotide l00µg), and Turbuhaler® (Pulmicort 200µg) at two 
different flows (30 and 60 Lmin
-1
). Regardless of the flow, the amount of drug delivered 
from the DPI inhalers was variable from device to device. The relative standard deviation 
(RSD) of the delivered dose for the DPI products ranged from 10 to 44%. In addition, the 
dose delivered from these DPI inhalers was generally less than the labelled amount and 
was dependent on the inhalation flow. A number of other studies have also shown that the 
dose emitted from some DPIs is dependent on flow. The variability of these parameters to 
changes in flow varies for different devices. For example, the resistance within the 
Accuhaler® device is low and dose emission is relatively unaffected by flow (Agertoft and 
Pedersen, 1999). The in- vitro total emitted dose from a salbutamol Accuhaler® was 
reported to be consistent throughout the life of the device with very similar results obtained 
at flow of 30- 90 Lmin
-1
 (Malton et al, 1996). In another study,  (Gunawardena et al. 1995) 
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have shown that young patients (three years old) can achieve the desired flow of 30 L min
-1
 
and above when using an Accuhaler®, at which they would received 100% of the labelled 
dose. The Turbuhaler® dose emission has been shown to be more dependent upon flow 
than the Accuhaler®. The Turbuhaler® showed greater variation of dose throughout its life 
(Malton et al, 1995). These researchers found that the fine particle fraction of terbutaline 
from a Turbuhaler was just 8.3% of the label claim at a flow of 28.3 L min
-1
.  However, at 
a flow rate of 60 L min
-1
 this was increased to 25.8% of the label claim. 
In - vitro  (Barrowcliffe et al. 1997) and clinical, (Newhouse et al. 1999) studies using 
Clickhaler® together with lung deposition using gamma scintigraphy (Warren and Taylor 
1998) and urinary pharmacokinetics methods (Chege and Chrystyn 2000) have shown that 
inhalation flow is a minor issue. Asthmatic patients aged 6 or more could produce 
sufficient inspiratory airflow to operate the Clickhaler® and receive the required 
therapeutic outcome (Newhouse et al., 1999 b).  
The results of these studies indicate there is a difference in the emitted dose (fine particle 
dose) from dry powder inhalers with respect to the inhalation flows used. This variation of 
the emitted dose with respect to the inhalation flow differs from device to device. 
 (c)  How patients use inhalers 
Different ways of performing the inhalation manoeuvre affect lung deposition. All 
currently available devices are flow-dependent; MDIs should be used with a flow as low as 
possible (Newman., 1982; Newman et al, 1995) and DPIs will deliver a larger pulmonary 
dose at a high inhalation flow than at a low flow (Newman et al, 1991 ; Pitcairn et al., 1994; 
Borgstrom, 1994). Hence the patient information leaflets for MDIs recommend an 
inhalation that is slow, deep and prolonged, whilst for DPIs the inhalation manoeuvre 
should be fast from the start of the inhalation and sustained for as long as possible.  
To ensure effective drug delivery to the lung, the turbulent airstream created in any DPI 
during inhalation must be sufficient to produce an adequate aerosol cloud with respirable 
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fine particles. This involves a balance between the design of the DPI, the formulation and 
the patient's generated inhalation flow. A period of breath holding after inhalation 
improves delivery of inhaled medication because it gives time for the process of 
sedimentation.  
A meta-analysis of inhaler studies concluded that maximum inhaler scores were achieved 
by 59% of those using a DPls. 43% with the MDI alone and 55% with the MDI when it 
was attached to a holding chamber (Brocklebank et al. 2001). These data support the 
intuitive view that DPls are used correctly more often than MDls alone. However patient 
instruction in correct inhaler use eliminated that difference, increasing the percentage of 
subjects who showed correct technique to 65% for DPls and 63% for MDls (Wright et al. 
2002). Such data provide evidence of the positive effect of teaching patients to achieve 
correct inhaler use. Thus an increase in the lung deposited fraction would have a valuable 
response effect. Lung deposition and, therefore, clinical response to inhaled medication 
depends on the inhalation technique of the patients. The degree of lung deposition 
increases as a patient uses their inhaler correctly. A recent study by (Leach et al. 2005) 
showed that patients received optimal lung deposition with a good technique compared to 
patients with a poor technique.  
Many asthmatic and COPD patients have been found to be unable to use DPls and MDI 
adequately. (Melani et al. 2004) found that similar percentages of patients failed to perform 
essential steps needed for reliable lung deposition of inhaled aerosol from a MDI three 
different (Aerolizer®, Turbuhaler® and Diskhaler®). Figure 2.23 shows the percentages of 
patients of patients who failed to correctly perform steps in inhaler use that are critical for a 
reliable drug delivery to the lungs with three different dry powder inhalers and a metered 
dose inhaler. 
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Figure  2.23 Failure to correctly perform essential steps through different inhalers by 
patients (adapted from Melani et al, 2004). 
A similar study assessed inhalation technique among asthmatic and COPD patients and 
found that 52% of patients exhibited mistakes with the Diskhahler® 73% the Rotahaler® 
and 80% the Ingelheim DPIs (Van Beerendonk et al. 1998). In one study of patients with 
COPD 58% reported no problems using Accuhaler compared with only 11% using the 
Handihaler®; 72% of the patients also reported that they would not be happy to use the 
Handihaler® (Moore and Stone 2004). 
 Studies suggested that 28-68% of patients with asthma have problems using their MDI or 
DPI sufficiently well to benefit from the dose (Raul 2006). Table 2.9 summarises the range 
of problems patients have with the use of these inhalers (Crompton 1982; Rau 2005; 
Rönmark et al. 2005; Rau 2006). 
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Table  2.9 Errors in patients’ use of MDIs and DPIs (adapted from Chrystyn, unpublished) 
 
Error  per cent of 
patients 
MDI DPI 
Failure to co-ordinate actuation and inhalation 27 - 
Inadequate or no breath hold after inhalation 26 23 
Too rapid inspiration / not inhaling forcibly 19 17 
Inadequate shaking / mixing before use 13 - 
Cold Freon effect 6 - 
Actuation at total lung capacity / Not exhaling to residual 
volume before inhaling 
4 24 
Multiple actuations during single inspiration 3 - 
Inhaling through nose during actuation 2 - 
Exhaling during activation / through the mouth piece 1 19 
Putting wrong end of inhaler in mouth <1 - 
Holding device in wrong position / incorrectly <1 35 
Exhaling into the mouth piece after inhalation - 20 
 
In general, a review by Crompton et al, (2000) found that approximately 50% of the 
patients in Europe are unable to use their inhaler devices correctly. 
Also, children generally cannot use DPIs properly. Pedersen (1990) reported that young 
children did not have enough inspiratory effort to use the Turbuhaler®. (de Boeck et al. 
1999) showed that although the vast majority of children older than 8 years could perform 
every step of the inhalation manoeuvre through the Turbuhaler correctly after training, 
only half of the children younger than 8 years were able to do so. Thus, some studies have 
recommended that the Turbuhaler device was not suitable for pre-school children because 
they cannot use the inhaler correctly (Pedersen et al, 1990; Bisgaard et al, 1994). Table 
2.10 shows the critical steps for using various inhalers (Fink and Rubin 2005). 
Ideally GPs and nurses should teach patients how to use their inhalers correctly when they 
are prescribed. Alternatively the pharmacist could play an important role in teaching 
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patients correct inhalation technique when the drug is prescribed for the first time and also 
when the prescription is repeated. A number of methods have been used to teach the 
patients a correct inhalation technique these methods include: patient information leaflets, 
face to face demonstration and multimedia methods such as video demonstrations and 
touch screen computer methods. A recent study showed that the use of multimedia and 
touch screen computer improved the patient's inhalation technique more effectively than 
provision of a patient information leaflet (Savage and Goodyer 2003). This form of 
education was acceptable to patients of all age groups. 
Overall, the issue of correct use of inhalers is of critical importance in maintaining optimal 
asthma control as patients who misuse their inhalers tend to have less stable asthma than 
those who use their device correctly (Giraud and Roache 2002). 
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Table  2.10 Critical steps for using various inhalers (adapted for Finks et al., 2005) 
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2.5.2.3 Characteristics of the patients  
Each patient’s ability to use inhaler devices correctly is pertinent to aerosol therapy. Many 
patients experience problems using their devices correctly.  MDIs require co-ordination 
between the inhalation manoeuvre and the release of the dose from the device, which many 
patients; especially children and the elderly find difficult (Crompton 1982). In addition 
some patients naturally stop inhaling partway through inhalation because of their response 
to the cold aerosol hitting the back of their mouth (Fink, 2000).   
Single dose (capsule) dry powder inhalers require each dose to be loaded separately into 
the device. This procedure requires manual skill that is difficult for the elderly, arthritic 
and disabled patients (Crompton 1990).  
Dry powder inhalers (DPIs) are dependent on the patient’s initial inspiratory effort to de-
aggregate the powder formulation and generate drug particles in the optimal size range to 
reach the target sites in the lungs. Studies have shown that young children with asthma 
(Pedersen et al.; 1990) and patients with chronic obstructive pulmonary disease (COPD) 
(Nsour et al; 2000) have problems achieving the minimum required inhalation rate through 
a DPI. A reduced inspiratory flow can result in poor drug release and low pulmonary 
deposition (Newman et al. 1991; Pitcaim et al., 1994; Borgstrom 1994). 
The state of the patient’s airways may alter due to the disease progression. For example, 
inflammation , obstruction or mucus produces narrowing of the airways, which in turn will 
increase the linear velocity of air in those airways and so enhances impaction and produces 
a more central deposition pattern (Clarke 1990). 
These studies highlight that although the patients are trained on how to use an inhaler 
device, if they do not have the ability to achieve the required inhalation manoeuvre through 
the device then dosing will not be as expected and  could even be zero (Chrystyn, 2006). 
It is, therefore, important that healthcare professionals should consider patients preference 
together with their competence to use an inhaler before prescribing. Carefully choosing the 
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most appropriate inhaler device along with teaching the patient correct inhalation 
technique can maximise asthma management and optimise overall clinical outcomes.  Also 
consideration should be given to those inhalers that are least affected by the inhalation 
method used by the patient and those with more efficient lung deposition with reduced 
oropharyngeal impaction. Hence, the use of the In-Check Dial® by the healthcare 
professionals to identify a patient’s inhalation rate through an inhaler and thus, the device 
to suit the patient’s natural technique prior to prescribing is very important.  Also the 
healthcare professionals should consider these issues before changing the dose of inhaled 
steroid or adding other treatments to the regimen of patients poorly controlled at any 
particular step of the guidelines. 
2.6  The In-check Dial® (Clement Clarke International) 
Each type of dry powder inhaler (DPI) is designed to emit a consistent fine particle dose 
over a range of inhalation rates. Thus it is important that the patient can achieve these rates 
when they use their DPI. The In-Check Dial® (Figure 2.24) has been introduced to identify 
a patient’s inhalation rate through an inhaler and therefore the device to suit a patient’s 
natural technique. The Dial is similar in appearance to a peak flow meter except that the 
patient inhales through it rather than a forced expiration. The mouthpiece has a dial that it 
can be turned so that it is set to simulate the resistance of several commonly used inhaled 
products such as Accuhaler®(Diskus), Clickhaler®, Easyhaler®, Easi-Breathe®, 
Autohaler®, and Turbuhaler®. This is achieved by altering the diameter of the inhalation 
orifice/hole such that the resistance is the same as that of the selected inhaler. The In-
Check Dial® is designed to mimic the use of a specific inhalation device. The rate of 
inhalation is measured by reading the value on the meter. When the patient inhales through 
the In-Check Dial® the reading identifies the inhalation rate that would be obtained when 
using the inhaler for which the meter has been set for. The use of the Dial in the clinic 
should enable the prescriber to choose the inhaled device that requires minimum training 
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of the recommended inhalation technique. The In-Check Dial® has been externally tested 
in vitro by AEA Technology and found to provide similar resistance to the inhalation 
devices available (http://www.clement.clarke.com/inspiratory/In-check). 
There has been no simple way to determine if the patient can use a preferred inhaler 
properly or not. The literature highlights that there is a link between the emitted dose 
(particularly the fine particle dose), total lung deposition and ultimately clinical response 
(Newman et al. 1991; Engel et al. 1992). The results of these studies indicate there is a 
difference in the emitted dose from dry powder inhalers with respect to the inhalation rates 
used. Studies have highlighted the potential of the In-Check Dial® to identify inhalation 
rate and thus inspiratory effort of all type of patients using different dry powder inhalers 
(Tarsin et al. 2000). In these studies the In-Check Dial® showed that 6 (8%) out of 74 
COPD patients (Nsour et al. 2001) together with 48 (Emeryk et al. 2000; Amirav et al. 
2005) children out of 64 (75%) and 57 (30%) respectively could generate an inspiratory 
flow of >60 Lmin
-1
 when using the Turbuhaler. Also a  study by (Tarsin 2000) showed  
that the measurements of inhalation rates using the Dial to be as accurate as the electronic 
measurements (using an Inhalation Profile Recorder) when patient inhaled through  the 
Accuhaler® and Turbuhaler® respectively. In the clinic the In-Check Dial® can be used to 
identify an inhaler that patient can use without training. 
  
Figure  2.24 In-Check Dial® (Clement Clarke International Limited, UK 
(http://www.clement.clarke.com/inspiratory/In-check)) 
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2.7 Methods of determination of the bioequivalence of inhaled products 
In the Pharmacopoea two products may be pharmaceutically equivalent if they have the 
same composition and in-vitro performance. They may be bioequivalent if they have the 
same pharmacokinetic and lung deposition profiles. They may be clinically equivalent if 
they have the same therapeutic effects and side effects (Barry and O'Callaghan 2003). 
There are four methods available for determining the bioequivalence of different inhaled 
products: simulated in vitro dose emission and particle size distribution measurements, in 
vivo gamma scintigraphy (radioaerosol drug deposition), pharmacokinetic, and 
pharmacodynamic. In combination, these methods can indicate the fate of an inhaled drug 
as the pulmonary fate of the aerosolized drug is influenced by where the aerosol particle is 
deposited in the lung (Chrystyn 2000; Chrystyn 2001; Mobley and Hochhaus 2001).  
2.7.1  In-vitro methods 
In vitro methods are a major component of quality assurance procedure used to determine 
the pharmaceutical performance of the inhaled products using parameters such as the total 
emitted dose, uniformity of dose, aerodynamic particle size distribution and the fine 
particle dose. The efficacy and safety of an inhaled product are dependent on these 
parameters. In addition, they are often used to predict lung deposition. The most used 
techniques are inertial separation methods and laser diffraction. Microscopic methods have 
also been used. 
Aerosol particles are not perfectly spherical, instead they are of an uneven shape, weight 
and surface area that would be impossible to be described accurately by any one variable. 
Instead, such particles are generally described by their aerodynamic diameter. This is the 
diameter of a unit density sphere that has the same settling velocity in air as the particle. 
This aerodynamic diameter takes into account particle density, shape and size (Hickey 
1992). The mass median aerodynamic diameter (MMAD) of an aerosol is the diameter that 
separates the mass of the particles equally by 50%.The MMAD can be determined by 
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plotting the cumulative mass of active ingredient versus the  cut-off diameter on a log 
probability graph (BP, 2001). The MMAD can then be determined by reading from the 
(sigmoid) curve at the 50% co-ordinate. The GSD is a measure of the polydispersity, or 
spread, of an aerosol. A monodispersed aerosol has a GSD of 1 and heterodispersed 
aerosol has a GSD greater than 1.2. The amount of an aerosol which contained particles 
with an aerodynamic diameter less than 5µm, is generally referred to as the fine particle 
dose [FPD] (Newman 1991). This is the quantity of drug in the prescribed dose of an 
inhaled product that is generally considered to be of a size capable of penetrating the lung 
during an inhalation i.e. respirable amount. Since the label claims of the various inhalers 
differ, for ease of comparison in terms of performance, the FPD is expressed as a 
percentage of the nominal (label claim) dose to give the fine particle fraction (FPF). 
Although the respirable fraction does not equal the amount of aerosol deposition in the 
lung, it provides an estimate of the fraction of the dose that has the potential to be 
deposited into the lungs (Dhand and Fink 1999; Barry and O'Callaghan 2003). 
2.7.1.1 DPI dose emission unit:  
The DPI dose emission unit, as shown in Figure 2.25, is used to perform those tests 
specified by the Pharmacopoeia (European Pharmacopeia 2007; British Pharmacopoeia 
2008; United States Pharmacopeia 2009) that relate to content uniformity namely 
‘Delivered Dose Uniformity’ and in the case of a multi-dose DPI, ‘Dose Uniformity over 
the Entire Contents’. In the case of DPIs, both the emitted and fine particle dose is affected 
by the strength and duration of the patient’s inspiration (Newman et al. 1991; Ross and 
Schultz 1996). Furthermore, different inhalers provide varying degrees of resistance to 
flow (Clark and Hollingworth 1993). For these reasons, according to the compendial 
methods, it is essential, particularly when testing DPIs of intermediate to high flow 
resistance, to determine the appropriate test flow and duration based on the pressure drop 
developed over the specific inhaler under test. Assuming this is done, it is then important 
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to ensure that critical (sonic) flow occurs in the flow regulating valve employed in the 
system. This ensures that the flow through the dose emission unit is set as required and that 
it is unaffected by minor fluctuations in the pump. The resulting airflow that produces a 
drop of 4.0 kPa over the inhaler to be tested, should then be used for the determination of 
the delivered dose and particle size distributions as recommended by the compendial 
methods (European Pharmacopeia 2007; British Pharmacopoeia 2008; United States 
Pharmacopeia 2009). 
The only exception to this criterion is for those low resistances DPI that produce a flow in 
excess of 100 L min
-1
. In this case, a flow of 100 L min
-1
 should be used. 
 
 
Figure  2.25 Parts and fitting of the DPI dose emission unit (Reproduced from Copley 
2008) 
2.7.1.2 Characterisation of the emitted dose: 
Inertial impaction as a size separation factor by cascade impaction methods has been 
widely used as the ‘gold standard’ to determine the aerodynamic characteristics of the 
emitted dose from aerosols (European Pharmacopeia 2007; British Pharmacopoeia 2008; 
United States Pharmacopeia 2009). The application of this class of particle size analysis to 
the assessment of medical aerosols has recently been extensively reviewed, focusing on the 
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types of impactor that are in current use together with their strengths and limitations for 
measurements with the different classes of inhalers (Mitchell and Nagel 2003).  
(a) Twin Stage Impinger: 
 The Twin Stage Impinger shown in Figure 2.26 (United States Pharmacopeia 2005) can be 
operated using inhalation flows of 30 and 90 L min
-1
. It has been retained in the 
Pharmacopoeias because of its value as a simple and inexpensive quality control tool 
(Newman and Kenyon 1994). 
 
Figure  2.26 The Twin Stage Impinger (Reproduced from Copley, 2008). 
 
(b) Multistage Liquid Impinger: 
The Multistage Liquid Impinger [MSLI] (United States Pharmacopeia 2005) consists of a 
metal throat, impaction stages and a final filter. The MSLI operates at 60 L min
-1
 and has 
cut-off diameter of 25, 13, 6.8, 3.1 and 1.7 µm, thus giving a much more detailed particle 
size distribution then the Twin Stage Impactor (Figure 2.27). However the number of cut-
off diameters is limited. 
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Figure  2.27 The Multi-stage Liquid Impinger (Reproduced from Copley, 2008) 
 (c) Anderson Cascade Impactor: 
As shown in Figure 2.28 the Anderson Cascade Impactor (ACI) consists of a stack of eight 
plates, each containing a series of precision drilled holes, and a final filter stage (European 
Pharmacopeia 2001; British Pharmacopoeia 2005; United States Pharmacopeia 2005). The 
diameter of the holes decreases progressively in each succeeding stage. Therefore, the jet 
velocity increases as a particle travels through the impactor. The standard ACI is designed 
to operate at a flow of 28.3 L min
-1
 with stage cut-off diameters of 9, 5.8, 4.7, 3.3, 2.1, 1.1, 
0.65 and 0.43 µm, respectively. This method allows a more detailed description of the 
particle size distribution than either the MSLI or the Twin Impinger. Although the ACI is 
designed to be used at inhalation flows of 28.3 L min
-1
, modifications are available for the 
use at high flows 60 and 90 L min
-1
. For an inhalation flow of 60 L min
-1
 stages 0 and 7 are 
removed and replaced by stages -1 and -0 on the top of the ACI. For an inhalation flow of 
90 L min
-1
 stages 0, 6 and 7 are removed and replaced by stages -2, -1, and -0 on the top of 
the ACI. Alternatively the standard ACI can be operated at different flows with the cut-off 
stages altered according to the following equation (ECDF2 = ECD28.3 (28.3/F2)
0.5
). Where 
ECDF2 = the Effective Cut-Off Diameters at the other flow; ECD28.3 is the ECD at the 
manufacturers flow (28.3 L min
-1
) and F2 is the other flow rate in L min
-1
 (Van Oort 1995). 
When sampling DPI aerosols, a pre-separator with a small amount of solvent is added to 
the ACI to prevent those particles greater than 10µm from bouncing into the ACI stages 
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(Figure 2.22). Furthermore, it is important in predicting lung deposition of inhaled 
products to use conditions that simulate normal patient’s use. Thus, the need to use  the 
Andersen Cascade Impactor containing modification kits together with the mixing inlet 
(Copley 2003) that allows the determination of dose emission and aerodynamic particle 
size distribution of dose from DPIs at a variety of inhalation rates and for different inhaled 
volumes. 
 
. 
 
Figure  2.28 (a) The Anderson Cascade Impactor set for MDI. (b) The Anderson Cascade 
Impactor set for DPI (Reproduced from Copley, 2008). 
(d) Next Generation Impactors: 
The Next Generation Impactor has been designed specifically for pharmaceutical inhaler 
testing (Figure 2.29). This impactor has seven stages and is intended to operate at any 
inhalation flow between 30 and 100 L min
-1
. 
The cut-off size ranges from 0.54 µm to 11.7 µm aerodynamic diameter at 30 L min
-1
 and 
0.24 µm to 6.12 µm at 100 L min
-1
. The NGI has several features to enhance its utility for 
inhaler testing: 
(a) (b) 
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1. Particles deposited on collection cups are held in a tray from the impactor as a single 
unit, facilitating quick sample turn-around times if multiple trays are used.  
2. The user can add up to approximately 40 ml of an appropriate solvent directly to the 
cups for more efficient drug recovery.  
3. The Micro-orifice Collector (MOC) captures, in its collection cup, extremely small 
particles normally collected on the final filter of other impactors. The particles captured in 
the MOC cup can be analyzed in the same manner as the particles collected in the other 
impactor stage cups.  
 
 
Figure  2.29 Next Generation Impactor (Reproduced from Copley, 2008). (a) NGI 
including preseparator and induction port. (b) NGI (open view) showing nozzles & 
collection cups. (c) NGI (open view) showing cup tray removed. (d) Collection cups 
showing typical deposition pattern.  
2.7.1.3 Principles of operation of the cascade impactors 
The term ‘impactor’ is generally used for an instrument where the particles ‘impact’ on a 
dry impaction plate or cup. If the collection surface is liquid, as in the case of the multi 
(a) 
(b) 
(c) (d) 
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stage liquid impinger, then the term ‘impinger’ is used. The general principles of inertial 
impaction apply to both ‘impactors’ and ‘impingers’ 
Cascade impactors operate on the principle of inertial impaction. Each stage of the 
impactor comprises a single or series of nozzles or jets, as shown in Figure 2.30, through 
which the sample laden air stream is drawn directing any airborne particles towards the 
surface of the collection plate for that particular stage. Whether a particular particle 
impacts on that stage is dependent on its aerodynamic particle size. Particles having 
sufficient inertia will impact on that particular stage collection plate, whilst smaller 
particles with insufficient inertia will remain entrained in the air stream and pass to the 
next stage where the process is repeated. 
 
Figure  2.30 Principle of cascade impactor operation (Reproduced from Copley, 2008). 
 
The stages are assembled in a stack, in order of decreasing particle size. As the jets get 
smaller, the air velocity increases and finer particles are collected. Any remaining particles 
are collected on a final filter. At the end of the test, the particle mass relating to each stage 
collection plate is recovered using a suitable solvent and then analysed usually using 
HPLC to determine the amount of active drug actually present. 
By analysing the amount of drug deposited on the various stages in this manner, it is then 
possible to calculate the Fine Particle Dose (FPD) and Fine Particle Fraction (FPF) as well 
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as the Mass Median Aerodynamic Distribution (MMAD) and Geometric Standard 
Deviation (GSD) of the active drug particles collected. 
In some instances, particles may bounce in response to impact when they contact the 
collection plate, in which case they are normally re-entrained into the air stream and 
carried to a lower stage. This can be a particular problem with a DPI and certain MDIs 
(where measurements are based on a limited number of actuations from the inhaler). This 
tendency may be avoided by coating the collection plate with a suitable surface coating 
(Allen 1990). Particle deposition on parts of the  impactor other than the collection plates is 
called ‘inter-stage losses’ (Kamiya et al. 2004). 
2.7.2 In vivo methods 
2.7.2.1 Pharmacokinetic methods (using plasma or urine samples): 
The Pharmacokinetic methods exploit the rapid absorption of drugs through the lung and 
the lag time for the drug to be absorbed following oral administration to determine the 
relative bioavailability of inhaled products. The dose emitted from an inhaler either enters 
the systemic circulation via the lungs or through being swallowed and absorbed in the 
gastrointestinal tract as shown in Figure 2.31. Also the gastrointestinal absorption of any 
drug that is swallowed can be blocked by the coadministration of oral charcoal thereby 
allowing the determination of lung deposition. Lung absorption (hence effective dose lung 
dose) can also be distinguished by the timing of sample collection (Hindle and Chrystyn, 
1992; Lipworth 1996). 
Both drug plasma concentration (Lipworth and Clark, 1997) and urinary excretion data 
(Hindle and Chrystyn, 1992; Chege et al, 1997) have been used to assess salbutamol lung 
deposition and relative bioavailability of inhaled products. Plasma studies can be difficult 
to perform due to high volume of distribution of salbutamol (being polar and basic) 
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(Morgan et al, 1998) resulting in very low plasma concentration after an inhalation 
(Chrystyn, 1994). 
To compare lung deposition of inhaled products, Lipworth and Clark (1997) performed a 
plasma pharmacokinetic study in which a breath activated MDI and two DPIs (Diskhaler 
and Accuhaler) delivered 200µg salbutamol to 10 healthy volunteers over 6 minutes. 
Plasma concentrations were measured at 5, 10, 15 and 20 minutes post inhalation. 
Maximum concentration values reported were: 4.35 ng/ml (Diskhaler), 3.98ng/ml (MDI) 
and 3.22ng/ml (Accuhaler). Both the Diskhaler and the MDI produced significantly 
(p<0.05) higher plasma concentration than the Accuhaler. 
 The urinary pharmacokinetic has been introduced to overcome the problem associated 
with low plasma concentrations. Due to the relatively small volume of urine with respect to 
systemic volumes of distribution, the drug concentrations in urine are much high than those 
measured in the plasma (Chrystyn, 1994). By collecting urine up to 24 hours post dose, via 
inhalation and oral administration, it possible to determine the relative bioavailability of 
salbutamol to the body (Hindle and Chrystyn, 1992). However, to identify lung deposition, 
methods that distinguish between absorption via the lung and the swallowed portion are 
necessary.  
The use of oral charcoal doses taken before and after the inhalation to block the 
gastrointestinal absorption of the oral ingested portion has been demonstrated (Borgstrom 
and Nilsson 1990). However, because this method uses oral charcoal it would be unethical 
to extend the method to patient studies due to their concomitant oral therapy (Chrystyn 
2000). Lung absorption can also be distinguished by timing of urine sample collections 
(Hindle and Chrystyn 1992). 
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Figure  2.31 Pharmacokinetics of inhaled drug [Reproduced from (Chrystyn 2001).] 
Using the lag time of the gastrointestinal absorption Hindle and Chrystyn (1992) developed 
a urinary pharmacokinetic method to determine the relative lung and systemic 
bioavailability of inhaled salbutamol. They showed that in the first 30 minutes after the 
oral administration of salbutamol, insignificant amounts of salbutamol were excreted in the 
urine, 0.18 (0.14) % of dose. This small amount is due to lag time between administration 
and absorption from the small intestine. On the other hand, they found significantly 
(p<0.001) more salbutamol was excreted in the urine over the first 30 minutes post 
inhalation, 2.06 (0.80) of the dose as shown in Figure 2.32. Using this method Hindle and 
Chrystyn (1992) reported a low intra-subject variability. The relative standard deviation for 
two volunteers was 6.4 % and 5.8 % (n=10). They therefore reported that an index of 
relative bioavailability can be obtained from the amount of salbutamol excreted in the first 
30 minutes post inhalation. Furthermore, by the coadministratration of oral charcoal with 
salbutamol, urine and collecting urine over 24 hours then data concerning total lung 
deposition can be measured (Chrystyn et al, 1997). 
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 The urinary pharmacokinetic method is very simple and non-invasive. The method has 
been extended to assess the relative lung bioavailability of inhaled sodium cromoglycate 
(Aswania et al. 1997; Aswania et al. 1999; Aswania and Chrystyn 2001; Aswania and 
Chrystyn 2002), nedocromil (Aswania et al. 1998), gentamicin (Al-Amoud et al. 2002), 
tobramycin (Barber 2002) and formoterol (Nadarassan et al. 2007). 
The disadvantages of the pharmacokinetic methods are the need to differentiate between 
the swallowed and inhaled fraction of the inhaled dose. They do not identify dose 
deposition into different zones of the lungs and some assays do not have the sensitivity to 
measure the low concentrations (Chrystyn 2001). 
 
Figure  2.32 Mean and individual amounts of urinary salbutamol excreted during the first 
30 minutes post inhalation and oral dosing (Hindle and Chrystyn 1992).  
2.7.2.2 Gamma scintigraphy: 
There are two types of gamma scintigraphy used in pulmonary imaging, two dimensional 
and three-dimensional imaging methods (Newman and Wilding 1999; Chrystyn 2000).  
The two dimensional gamma scintigraphy (planer imaging) method usually uses 99m 
Technetium adhered to either the formulation or the drug molecules in the dosage form 
(physical attachment). The subjects inhale the combination and then use rapid imaging of a 
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radionuclide to identify the drug deposition in the lung following inhalation (Borgstrom 
and Newman 1993; Newman and Wilding 1999; Bondesson et al. 2003). The planar 
images obtained with this method may be insensitive to the relative deposition in the 
different zones of the lungs.  
Three-dimensional imaging methods (SPECT and PET) have recently been introduced to 
overcome the disadvantage of planner imaging. SPECT (single photon emission computed 
tomography) is similar to two-dimensional gamma scintigraphy (physical attachment of the 
radiolabelling of the drug) except that the gamma camera rotates through 360
o
C. This 
increases the data collection time. Hence, a very large dose is required. The dose may be 
40 times larger than that required for the planar imaging and thus introduces formulation 
and preparation problems (Newman and Wilding 1999).  
PET (Positron emission tomography) is a direct incorporation of a radiolabel into the drug 
molecule (chemical attachment). The ones recently used are positron emitters such as 
11
C 
(short half life) or 
18
F (long half life). The positron emitters used so far have short half-
lives and the method is very expensive. 
11
C has been introduced into triamcinolone 
acetonide and studies have highlighted the greater peripheral deposition when a spacer is 
attached to an MDI. This was mainly due to a substantial increase in the total amount of 
drug deposited in the lungs (13.6% with and 4.9% without the spacer). This technique has 
also been used for fluticasone (Berridge et al. 1998). 
Gamma scintigraphy produces data of the total lung dose that is absorbed through the 
airways and cleared by mucociliary clearance. Since the former is the part of the dose that 
is responsible for the therapeutic action in the airways then gamma scintigraphy will 
overestimate the effective dose reaching the lung. The charcoal block method using urinary 
excretion of terbutaline (Borgstrom and Nilsson 1990) has been compared with total lung 
deposition measured by gamma scintigraphy (Borgstrom et al. 1992). The mean (SD) 
terbutaline excreted in the urine post inhalation with concurrent charcoal administration 
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was 21.1 (3.2) % of the nominal dose whilst gamma scintigraphy showed the total lung 
deposition to be 26.9 (3.8) %. The difference obtained is because part of the inhaled dose is 
cleared by mucociliary clearance. This fraction of the dose delivered to the lungs is 
identified by gamma scintigraphy but not by pharmacokinetic methods.  
The long term safety and the expensive study costs are considered disadvantages of gamma 
scintigraphy (Chrystyn 2001). In addition, the labelling procedure involves manipulations 
of the formulations. Consequently, the radiolabelled formulation is different from the 
formulation in the original product although in-vitro tests are carried out to confirm 
similarity (Snell and Ganderton 1999). However, a previous report has shown that when 
using the Andersen Cascade Impactor the mass median aerodynamic diameter (MMAD) of 
a labelled drug was larger than the original product and that there was a difference in the 
homogeneity of the size distribution (Newman et al. 1982). Furthermore, particle size 
ranges should be quoted as amounts emitted rather than a percentage, and in-vitro 
determinations should use the same number of doses that were used in the scintigraphy 
study. Agencies such as the FDA are very cautious in using results from imaging studies 
for assessing bioequivalence (Mobley and Hochhaus 2001).  
There are also non-radioactive assessment methods such as nuclear magnetic resonance 
imaging (MRI) and magnetic marker monitoring (MMM) but their use is not well 
established yet (Newman and Wilding 1999). 
2.7.2.3 Pharmacodynamic method: 
Clinical studies using spirometry or bronchoprovocation challenge have been used to 
identify the bioequivalence between two inhaled products (Eiser et al. 2001; Rodriguez-
Carballeira et al. 2001). A method often used in the evaluation of the efficacy of inhaled 
drugs is the protective effect on methacholine or histamine induced bronchoconstriction 
(Tattersfield 1987; Britton et al. 1988). The inhalation of a short-acting β2-agonist 
increases the provocative dose of inhaled methacholine or histamine from 1.1 to 3.9 times 
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(Casterline et al. 1976; Cockcroft et al. 1977). More recent studies have demonstrated that 
salbutamol increases the provocative dose of methacholine by 2.8 to 3.1 times (Wong et al. 
1997; Seppälä et al. 1998). Most clinical studies that utilise spirometry as the primary 
outcome are carried out using measurements at the flat (plateau) portion of the dose-
response relationship. For instance, a doubling of the therapeutic fluticasone inhaled dose 
has been shown to increase the peak expiratory flow rate (PEFR) by only 4.3 L min
-1
 from 
a baseline of almost 200 L min
-1
 (Dahl et al. 1993). Also for beclomethasone the FEV1 
(forced expiratory volume in the first second) increased by 0.18 L above baseline after 200 
mg inhaled twice daily and by 0.21 L after 400 mg twice daily (Raphael et al. 1999). For 
the β2-agonists the maximum response from therapeutic inhaled doses has been studied 
(Barnes and Pride 1983). It has been found that in normal subjects a maximum airway 
response to inhaled salbutamol was achieved with a cumulative dose of 110 µg. By 
contrast the dose required to produce a maximal bronchodilator response in asthmatic 
subjects was significantly higher and increased as the severity of bronchoconstriction 
increased (Barnes and Pride 1983). Newman et al. (1991) also demonstrated this in 
asthmatic subjects except that they also measured lung deposition using gamma 
scintigraphy. When these subjects inhaled radiolabelled salbutamol from a MDI and a MDI 
attached to a large volume spacer the total lung deposition was 12.3 and 23.1% (of the 
dose), respectively, but there was no difference in spirometry measurements (Newman et 
al. 1991). Also bronchoprovocation challenge cannot differentiate between different 
inhalation techniques due to the large variability of the method (Tomlinson et al. 2005). 
The inter-patient variability in clinical studies is high. Thus sensitivity to detect a 
difference is low and so a large number of subjects need to be studied (Barry and 
O'Callaghan 2003). Furthermore the bronchoprovocation agents may stimulate different 
receptors to those of the drug studied causing deterioration of lung function. 
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2.8 ß2-adrenoreceptor agonists 
β2-adrenoreceptors are located in many tissues including the airways. Salbutamol and 
terbutaline are short acting β2-adrenoreceptor agonists. They stimulate β2-recetors located 
on the cell membrane of smooth muscles present in the airways resulting in 
bronchodilation and therefore providing relief for asthma sufferers and other conditions 
associated with airways obstruction. 
2.8.1 Salbutamol sulphate 
  
 Figure  2.33 Molecular structure of Salbutamol 
(Sweetman, Martindale (Eds) 2009) 
 
Salbutamol is a white, crystalline odourless powder with the chemical name a'-[ (tert-
Butylamino)methyl]-4-hydroxy-m-eylene-a.a'-[[1,1-dimethylethy]amino]methyl]-4-
hydroxy-1,3-benzeedimethanol. It has molecular weight of 239.3 and is relatively polar, 
hydrophilic compound with basic properties. Salbutamol is soluble in 70 parts of water and 
in ethanol (750g/L) while slightly soluble in ether. The pharmacological activity is usually 
in the (R)-enantiomer, so far there is no evidence that (S)-enantiomer is harmful to the 
patient (Waldeck 2002). Due to salbutamol`s relatively polar and basic properties 
(Figure2.33), following inhalation passive tubular reabsorption does not occur, as 
ionisation of the drug is unaffected by changes in urine pH (Chrystyn, H., 1998). Once 
administered salbutamol is eliminated either as unchanged drug or as an inactive 
metabolite (Martin et al. 1971). Following oral administration salbutamol is absorbed from 
the gastrointestinal tract and has an absorption half life of 20 to 30 minutes (Goldstein et al. 
1987). Peak plasma levels occur within 1.8 to 3 hours after oral administration (Martin, 
1971; Goldstein, 1987), and 48% of the dose is eliminated as the metabolite, and 32% as 
unchanged salbutamol (Morgan et al. 1986). This is half the amount that is eliminated as 
unchanged drug following intravenous administration (64%). The low bioavailability 
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following oral administration of salbutamol is due to extensive first pass metabolism in the 
liver and gastrointestinal wall.  
A study by Shenfield and colleagues found that after direct bronchial instillation of radio 
labelled salbutamol, 62% of the drug was eliminated as unchanged drug. They concluded 
that metabolism does not therefore occur in the lungs (Shenfield et al. 1976). Due to the 
rapid renal elimination of the portion of the drug absorbed through the lung, the peak 
urinary excretion of salbutamol is within 30 minutes post inhalation (Hindle and Chrystyn 
1992). 
2.8.2 Terbutaline sulphate 
Terbutaline sulphate is a synthetic resorcinol derivative β2-adrenergic agonist that is used 
as a bronchodilator in the treatment of asthma. It was first introduced in 1970s (Waldeck 
2002; Sears and Lotvall 2005). 
The Molecular Weight is 548.658 and the  empirical formula is (C12H19NO3)2.H2SO4. Its 
chemical name is [(1RS)-1-(3,5-Dihydroxyphynyl)-2-(tert-butylamino)-ethanol] sulphate 
(2:1 salt) (British Pharmacopoeia 2005). Figure 2.34 shows the molecular structure of 
terbutaline sulphate. 
N
H
CH3
CH3
CH3
OH
OH
OH
 2
.H2SO4
Tebutaline Sulphate M.W.548.658 C24H40N2O10S
 
Figure  2.34 Molecular structure of terbutaline sulphate. 
It is a hydrophilic white to grey-white crystalline powder, odourless or with a faint odour 
of acetic acid, soluble in water and 0.1N-hydrochloric acid, insoluble in chloroform and 
slightly soluble in methanol (United States Pharmacopeia 2002).  
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The commercially available terbutaline sulphate is a racemic mixture. Its melting point 
range differs according to the crystal type, as there are two types of the crystal form. 
Crystal form A has a melting point range from 268
0
C
  
to 271
0
C
 
and the crystal form B has a 
melting point range from 258
0
C 
 
to 260
0
C
  
(Analytical Profiles 1990). Terbutaline sulphate 
is present in many dosage forms (inhalation, oral solution, injection and tablet) for 
prophylactic and acute bronchodilator treatment 
Terbutaline sulphate is a β2-adrenoreceptor agonist that is used as bronchodilator to open 
up constricted airways. Terbutaline sulphate is present in many dosage forms (inhalation, 
oral solution, injection, and tablet). After inhalation, the bronchodilating effect of 
terbutaline usually begins within 5 minutes and last for about 3 to 4 hours (Florey 1990). 
Orally administered terbutaline sulphate is usually absorbed from the gastrointestinal tract 
(Florey, 1990; (Sears and Lotvall 2005). The onset of action of orally administrated 
terbutaline is about 30 minutes and its duration of action is up to 8 hours (Martindale 2002).  
About 60% of the absorbed dose undergoes first pass effect metabolism to the sulphate 
ester (Sweetman and Britain 2002). Terbutaline is excreted in the urine as an inactive 
conjugate and the unchanged terbutaline. Its biological half life is 3 to 4 hours (Florey, 
1990). 
2.9 Summary 
The literature highlights that the efficacy of inhaled therapy depends on the ability to 
deliver adequate aerosol in an optimal size-range to the lungs, which in turn depends on 
aspects of airway anatomy and physiology that will alter with age and disease status. The 
treatment of asthma, although based on regular use of corticosteroids as preventers, still 
relies heavily on the use of ß2-agonists such as salbutamol and terbutaline as reliever 
therapy. The management of COPD includes smoking cessation, the use of bronchodilators 
(ß2-agonists/antimuscarinics) and a combination of long acting ß2-agonist and 
corticosteroid as well as supplemental long-term oxygen therapy. COPD patients may 
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benefit from antibiotics and mucolytic drugs, especially during exacerbation, together with 
appropriate management of any associated cardiovascular disease.  
All currently available DPIs rely on a patient’s inspiratory effort to generate sufficient 
inspiratory flow that creates turbulent energy in the device for the dispersion and delivery 
of aerosol to the lungs. Each type of DPI has a different intrinsic resistance (due to design) 
against inspiratory flows, therefore, requires a specific inhalation technique for optimal 
aerosol generation and delivery to the lungs. Some COPD patients are not able to generate 
the optimal inspiratory flow through a DPI for efficient aerosol delivery to the lung, while 
others are not able to generate the threshold inspiratory flow required to lift the metered 
dose out of the device for delivery to the lungs. There is a link between the emitted fine 
particle dose, lung deposition and clinical response. Recently, the In-Check Dial has been 
introduced to identify a patient’s inhalation rate through an inhaler and therefore the device 
to suit a patient’s natural technique. Also study of ex vivo dose emission of DPIs using 
healthy volunteers could be carried out with the aid of the In-Check Dial. 
Adaptation and modification of the compendia in-vitro methods enable the studies of 
patients simulated inhalation technique for various DPIs.  The in vitro methods in 
combination with in vivo (gamma scintigraphy, pharmacokinetics and clinical) methods 
could be used for the determination of bioequivalence of inhaled products. 
Lung deposition from an inhaler is dependent on the inhalation technique used. For an 
MDI a slow, deep and prolonged inhalation is required whilst for a DPI the inhalation 
manoeuvre should be fast from the start of the inhalation and sustained for a long as 
possible. The quality of the emitted dose for a DPI is dependent on inhalation flow and 
inhalation volume along with the ability to empty the dose out of the metering cup or 
capsule. For the latter reason patients may need to inhale each dose twice. 
The studies in this thesis have been designed to identify the effect and influence of 
inhalation flow, inhalation volume and the number of inhalations for each dose. Four 
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different DPIs have been used to identify the minimum criterion of the inhalation 
manoeuvre to deliver a dose into the lungs of patients. 
2.9.1 Criteria for the selection of the four different dry powder inhalers (DPIs) 
Previously, an in-vitro study on the effects of inhalation manoeuvre on the emitted dose of 
tiotropium from a Handihaler (a single dose capsule) DPI has been performed. The results 
of the study have shown that dose emission was influence by inhalation flow and volume 
and that two inhalations were required for each dose (Al-Fadhl, 2005). The results of that 
study have, in part, generated a considerable interest for a similar study on multiple dose 
DPIs, which has never been done. At present the instructions (manufacturer’s patient 
information leaflet) for using available multi-dose DPIs state only one inhalation per dose 
and patients should inhale as fast as they can. The criteria for the selection of the four 
different multiple dose DPIs used for the studies in this Thesis are as shown in Table 2.11. 
Table 11 Criteria for the selection of the four different dry powder inhalers (DPIs) 
Device Company (Country) 
Licensee 
Drugs available Type 
Accuhaler GlaxoSmithKline (UK) Salbutamol  
 
Multiple unit-dose strip 
Low resistance 
Clickhaler ML Laboratories (UK) Salbutamol Multiple-dose reservoir 
Intermediate resistance 
Easyhaler Orion Pharma (Finland) Salbutamol Multiple-dose reservoir 
High resistance 
Turbuhaler AstraZeneca (Sweden) terbutaline Multiple-dose reservoir 
High resistance 
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3 High Performance Liquid Chromatography (HPLC) 
3.1 Introduction 
Generally, chromatography is a separation technique in which the sample components, 
carried by the mobile phase are separated by adsorption-partition steps on a stationary 
phase. High-performance liquid chromatography (HPLC) comprises all liquid 
chromatographic techniques with the use of high pressure to force the liquid (mobile phase) 
through the stationary phase. The sample to be analysed is introduced in a small volume to 
the stream of mobile phase and is retarded by chemical or physical interactions with the 
stationary phase as it traverses the length of the column. Separation of analytes is based on 
their relative affinity for the stationary and mobile phases and selectivity is influenced by 
the column temperature and pH (Watson 2005). 
Early forms of HPLC utilised polar stationary phases and non-polar mobile phases. This 
type of chromatography is known as normal phase chromatography. Most separations by 
HPLC nowadays utilise reversed-phase chromatography where a non-polar stationary 
phase is used in conjunction with a polar mobile phase (Hagan 1994). Using this system, 
polar analytes elute faster than non-polar analytes. 
3.2 HPLC assay for aqueous salbutamol sulphate 
In this study the HPLC assay for aqueous salbutamol sulphate was based on that published 
by  Silkstone, (1999) with minor modifications to the mobile phase made by Richardson 
(2003). The modified mobile phase consisted of phosphate buffer: acetonitrile (80:20) 
adjusted to pH 2.5 with orthophosphoric acid and a flow rate of 1ml/minute used. This was 
further modified using 5mM potassium dihydrogen phosphate: acetonitrile (75:25), 
adjusted to pH 3 with orthophosphoric acid using the flow rate of 1ml/minute. The method  
was re-validated according to the International Conference on Harmonisation of Technical 
Requirements for registration of pharmaceuticals for human use guidelines (ICH 1994).  
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3.2.1 Chemicals  
Salbutamol sulphate (Sigma), terbutaline sulphate (Sigma), bamethane sulphate (Sigma), 
potassium dihydrogen orthophosphate (BDH), orthophosphoric acid (BDH), acetonitrile 
(Fisher) and double distilled water were of HPLC grade. 
Table  3.1 Instrumentation and HPLC conditions 
 
 Stationary phase: Phenomenex Sphere Clone column 5µ ODS 
(2) 250×4.6mm set at temperature of 30
o
C   
Mobile phase: Buffer: acetonitrile (75:25), the buffer was 
5mM potassium dihydrogen 
orthophosphate buffer adjusted to pH3, 
with orthophosphoric acid. The mobile 
phase was filtered through a 45mm 
membrane filter (Millipore, Whatman Ltd, 
UK) and degassed under vacuum in an 
ultrasonic bath for 10 minutes prior to use. 
Internal standard: Bamethane sulphate 8000µg L
-1
 
Flow rate: 1 ml min
-1
 
Pump: HP 1050 pumping system (Hewlett 
Packard, Germany) 
Injector: HP 1050 Autosampler with a 200µl loop 
Detector: UV- detector, set at wavelength 202 nm 
Integrator: A package using Prime software (HPLC 
Technology Ltd, UK ) 
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3.2.2 Standards 
Aqueous stock solutions of salbutamol sulphate and terbutaline sulphate were respectively 
prepared and stored in a refrigerator. From the respective stock solution, working standards 
were prepared by serial dilution using aqueous bamethane solution internal standard 
(8000µg/L) to yield nominal salbutamol sulphate and terbutaline sulphate concentrations 
of 250, 500, 750 and 1000, 1500 and 2000µg L
-1
 (w/v). The working solutions were stored 
in well closed, light resistant containers kept in a refrigerator prior to analysis. 
3.2.3 Linearity 
The linearity of an analytical procedure is its ability (within a given range) to obtained test 
results which are directly proportional to the concentration (amount) of analyte in the 
sample. Calibration curves were obtained using six salbutamol sulphate standards between 
250 and 2000µgL
-1
 with bamethane sulphate (8000µgL
-1
) as an internal standard. Two 
injections were performed for each salbutamol sulphate standard. The peak area ratio of 
salbutamol to bamethane was plotted against the nominal concentration of salbutamol 
sulphate standard. A straight line was fitted to the data using linear regression. A 
representative plot described by the equation y=0.0003x+0.0006 (r²=0.9996) is shown in 
Figure-3.1. Representative chromatograms are as shown in Figure 3.2. The detector 
response was shown to be linear over the range of 250 to 2000µgL
-1
 of salbutamol sulphate 
in aqueous sample containing 8000µgL
-1
 of bamethane with correlation coefficients of 
0.9996. 
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Figure  3.1 A representative calibration curve of the peak area ratio of salbutamol sulphate 
to bamethane sulphate against the concentration of salbutamol sulphate standard  
 
Figure  3.2 Typical chromatograms of (1) salbutamol sulphate aqueous standard (2000µg/L) 
and (2) bamethane sulphate aqueous standard (8000µgL
-1
) injected under the following 
chromatographic conditions- Phenomenex Sphere Clone 5µ ODS (2) 250×4.6mm set at 
temperature of 30
o
C; Mobile phase (25:75 v/v%) acetonitrile: 5mM potassium dihydrogen 
orthophosphate buffer adjusted to pH3, with orthophosphoric acid; flow rate 1.0 mLmin
-1
; 
wavelength =202 nm; injection volume 50µL 
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3.2.4 Precision 
This is a measure of the distribution of individual measurements around the mean. This 
parameter is generally assessed by repeated analysis of the same solution and expressed as 
the relative standard deviation (RSD) otherwise known as the coefficient of variation (CV). 
The lower the value the better is the assay performance. Six injections per salbutamol 
standard (concentration ranging from 250-2000 µgL
-1
) were performed on the same day for 
intra-day precision of the assay, while inter-day precision of the assay was determined on 
different days under the same HPLC conditions for six days. Intra-day and inter-day 
variations, expressed as the relative standard deviation (RSD in peak area ratio, were 
calculated by dividing the standard deviation of the calculated concentrations by the mean 
concentration and multiplying by hundred. The mean of (RSD) intra-day assay variability, 
determined for the six (250-2000 µgL
-1
 ) standard concentrations of salbutamol sulphate on 
six occasions, was 0.89. The inter-day assay variability, determined at the same six 
standard concentrations, using six replicate runs on different days was 1.68. The results are 
shown in Table 3.1. 
Table  3.2 Precision of salbutamol sulphate assay (n=6) 
 
Nominal concentration  
µgL
-1
 
Intra-day 
 (RSD)% 
Inter-day 
 (RSD)% 
250 2.21 0.99 
500 0.55 2.22 
750 0.73 1.18 
1000 0.57 1.88 
1500 0.55 1.15 
2000 0.74 2.64 
Mean 0.89 1.68 
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3.2.5 Accuracy 
This describes the closeness of test results obtained by an analytical method to the true 
value (concentration) of the analyte. Three different concentrations (400, 800 and 
1250µgL
-1
) of salbutamol standards within the linear range of 250 to 2000µgL
-1
 were made 
and six chromatographs per concentration of these standards were performed. The 
accuracy of the assay was measured by comparing the mean observed concentration 
obtained from the linear regression, described by the equation y=0.0003+0.0006 to the 
nominal salbutamol concentration. The accuracy was evaluated by determining the 
percentage relative error (RE %) that is the difference between the true value (nominal 
concentration) and the observed concentration divided by the true value and multiplied by 
hundred. The results are as shown in Table 3.2. The accuracy is within the acceptable 
range of 100±2%. 
Table  3.3 Accuracy of salbutamol sulphate assay (n=6) 
3.2.6 Limits of detection and quantitation 
The ICH and FDA guidelines recommend the use of a method based on the signal-to-noise 
approach and a method based on the standard deviation of the response and the slope (liner 
regression line method) to determine the limit of quantitation (LOQ) and the limit of 
detection (LOD).  
According to the method based on the signal-to-noise approach, the limit of detection 
(LOD) is the lowest concentration of analyte that can be detected but not quantified and it 
should be a value greater than 3:1 for the signal to noise ratio. The limit of quantitation 
Nominal concentration 
( µgL
-1
) 
Mean observed  concentration 
(µgL
-1
 ) 
Accuracy 
(RE %) 
400 401.6 0.4 
800 794.4 -0.7 
1250 1252.4 0.19 
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(LOQ) is the lowest concentration of analyte that can be measured with acceptable 
precision and accuracy by the assay and it should be a value greater than 10:1 for the signal 
to noise ratio. The limit of detection (LOD) and the limit of quantitation (LOQ) can be 
calculated from the mean of the slope and SD of the intercept of five calibration curves 
using the linear regression line method. The LOD is equal to 3.3 multiplied by the SD of 
the intercept of the linear regression line divided by its slope. The LOQ is equal to the 10 
multiplied by SD of the intercept of the linear regression line divided by its slope. The 
linear regression line method was used here to determine LOD and LOQ. 
The limit of detection (LOD) and the limit of quantitation (LOQ) were calculated from the 
mean and standard deviation (SD) of the intercept and slope of five salbutamol sulphate 
calibration curves. The LOD and LOQ with 50µL injection volume were 75.2µgL
-1
 and 
228µg/L of salbutamol sulphate respectively. 
3.2.7 Recovery 
1ml of salbutamol sulphate standard (100,000µgL
-1
) was added to a filter (type A/E) in a 
Petri dish and allowed to dry overnight. The filter was then transferred into a beaker 
containing 100ml of bamethane 8000µgL
-1
 (in distilled water); the beaker was covered 
with parafilm and left overnight. The resultant salbutamol sulphate solution was placed in 
sonic bath for three minutes and then filtered for HPLC assay. The procedure was repeated 
for ten different filters. The mean recovery of salbutamol   sulphate   from the filter 
following the HLPLC assay is 99.96 (n=10) with RSD=6.3%. 
3.3 HPLC Assay for aqueous terbutaline sulphate 
The HPLC assay conditions were as for salbutamol sulphate described in section 3.2. 
3.3.1 Linearity 
Calibration curves were obtained using six terbutaline sulphate standards between 250 and 
2000µg/L with bamethane sulphate (8000µgL
-1
) as an internal standard. Two injections 
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were performed for each terbutaline sulphate standard. The peak area ratio of terbutaline to 
bamethane was plotted against the concentration of terbutaline sulphate standard. A 
representative plot described by the equation y=0.0003x+0.0297 (r²=09996) is as shown in 
Figure 2.3. Typical chromatograms of terbutaline sulphate standard concentration (1) and 
bamethane sulphate internal standard (2) are as shown in Figure 3.3. 
 
Figure  3.3 A representative calibration curve of the peak area ratio of terbutaline sulphate 
to bamethane sulphate against the concentration of terbutaline sulphate performed 
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Figure  3.4 Typical chromatograms of (1) terbutaline sulphate aqueous standard (2000µg/L) 
and (2) bamethane sulphate aqueous standard (8000µg/L) injected under the following 
chromatographic conditions- Phenomenex Sphere Clone 5µ ODS (2) 250×4.6mm set at 
temperature of 30
o
C; Mobile phase (25:75 v/v%) acetonitrile: 5mM potassium dihydrogen 
orthophosphate buffer adjusted to pH3, with orthophosphoric acid; flow rate 1.0 mL/min; 
wavelength=202nm; injection volume 50µL 
3.3.2 Precision 
This is a measure of the distribution of individual measurements around the mean. This 
parameter is generally assessed by repeated analysis of the same solution and expressed as 
the relative standard deviation (RSD) otherwise known as the Coefficient of Variation 
(CV). The lower the value the better is the assay performance. Six injections per 
terbutaline standard (concentration ranging from 250-2000µgL
-1
) were performed on the 
same day for intra-day precision of the assay, while inter-day precision of the assay was 
determined on different day under the same HPLC conditions for six days. Intra-day and 
inter-day variations, expressed as the relative standard deviation (RSD) in peak height ratio, 
were calculated by dividing the standard deviation of the calculated concentrations by the 
mean concentration and multiplying by hundred. The mean of intra-day (RSD) assay 
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variability, determined for the six standard concentrations of terbutaline sulphate on six 
occasions, was 0.96. The mean of inter-day (RSD) assay variability, determined at the 
same three concentrations, using six replicate runs on different days was 1.59. The results 
are shown in Table 3.3. 
Table  3.4 Precision of terbutaline sulphate Assay (n=6) 
 
Nominal concentration 
µgL
-1
 
Intra-day 
( RSD)% 
Inter-day 
( RSD)% 
100 2.4 1.47 
200 1.13 3.84 
250 1.21 0.98 
500 0.92 1.90 
750 0.32 1.17 
1000 0.36 0.07 
1500 0.35 1.68 
Mean 0.96 1.59 
3.3.3 Accuracy 
This describes the closeness of test results obtained by an analytical method to the true 
value (concentration) of the analyte. Three different concentrations (300, 800 and 
1200µgL
-1
) of terbutaline sulphate standards within the linear range of 250 to 2000µgL
-1
 
were made and six chromatographs per concentration of these standards were performed. 
The accuracy of the assay was measured by comparing the observed concentration 
obtained from the linear regression, described by the equation y=0.0005x+0.0297 to the 
nominal concentration of terbutaline sulphate. The accuracy was evaluated by determining 
the percentage relative error (RE %) and the results are as shown in Table 3.4. The 
accuracy is within the acceptable range of 100±2%. 
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Table  3.5 Accuracy of terbutaline sulphate assay (n=6) 
 
Nominal concentration 
µgL
-1
 
Mean observed concentration 
µgL
-1
 
Accuracy 
(% RE) 
300 299.2 -0.26 
800 805 0.62 
1200 1195.7 -0.36 
   
3.3.4 Limits of detection and quantitation 
The limit of detection (LOD) and the limit of quantitation (LOQ) were calculated from the 
mean and standard deviation (SD) of the intercept and slope of five terbutaline sulphate 
calibration curves. The LOD and LOQ with 50µL injection volume were 45.9µgL
-1
 
and139µgL
-1
 of terbutaline sulphate respectively. 
3.3.5 Recovery 
1ml of terbutaline sulphate standard (100,000µgL
-1
) was added to a filter (type A/E) in a 
Petri dish and allowed to dry overnight. The filter was then transferred into a beaker 
containing 100ml of Bamethane in distilled water (8,000µgL
-1
); the beaker was covered 
with parafilm and left overnight. The recovered terbutaline sulphate solution was placed in 
a sonic bath for three minutes and filtered for HPLC assay. The procedure was repeated for 
ten different filters. The mean recovery of   terbutaline sulphate   from the filter following 
the HLPLC assay was 99.86 (n=10) with RSD=4.3%. 
3.4 Summary 
The results show the aqueous HPLC assay methods for salbutamol sulphate and terbutaline 
sulphate were precise, accurate and sensitive. The relative standard deviations (RSD) for 
both assays were low (in the range 0.89 to 1.68). Also the assays both showed very little 
deviation from the nominal concentration when the concentrations of salbutamol sulphate 
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and terbutaline sulphate were calculated from the chromatographic peak area ratio. The 
accuracy is within acceptable range 100±2%. 
The LOD and LOQ with 50µL injection volume were calculated to be: 75.2µgL
-1
 and 
228µgL
-1
 (salbutamol sulphate) and 45.9µgL
-1
 and 139µgL
-1 
(terbutaline sulphate) these 
were well below the expected concentrations for samples to be analysed in this study. The 
LOD and LOQ in agreement with those obtained for salbutamol (Richardson, 2003). 
Therefore, the methods could be used to determine the amounts of salbutamol and 
terbutaline in aqueous samples.  
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4 In vitro determination of dose emission of dry powder inhalers 
(DPIs) at different inhalation flows using low and high inhalation 
volumes 
4.1 Introduction 
Inhalation of aerosolised drugs has been widely recognised as the therapy of choice for 
asthma and chronic obstructive pulmonary disease (COPD). Dry powder inhalers (DPIs) 
require an internal turbulent energy to be generated inside the device during an inhalation 
to lift the powder formulation from the metering system and disperse the emitted dose that 
contains particles with the potential for lung deposition. This internal turbulent energy is 
created by the interaction between the inhalation profile generated from the patient’s 
inspiratory effort and the intrinsic resistance of the inhaler device (Chrystyn, 2003). Thus, 
aerosol generation within DPIs and the release of a dose for delivery to the lungs of 
patients are dependent on patient variability such as the inhalation flow, its acceleration 
rate, the inhalation volume and the number of inhalations per dose.  
The pharmaceutical performance of inhaled products can be characterised by the emitted 
dose, fine particle dose and its aerodynamic particle size distribution. The efficacy and 
safety of an inhaled product are related to these parameters. In addition, they are often used 
to predict lung deposition and systemic delivery. The total emitted dose from a DPI can be 
measured in vitro using the uniformity of dose sampling apparatus described by the 
Pharmacopoeias (USP, 2009; EP, 2007; BP, 2008). According to these Pharmacopoeias, 
DPIs should be tested using a constant airflow drawn from a vacuum pump corresponding 
to a pressure drop of 4kPa across the inhaler using an inhalation volume of 4L. However, 
patients inhale at varying flows and volumes through DPIs. Furthermore, when patients 
inhale through a DPI, the inhalation volume is less than 4L, for example, it has been 
reported that the inhaled volume of asthmatic and COPD patients when using a DPI is 
about 2L (Hawskworth, et al., 2000). Also studies have shown that DPIs operate 
effectively at peak inhalation flows >30 Lmin
-1
 and that the optimum flows for DPIs in 
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terms of the total emitted dose and fine particle dose is >60 Lmin
-1
 (Bisgaard et al. 1998; 
Nielsen et al. 1998). Other studies have shown that some patients, especially those with 
COPD (Broeders et al. 2003) and children with severe asthma (Pedersen et al, 1990) were 
not able to generate the minimum flows through a DPI that is required to generate an 
emitted dose with the required characteristics for lung deposition. It is possible that these 
patients may require two inhalations in order to maximise the generation and the release of 
a dose for delivery to the lungs. At present unless the DPI is presented as a single dose 
capsule then patient information leaflets instruct that patients should inhale once per 
metered dose. 
Since DPIs are tested using specific inhalation criteria that do not represent that of patients 
then it is important to assess the effects and influence of inhalation flow, inhalation volume 
and the number of inhalations. Hence, this study was designed to determine the dose 
emission from the Accuhaler®, the Clickhaler®, and the Easyhaler®,  all containing 
salbutamol sulphate and the Turbuhaler®,  containing terbutaline sulphate, following one 
and two inhalations at varying inhalation flows (10-60 L/min), using inhalation volumes of 
2 and 4L .  
 The aims of this study were to use in-vitro studies to:  
• Determine the effects of different inhalation rates and inhalation volume on the 
emitted dose from the Accuhaler®, the Easyhaler®, the Clickhaler® and the 
Turbuhaler®.  
• Identify if there is a difference in the emitted dose from the above mentioned 
inhalers, when inhaling once or twice per dose. 
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4.2 Method 
4.2.1 Instrumentation and inhaler devices 
 DPI sampling apparatus (Copley Scientific Ltd, UK) 
 A/E fibre glass filter discs 47 mm (Pall Corporation, New York, USA). 
 Vacuum pump GAST 1023-703QER56X (Brook Crompton, UK). 
 Flow meter (Model DFM, Copley Scientific Ltd, UK) 
 Integrated mass flow meter-pressure transducer (MKS Instruments, USA) 
 Parafilm M Laboratory parafilm (American National Can, USP) 
Inhaler devices: Ventolin® Accuhaler® [ACC] containing salbutamol sulphate 200 µg per 
dose (GlaxoSmithKline); Clickhaler® [CLICK] containing salbutamol sulphate 114 µg per 
dose; Easyhaler® [EASY] containing salbutamol sulphate 200 µg per dose (Orion Pharma, 
Finland) and Bricanyl® Turbuhaler® [TBH] containing terbutaline sulphate 500 µg per 
dose, (Astra Zeneca, UK). 
4.2.2 Procedure 
The duration of inspiration (inhalation time) was set to allow inhalation volumes of 2 and 
4L using the relation described in the USP (2005). 
Time T = (60 sec x V) / Q  
T = duration of inspiration consistent with withdrawal of air from the inhaler 
Q = inhalation rate 
V = 2L or 4L to be drawn through the inhaler    
Table 4.1 Calculated inhalation time (sec) 
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Table  4.1 Calculation of inhalation time  
 
Inhalation flow  
 (L min
-1
 )  
Time  T (sec)  
2L 
Time  T (sec)  
 4L 
   
10 
20 
30 
40 
60 
12 
6 
4 
3 
2 
24 
12 
8 
6 
4 
The emitted dose from each type of inhaler was measured using a DPI sampling apparatus 
as shown in Figure 4.1. The inhaler device was inserted into a mouthpiece adapter in an air 
tight chamber aligned along the horizontal axis with the sampling tube. The other side of 
the chamber was connected to the flow meter (Model MKS). A tube (T1) from the 
chamber was connected to one end of the pressure transducer and another tube (T2) from 
the sampling unit was connected to the other end of the pressure transducer as shown in 
Figure 4.1. This enabled pressure drop across the device to be monitored. 
 
Figure  4.1 A Schematic diagrams of dose emission apparatus 
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The sampling apparatus was then connected to a critical flow controller (Model TPK) via a 
tube T3. The critical flow controller contains a two-way solenoid valve which controls the 
time and the pressure of the airflow. The two-way valve enabled air to be drawn through 
the mouthpiece of the inhaler at a set flow by a vacuum pump. The inhalation flow through 
the mouthpiece of each type of inhaler was set at 10, 20, 30, 40 and 60 L min
-1 
 with 
corresponding calculated flow-durations as shown in Table 4.1 to allow the inhaled 
volumes of 2L and 4L respectively to be drawn through the inhaler (BP, 2005; USP, 2005). 
Critical (sonic) flow was ensured during each operation (absolute pressure ratio P3/P2 
should be less or equal to 0.5).  
Ten separate inhalers of each inhaled products were used in the study. For each 
determination a single dose was used. Each type of inhaler was loaded according to the 
instructions in the patient information leaflet and inserted into the dose sampling tube. 
Then the TPK timer controlling the solenoid valve was activated once to discharge the 
metered dose into the sampling tube at each set inhalation flow. Following discharge the 
inhaler device was flushed to waste at flow of 90 L min
-1
 for sixteen seconds to remove 
any remaining powder before proceeding to the next determination. The sampling tube and 
the filter were rinsed with standard aqueous bamethane solution (8000 µgL
-1
) and the 
resultant solution was placed in a sonic bath for three minutes. Preliminary analysis 
(sections 3.2.8 and 3.3.5) revealed that this procedure removes the entire entrained drug on 
the filter. All the solutions were collected and made up to a volume of 50, 50, 100, 100, 
and 100ml, for the flow of 10, 20, 30, 40, and 60 L min
-1
, respectively. The amount of 
active drug collected on the filter and deposited on the wall of the tube was determined by 
high liquid performance chromatography (HPLC) described in chapter 3.  
This procedure was repeated for each determination using two inhalations per metered 
dose, except that the TPK timer controlling the solenoid valve was activated twice to 
obtain two separate discharges of powder into the sampling tube at each set inhalation flow.  
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A total of ten doses (randomised), three at the beginning, four in the middle and three 
drawn at the end of the lifetime of each type of inhaler as shown in the Table below, were 
analysed at each inhalation flow following one and two inhalations per dose for 2L and 4L 
inhaled volume respectively. 
Turbuhaler 
label claim 100 doses 
Easyhaler and  
Clickhaler 200 doses 
 Accuhaler 
60 doses 
Discharge 
1 1 1 waste 
2, 3, 4 2, 3, 4 2, 3, 4 collect 
5-48 5-98 5-28 waste 
49, 50, 51, 52 99, 100, 101, 102 29, 30, 31, 32 collect 
53-97 103-197 33-57 waste 
98, 99, 100 198, 199, 200 58, 59, 60 collect 
 
4.2.3 Analysis of data 
The emitted dose as determined from the dose sampling unit was calculated as µg per dose. 
Since the label claims of the studied inhalers differ, the emitted dose from each inhaler was 
expressed as a percentage of the nominal dose (label claim). 
4.2.4 Statistical analysis 
SPSS version 15.0 software (SPSS Inc., Chicago, USA) was used for the statistical 
analysis. A two-way analysis of variance (ANOVA) with the application of the General 
Linear Model Univariate was used to determine any significant differences in the emitted 
dose from four different inhalers under different flows. Also the statistical comparisons of 
the emitted dose between two different inhalation volumes as well as between one and two 
inhalations for each metered dose under the same flows were made. The mean difference 
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(95% confidence interval) was calculated and a probability value of p<0.05 was considered 
being significant. 
4.3 Results 
The individual emitted dose from the Accuhaler, Easyhaler, Clickhaler and Turbuhaler 
used in this study was expressed as a percentage of the nominal dose (the label claim). The 
individual emitted dose, mean (n=10), SD and RSD of the total emitted dose from each dry 
powder inhalers (DPIs) at varying inhalation flows (10-60 Lmin
-1
) following one and two 
inhalations using 2L and 4L inhaled volume respectively are shown in Tables 4.2 to 4.9.  A 
summary of  the total emitted dose, expressed as % nominal dose from the four dry powder 
inhalers at varying inhalation flows (10-60 Lmin
-1
) using 2L and 4L inhalation volumes 
following one and two inhalations per metered dose respectively is shown in Table 4.10. 
Figures 4.2 to 4.5 describe the variation of the emitted dose from the Accuhaler, Easyhaler, 
Clickhaler and Turbuhaler with respect to the inhalation flow under the same inhalation 
volumes and the number of inhalations. 
Tables 4.11 and 4.12 show  the statistical comparison of the emitted dose (% nominal dose) 
from four different dry powder inhalers at varying inhalation flows (10-60) Lmin
-1  
using a 
2L and a 4L inhaled volume respectively. This highlights the effect of the inhalation flow 
on the emitted dose from the inhalers.  
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Table  4.2 Emitted dose of salbutamol sulphate, expressed as % nominal dose, from the Accuhaler (salbutamol sulphate 200 µg / nominal dose) at 
different inhalation rates following one and two inhalations per metered dose using a 2L inhaled volume 
  Emitted dose of salbutamol sulphate (% nominal dose) 
Inhalation flow 
(L min
-1
) 10  20  30  40  60  
No. of 
inhalations one two one two one two one two one two 
Dose 
1 49.37 53.30 32.78 51.06 79.03 81.65 63.35 68.39 87.35 89.39 
2 50.27 52.11 49.14 65.16 61.4 61.4 67.39 67.39 87.65 87.65 
3 53.78 51.70 63.14 80.69 62.38 64.97 76.91 76.91 84.02 84.02 
4 48.78 61.69 50.78 58.64 71.3 71.3 73.73 73.73 88.4 88.4 
5 53.98 58.10 65.28 66.59 62.51 67.45 61.03 62.12 83.1 86.61 
6 43.68 58.62 56.78 67.93 66.28 68.39 71.38 71.38 87.71 90.34 
7 49.62 56.33 66.75 67.79 67.68 69.43 97.5 97.5 83.58 88.7 
8 52.64 52.91 43.93 57.02 73.42 82.67 67.88 72.57 81.92 84.52 
9 50.79 55.13 50.2 55.72 63.59 80.7 81.33 86 78.28 80.48 
10 46.76 57.18 47.57 48.18 69.63 74.47 65.56 77.88 75.57 75.86 
Mean 49.97 55.71 52.64 61.88 67.72 72.24 72.61 75.39 83.76 85.60 
SD 3.17 3.26 10.56 9.63 5.69 7.79 11.07 10.72 3.39 3.14 
RSD 6.34 6.52 14.82 16.14 11.40 14.78 12.52 13.30 8.60 9.07 
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Table  4.3 Emitted dose of salbutamol sulphate, expressed as % nominal dose, from the Accuhaler (salbutamol sulphate 200 µg / nominal dose) at 
different inhalation rates following one and two inhalations per metered dose using a 4L inhaled volume 
  Emitted dose of salbutamol sulphate (% nominal dose) 
Inhalation flow 
(L min
-1
) 10 20 30 40 60 
No. of 
inhalations one two one two one two one two one two 
Dose 
1 56.86 53.88 57.47 63.68 74.55 74.55 65.11 73.16 84.48 84.48 
2 37.45 57.22 50.38 54.52 81.57 81.57 66.32 66.32 85.67 94.52 
3 54.13 62.90 63.6 67.96 70.76 70.76 95.97 99.63 80.28 85.33 
4 50.45 61.16 50 53.55 75.24 77.8 74.1 74.1 88.73 88.73 
5 62.03 59.94 58.77 60.61 75.93 79.56 75.21 75.31 78.19 78.19 
6 56.49 58.44 41.56 42.61 75.79 81.43 78.71 78.95 82.56 82.56 
7 54.62 63.84 64.3 73.07 75.01 75.36 84.09 84.31 79.19 79.19 
8 49.78 59.46 65.87 71.77 71.81 71.81 67.96 68.65 83.71 83.71 
9 60.79 54.84 65.21 65.21 76.77 76.77 79.18 79.18 77.23 77.23 
10 57.34 60.26 75.11 75.11 79.86 79.86 76.31 76.31 76.85 76.85 
Mean 53.99 59.19 59.23 62.81 75.73 76.95 76.30 77.59 81.69 83.08 
SD 7.00 3.21 9.75 10.20 3.24 3.89 9.76 9.87 3.80 5.47 
RSD 12.96 5.42 14.03 14.49 4.26 4.77 12.06 12.00 4.89 6.78 
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Table  4.4 Emitted dose of salbutamol sulphate, expressed as % nominal dose, from the Easyhaler salbutamol sulphate (200 µg / nominal dose) at 
different inhalation rates following one and two inhalations per metered dose using a 2L inhaled volume 
 Emitted dose of salbutamol sulphate (% nominal dose) 
Inhalation 
flow 
(L min
-1
) 10 20 30 40 60 
No. of 
inhalations one two one two one two one two one two 
Dose 
1 34.72 68.28 63.17 72.14 69.09 75.38 75.49 86.25 97.34 111.28 
2 44.19 48.49 64.94 73.28 77.88 84.31 77.65 90.13 68.9 81.06 
3 31.35 50.65 60.35 69.61 76.25 82.11 85.79 96.06 85.71 97.41 
4 36.49 49.74 63.14 68.1 81.48 89.36 76.9 87.67 73 86.35 
5 35.05 51.62 72.25 77.65 76.25 86.23 71.8 94.28 68.58 83.6 
6 33.79 63.11 67.95 123.56 74.7 83.39 79.96 102.25 77.41 93.4 
7 40.12 47.28 61.48 67.72 65.47 72.96 75.12 86.18 69.47 85.63 
8 37.96 62.68 76.44 81.09 80 85.89 72.28 81.64 78.69 94.34 
9 34.08 52.33 76.69 82.88 67.72 75.77 71.06 79.53 80.69 99.6 
10 36.79 49.13 77.06 83.41 61.95 70.25 78 89.74 74.7 91.01 
Mean 36.45 54.33 68.35 79.94 73.08 80.57 76.41 89.37 77.45 92.37 
SD 3.64 7.44 6.69 16.44 6.59 5.68 4.63 7.20 9.42 9.53 
RSD 9.99 13.70 9.29 7.96 9.10 8.13 5.76 7.59 11.54 9.74 
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Table  4.5 Emitted dose of salbutamol sulphate, expressed as % nominal dose, from the Easyhaler (salbutamol sulphate 200 µg / nominal dose) at 
different inhalation rates following one and two inhalations per metered dose using a 4L inhaled volume 
  Emitted dose of salbutamol sulphate (% nominal dose)     
Inhalation 
flow 
(L min
-1
)  10 20 30 40 60 
No. of 
inhalations  one two one two one two one two one two 
Dose 
1 33.9 43.19 67.05 71.23 70.04 80.12 70.18 82.57 79.91 96.12 
2 37.4 48.63 68.44 72.68 61.08 83.37 79.11 92.43 74.97 91.37 
3 42.6 51.38 82.74 88.13 79.63 88.5 82.90 94.46 79.86 96.12 
4 34.19 43.28 82.97 94.41 69.14 78.52 84.20 95.65 73.46 91.33 
5 41.84 51.51 55.18 61.77 72.49 83.04 89.61 100.29 86.76 105.28 
6 33.29 40.62 87.27 92.61 91.28 101.63 74.89 88.65 82.48 99.49 
7 36.62 43.61 70.45 76.62 93.46 104.05 73.05 84.12 90.08 107.67 
8 33.94 45.62 82.87 94.43 75.49 85.84 76.14 89.69 78.38 94.88 
9 41.09 38.17 70.38 75.02 70.79 79.56 74.55 88.80 90.68 108.33 
10 35.48 45.12 70.95 77.10 64.69 75.54 81.05 93.76 80.66 94.95 
Mean 37.04 45.11 73.83 80.40 74.81 86.02 78.57 91.04 81.72 98.55 
SD 3.57 4.35 9.89 11.29 10.59 9.43 6.21 5.61 6.20 6.64 
RSD 9.64 9.65 9.29 7.96 9.10 8.13 5.76 7.59 11.54 9.74 
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Table  4.6 Emitted dose of salbutamol sulphate, expressed as % nominal dose, from the Clickhaler (salbutamol sulphate 114µg / nominal dose) at 
different inhalation rates following one and two inhalations per metered dose using a 2L inhaled volume 
  Emitted dose of salbutamol sulphate (% nominal dose) 
Inhalation flow 
(L min
-1
)  10 20 30 40 60 
No. of 
inhalations one two one two one two one two one two 
Dose 
1 28.02 39.67 45.55 56.13 38.99 45.22 48.85 57.86 82.22 88.8 
2 25.65 30.92 44.06 50.91 54.78 54.78 56.80 62.37 93 101.52 
3 28.92 32.71 39.66 43.42 60.44 60.44 64.56 69.74 91.53 96.74 
4 27.5 31.51 57.43 58.06 52.89 52.89 56.93 63.57 91.92 97.84 
5 27.8 34.46 36.32 36.32 67.56 67.56 57.74 65.05 91.44 96.17 
6 23.52 28.58 41.06 41.06 51.63 51.63 63.28 68.80 82.62 87.24 
7 24.48 30.08 41.71 41.71 51.06 51.06 60.68 66.01 77.08 81.84 
8 35.17 25.80 55.76 63.97 39.07 39.07 64.97 69.47 77.99 82.56 
9 27.05 25.04 51 59.40 46.32 46.32 74.22 80.40 79.95 85.59 
10 32.68 31.30 52.93 60.22 46.18 46.18 80.42 85.26 76.7 81.94 
Mean 28.08 31.01 46.55 51.12 50.89 51.52 62.85 68.85 84.45 90.02 
SD 3.55 4.21 7.28 9.76 8.90 8.16 7.08 6.30 6.58 7.25 
RSD 12.62 13.59 14.83 19.10 17.49 16.79 14.47 12.02 8.02 8.22 
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Table  4.7 Emitted dose of salbutamol sulphate, expressed as % nominal dose, from the Clickhaler (salbutamol sulphate 114µg / nominal dose) at 
different inhalation rates following one and two inhalations per metered dose using a 4L inhaled volume 
  Emitted dose of salbutamol sulphate (% nominal dose) 
Inhalation flow 
(L min
-1
)  10 20 30 40 60 
No. of 
inhalations one two one two one two one two one two 
Dose1 23.62 24.61 42.22 47.21 68.48 73.36 76.58 81.77 77.89 84.63 
2 28.85 35.87 50.32 57.72 54.17 60.86 49.59 54.04 100.24 104.89 
3 34.33 37.21 46.68 55.31 59.59 65.25 67.81 74.85 78.34 83.44 
4 30.32 38.32 47.87 54.37 54.7 60.08 63.88 68.97 81.44 86.40 
5 32.12 42.85 44.22 50.29 53.19 62.06 63.51 68.49 90.76 95.62 
6 23.61 33.55 59.25 66.27 50.01 53.93 64.96 69.74 82.73 92.19 
7 32.21 27.38 46.74 53.27 49.99 53.83 66.21 71.4 101.51 106.96 
8 24.25 27.02 61.77 67.38 52.46 55.92 75.17 80.55 80.48 86.22 
9 22.71 25.41 59.36 65.13 50.12 54.39 75.39 80.97 90.19 94.69 
10 25.94 34.62 53.34 80.17 53.16 57.76 67.57 72.73 84.04 90.50 
Mean 27.80 32.68 51.18 59.71 54.59 59.74 67.07 72.35 86.76 92.55 
SD 4.29 6.22 6.91 9.93 5.66 6.46 8.36 8.70 9.08 8.64 
RSD 15.42 19.04 12.80 16.64 10.41 10.30 11.76 11.34 9.93 8.84 
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 Table  4.8 Emitted dose of terbutaline sulphate, expressed as % nominal dose, from the Turbuhaler (terbutaline sulphate emitted dose 500µg / nominal 
dose) at different inhalation rates following one and two inhalations per metered dose using a 2L inhaled volume 
  Emitted dose of terbutaline sulphate (%nominal dose) 
Inhalation flow 
(L min
-1
)  10 20 30 40 60 
No. of 
inhalations one two one two one two one two one two 
Dose 
1 25.36 50.25 40.04 52.18 51.78 46.06 47.07 47.73 76.25 77.39 
2 20.67 49.61 36.72 52.89 52.76 42.2 51.62 59.178 63 63.11 
3 28.69 49.64 38.35 54.99 54.5 43.97 54.55 54.85 66.41 69.58 
4 31.47 41.85 33.08 54.32 54.32 35.56 55.31 58.06 63.67 69.41 
5 21.25 38.79 53.16 52.23 52.23 55.92 53.08 53.33 63.94 69.28 
6 21.07 47.01 44.71 47.7 46.74 51.83 57.32 57.32 64.12 64.12 
7 27.25 43.29 50.34 40.63 40.63 55.82 57.87 57.9 64.96 66.29 
8 23.13 40.38 52.63 42.3 40.87 61.8 50.23 50.63 62.39 62.39 
9 25.18 36.71 49.63 37.39 37.39 56.55 50.73 50.73 62.93 62.93 
10 20.02 45.15 62.14 50.61 50.61 69.82 51.77 51.88 64.4 64.4 
Mean 24.41 44.27 46.08 48.52 48.18 51.95 52.96 54.16 65.21 66.89 
SD 3.86 4.84 9.05 6.58 6.35 10.17 3.36 3.89 4.04 4.64 
RSD 15.80 10.92 18.62 12.67 12.98 19.56 6.33 7.23 6.21 6.55 
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Table  4.9 Emitted dose of terbutaline sulphate, expressed as % nominal dose, from the Turbuhaler (terbutaline sulphate emitted dose 500µg / nominal 
dose) at different inhalation rates following one and two inhalations per metered dose using a 4L inhaled volume 
   Emitted dose of terbutaline sulphate (%nominal dose) 
Inhalation flow 
(L min
-1
)  10 20 30 40 60 
No. of 
inhalations one two one two one two one two one two 
Dose 
1 22.11 23.79 55.78 56.06 42.87 44.6 41.71 42.39 70.75 70.75 
2 34.93 36.13 43.08 43.08 53.95 55.16 59.55 60.56 74.54 76.59 
3 32.52 45.27 48.36 49.32 49.01 49.85 60.82 62.15 70.32 70.32 
4 41.59 37.79 46.87 46.96 50.07 50.17 61.89 62.61 70.31 72.8 
5 20.47 46.28 46.56 49.89 49.2 50.37 46.27 48.67 67.33 69.27 
6 42.75 22.98 50.1 50.22 48.34 49.79 67.33 67.97 70.28 73.44 
7 23.05 33.58 43.53 43.53 47.92 49.23 63.99 64.4 74.6 77.35 
8 36.39 40.97 48.92 49.38 61.59 61.59 55.71 56.48 74.98 77.98 
9 34.13 39.82 47.89 48.4 54.68 55.64 59.19 59.82 72.97 74.97 
10 31.65 33.45 49.42 49.51 55.84 55.84 55.83 56.32 71.4 72.3 
Mean 31.96 36.01 48.05 48.64 51.35 52.22 57.23 58.14 71.75 73.58 
SD 7.83 7.92 3.58 3.66 5.24 4.91 8.33 8.07 2.61 3.21 
RSD 24.49 22.01 7.45 7.53 10.21 9.20 13.72 13.11 3.44 4.15 
 
 123
Table  4.10 Mean (SD) total emitted dose, as % nominal dose from the four different dry powder inhalers following one and two inhalations per 
metered dose for 2L and 4L inhalation volumes  
  
Mean (SD) total emitted dose (% nominal dose) following one inhalation  
 
Device Accuhaler Easyhaler Clickhaler Turbuhaler 
Inhalation volume 2L 4L 2L 4L 2L 4L 2L 4L 
Inhalation flow 
(L min
-1
)                 
10 49.97 (3.2) 53.99 (7.0) 36.45 (3.6) 37.04 (3.6) 28.08 (3.6) 27.80 (4.3) 24.41 (3.9) 31.96 (7.8) 
20 52.64(10.6) 59.23 (9.6) 68.35 (6.7) 73.83 (9.9) 46.55 (7.3) 51.18 (6.9) 46.08 (9.1) 48.05 (3.6) 
30 67.72 (5.7) 75.73 (3.2) 73.08 (6.6) 74.81 (10.6) 50.89 (8.9) 54.59 (5.7) 48.18 (6.4) 51.35 (5.2) 
40 72.61(11.1) 76.30 (9.8) 76.41 (4.6) 78.57 (6.2) 62.85 (7.1) 67.07 (8.4) 52.96 (3.4) 57.23 (8.3) 
60 83.76 3.4) 81.69 (3.8) 77.45 (9.4) 81.72 (6.6) 84.45 (6.6) 86.76 (9.1) 65.21 (4.0) 71.75 (2.6) 
  
Mean (SD) total emitted dose (% nominal dose)  following two inhalations 
 
Device Accuhaler Easyhaler Clickhaler Turbuhaler 
Inhalation volume 2L 4L 2L 4L 2L 4L 2L 4L 
Inhalation flow 
(L min
-1
)                
10 55.71(3.3) 59.19(3.2) 54.33(7.4) 45.11(4.4) 31.01(4.2) 32.68(6.2) ) 44.27(4.8) 36.01(7.9) 
20 61.88(9.6) 62.81(10.2) 79.94(16.4) 80.40(11.3) 51.12(9.8) 59.71(9.9) 48.52(6.6) 48.64(37) 
30 72.24(7.8) 76.95(3.9) 80.57(5.7) 86.02(9.4) 51.52(8.2) 59.74(6.5) 51.95(10.2) 52.22(4.9) 
40 75.39(10.7) 77.59(9.9) 89.37(7.2) 91.04(5.61) 68.85(7.1) 72.35(8.7) 54.16(3.9) 58.14(8.1) 
60 85.60(3.1) 83.08(5.5) 92.37(9.5) 98.55(6.6) 90.02(7.3) 92.55(8.6) 66.89(4.6) 73.58(3.2) 
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Figure  4.2 Total emitted dose, as % nominal dose, of salbutamol sulphate from the 
Accuhaler at different inhalation flows (10-60) Lmin
-1 
 
 
Figure  4.3 Total emitted dose, as % nominal dose, of salbutamol sulphate from the 
Easyhaler at different inhalation flows (10-60) Lmin
-1 
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Figure  4.4 Total emitted dose, as % nominal dose, of salbutamol sulphate from the 
Clickhaler at different inhalation flows (10-60) Lmin
-1 
 
 
Figure  4.5 Total emitted dose, as % nominal dose, of terbutaline sulphate from the 
Turbuhaler at different inhalation flows (10-60) Lmin
-1 
 
 
 126
Table  4.11 Statistical comparison of the emitted dose (% nominal dose) from the four different dry powder inhalers at varying inhalation flows (10-60) 
Lmin
-1  
using a 2L inhaled volume  
Inhalation flow 
(Lmin
-1
) 
Mean difference (95 % confidence interval) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10vs20 -2.66 (-10.08, 4.74) -31.89(-37.45, -26.32) -18.47*(-22.80, -14.13) -21.67*(-30.01, -13.32) 
10vs30 -17.75***(-22.87, -12.63) -36.62**(-41.89, -31.35) -22.81***(-30.53, -15.09) -23.77*(-28.89, -18.65) 
10vs40 -22.63***(-30.72,  -14.55) 39.95***(-44.52, -35.37) -34.76***(-40.76, -28.76) -28.54**(-31.72, -25.37) 
10vs60 -33.79***(-37.84, -29.74) -40.99***(-49.15, -32.83) -56.36***(-62.45, -50.27) -40.79***(-44.41, -37.18) 
20vs30 -15.08*** (-22.61, -7.55) -4.70(-11.35, 1.95) -4.34(-12.06, 3.37) -2.10(-8.38, 4.17) 
20vs40 -18.55***(-26.35, -10.75) -7.96*(-14.81, -1.30) -16.29***(-24.01, -8.57) -6.87*(-13.15, -0.59) 
20vs60 -31.12*** (-38.65, -23.59) -9.00**(-15.66, -2.35) -37.89***(-45.61, -30.17) -9.28**(-15.56, -3.00) 
30vs40 -3.46 (-11.27, 4.33) -3.26(-9.91, 3.39) -11.95*(-19.675, -4.23) -4.77(-11.05, 1.50) 
30vs60 -16.03(-23.56, -8.50) -4.30(-10.95, 2.35) -33.55***(-41.27, -25.83) -7.18*(-13.46, -0.90) 
40vs60 -12.56** (-20.36, -4.76) -1.04(-7.69, 5.61) -21.60***(-29.32, -13.87) -2.41(-8.69, 3.86) 
*The mean difference is significant *(P<0.05); ** (P<0.01); *** (P<0.001) 
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Table  4.12 Statistical comparison of the emitted dose (% nominal dose) from the four different dry powder inhalers at different inhalation flows (10-60) 
Lmin
-1 
using a 4L inhaled volume  
Inhalation flow 
(Lmin
-1
) 
Mean difference ( 95% confidence interval) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10vs20 -5.23(-12.40, 1.94) -36.79*(-45.26, -28.32) -23.38*(-30.65, -16.10) -16.09*(-22.42, -9.76) 
10vs30 -21.73**(-27.84, -15.63) -37.77*(-45.98, -29.56) -26.79**(-31.87, -21.71) -19.38***(-24.69, -14.08) 
10vs40 22.3***(-29.05, -15.63) -41.53**(-45.28, -37.77) -39.21***(-46.85, -31.68) -25.27***(-29.72, -20.81) 
10vs60 -27.69***(-34.90, -20.48) -44.68**(-48.52, -40.85) -58.96*(-65.04,-52.89) -39.78***(-45.36,-34.21) 
20vs30 -16.50***(-23.49, -9.50) -0.97 (-8.59, 6.63) -3.41(-10.84, 4.02) -3.29(-8.08, 1.49) 
20vs40 -17.06***(-24.07, -10.07) -4.73(-12.35, 2.87) -15.89***(-23.32, -8.45) -9.17***(-13.97, -4.38) 
20vs60 -22.46***(-29.45, -15.46) -7.89*(-15.51, -0.27) -35.58***(-43.02, -28.14) -23.69***(-28.49, -18.90) 
30vs40 -0.57 (-7.56, 6.42) -3.75(-11.37, 3.85) -12.48**(-19.91, -5.04) -5.88*(-10.67, -1.08) 
30vs60 -5.96 (-12.95, 1.04) -6.91(-14.53, 0.70) -32.17***(-39.61, -24.73) -20.40***(-25.19, -15.60) 
40vs60 -5.39 (-12.38 , 1.60) -3.15(-10.77, 4.46) -19.69***(-27.13, -12.25) -14.51***(-19.31, -9.72) 
*The mean difference is significant *(P<0.05); ** (P<0.01); *** (P<0.001) 
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Figure 4.6 describes the effect of a 2L inhaled volume and a 4L inhaled volume on the 
emitted dose at each inhalation flow with one inhalation per metered dose. Table 4.12 
presents a statistical comparison of these results. 
Figures 4.7 and 4.8 describe the difference in the emitted dose from the Accuhaler, 
Easyhaler, Clickhaler and Turbuhaler between one inhalation and two inhalations at each 
inhalation flow for a 2L and a 4L inhaled volume. Tables 4.13 and 4.14 show the statistical 
comparison of the emitted dose (% nominal dose) from the four dry powder inhalers 
between one and two inhalations per metered dose at each inhalation flow using 2L and 
4Linhaled volumes. 
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Figure  4.6 Mean emitted dose, as % nominal dose, from the four different dry powder 
inhalers at different inhalation flows (10-60) Lmin
-1
 following one inhalation per metered 
dose for 2L and 4L inhalation volumes 
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Table  4.13 Statistical comparison of the emitted dose (% nominal dose) from the four different dry powder inhalers between 2L and 4L inhaled 
volumes each inhalation flow  
Inhalation flow 
(Lmin
-1
) 
Mean difference ( 95% confidence interval) 
(2L vs. 4L) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10 -4.02(-9.54, 1.48) -0.58(-4.72, 3.55) 0.28(-4.03, 4.60) -7.55(-13.58, -1.51) 
20 -6.59(-17.04, 3.86) -5.48(-14.67, 3.70) -4.62(-9.96, 0.71) -1.97(-8.87, 4.92) 
30 -8.00*(-13.21, -2.80) -1.73(-11.04, 7.58) -3.69(-11.92, 4.53) -3.16(-10.11, 3.78) 
40 -3.69(-10.37, 2.99) -2.16(-7.10,2.77) -4.22(-11.90, 3.46) 4.27(-8.36, -0.19) 
60 2.06*(0.23, 3.90) -4.27(-12.21, 3.66) -2.31(-10.09, 5.45) 6.34*(-10.27, -2.80) 
*The mean difference is significant *(P<0.05); ** (P<0.01); *** (P<0.001)  
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Figure  4.7 Mean (SD) total emitted dose, as % nominal dose, from the four different dry 
powder inhalers at different inhalation flows (10-60) Lmin
-1 
 following one and two 
inhalations per metered dose for a 2L inhaled volume 
 
Figure  4.8 Mean  (SD) total emitted dose, as % nominal dose, from the four different dry 
powder inhalers at different inhalation flows (10-60) Lmin
-1 
 following one and two 
inhalations per metered dose for a 4L inhaled volume 
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Table  4.14 Statistical comparison of the emitted dose (% nominal dose) from the four different dry powder inhalers between one and two inhalations 
per metered dose at each inhalation flow using 2L inhaled volume 
Inhalation flow 
(Lmin
-1
) 
Mean difference ( 95% confidence interval) 
(one vs. two inhalations) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10 -6.24**(-10.93, -1.54) -17***(-24.53, -11.22) -2.92(-7.08, 1.22) 19.85*(-24.38, -15.33) 
20 -9.24**(-14.22, -4.26) -6.59***(-7.78, -5.40) -4.57**(-7.54, -1.59) -5.87***(-7.35, -4.39) 
30 -4.55*(-8.26, -0.85) -7.48***(-8.45, -6.51) 0.00 (0.00, 0.00) -0.33 (-0.68, 0.02) 
40 -2.78 (-5.65, 0.089) -12.96***(-16.60, -9.32) -6.00***(-6.97, -5.04) -1.20 (-2.90, 0.49) 
60 -1.84 (-3.107, -0.59) -14.91***(-16.47, -13.36) -5.57***(-6.45, -4.70) -1.68*(-3.30, -0.06) 
*The mean difference is significant *(P<0.05); ** (P<0.01); *** (P<0.001) 
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Table  4.15 Statistical comparison of the emitted dose (% nominal dose) from the four different dry powder inhalers between one and two inhalations 
per metered dose at each inhalation flow using 4L inhaled volume 
Inhalation flow 
(Lmin
-1
) 
Mean difference ( 95 % confidence interval) 
(one vs. two inhalations) 
 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10 -5.20**(-10.80, 0.40) -8.07***(-11.03, -5.12) 4.88**(-8.35, -1.42) -4.04(-12.45, 4.35) 
20 -3.58** (-5.65, -1.51) -6.57***(-8.51, -4.62) -8.53**(-13.19, -3.87) -0.58 (-1.30, 0.13) 
30 -14.13** (-23.29, -4.98) -11.20***(-14.04, -8.37) -5.15***(-6.31, -3.99) -0.87**(-1.32, -0.42) 
40 -1.29 (-3.17, 0.58) -12.47***(-13.36, -11.58) -5.28***(-5.77, -4.79) -0.90***(-1.32, -0.48) 
60 -1.39 (-3.58, 0.80) -16.83***(-17.68, -15.98) -5.79***(-6.85, -4.72) -1.82***(-2.65,-1.00) 
*The mean difference is significant *(P<0.05); ** (P<0.01); *** (P<0.001) 
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4.4 Discussion  
In this chapter the total emitted dose from the Accuhaler®, the Turbuhaler, ® the 
Clickhaler® and the Easyhaler® DPIs as a function of inhalation flow, inhalation volume 
and the number of inhalations per metered dose has been evaluated. Each of these inhalers 
differs in device-design and formulation. 
The Accuhaler® contains multiple unit doses that are each dose factory dispensed in a 
sealed blister on a long strip. In contrast, the Turbuhaler®, Clickhaler® and Easyhaler® 
are the reservoir-type of multidose inhalers. In this type of inhalers, the powder 
formulation is stored in a reservoir from which single doses are volumetrically measured 
and dispensed using a special dose metering unit. The powder formulations in these 
devices also differ. The Accuhaler, Clickhaler, and Easyhaler-all contain salbutamol 
formulated from the admixture of pure drug and lactose carrier, while the Turbuhaler 
contains terbutaline formulated from pure spherical pellets of the pure drug. Thus, it is 
possible that the effects of the inspiratory parameters on the total emitted dose may differ.  
Several in-vitro studies have shown that the emitted dose from different DPIs varied with a 
change in the inhalation flow to a varying extent (de Boer et al, 1996; Malton et al, 1995; 
Palander et al, 2000; Tarsin et al, 2004). Tarsin et al. (2004) have measured the in-vitro 
dosage emission and the fine particle dose (FPD) from 100/6 and 200/6 Symbicort 
Turbuhalers (budesonide and formoterol) at different flows (30, 60 and 90 Lmin
-1
). The 
data showed that the amounts of budesonide and formoterol emitted from the Symbicort 
100/6 and Symbicort 200/6 inhalers were affected by the increased inhalation flow. 
Similarly Palander et al, 2000 using the Accuhaler, Easyhaler and Turbuhaler showed that 
the mean (SD) emitted dose (% nominal dose) of salbutamol increased from 76 (12), 
95(4.8), and 72(22) at inhalation flow 30 Lmin
-1
 to
 
92(9), 95 and 88(19) at inhalation flow 
of 60 Lmin
-1
 respectively. A study by de Boer et al (1996) showed that the emitted dose 
from three different DPIs (Spinhaler, Turbuhaler and Diskhaler) significantly increased 
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with an increase in inhalation flow. The Diskhaler was the most sensitive to inhalation 
flow, emitting <30% of the claimed label dose at 20 Lmin
-1
. The results identified in this 
chapter indicated that the total emitted dose (% nominal dose) from the Accuhaler, 
Easyhaler®, Clickhaler® and Turbuhaler® increased to varying extent with respect to the 
inhalation flow within the flow range of 10 to 60 Lmin
-1 
when tested using the same 
inhalation volume with one or two inhalations for each dose as shown in Figures 4.2 to 4.5. 
Furthermore, the data presented in Table 4.9 show that when using a 4L inhalation volume 
the mean emitted dose (% nominal dose) from the Accuhaler® and the Easyhaler® 
increased from 75.73 and 74.81 at an inhalation flow of 30 Lmin
-1
 to 81.69 and 81.72 at an 
inhalation flow of 60 Lmin
-1
 respectively. Similarly, the mean emitted dose (% nominal 
dose) from the Clickhaler® and the Turbuhaler® increased from 54.59 to 86.76 and 51.35 
to 71.75 respectively. The increase in the total emitted dose from the Clickhaler and the 
Turbuhaler® is steeper than that from the Accuhaler® and the Easyhaler® (Figures 4.2 to 
4.5, demonstrating higher sensitivity to the inhalation flow at the range of 30 to 60 Lmin
-1
. 
Statistical comparison of the emitted dose from the studied inhalers between inhalation 
flows (Tables 4.10 and 4.11) showed that although the emitted dose increased upon 
increasing the inhalation flow from 10 to 60 Lmin
-1
, generally there was no statistically 
significant difference with the Accuhaler and the Easyhaler at inhalation flow range of 30 
to 60 Lmin
-1
. This is true when inhaled volumes of 2L and 4L were used with the 
Easyhaler. However, flow dependent dose emission was significant at the inhalation flow 
range of 10 to 30 Lmin
-1 
when tested using inhaled volumes of 2L and 4L with the 
Accuhaler® (p>0.001)  and the Easyhaler® (p>0.05).  In contrast, the Clickhaler® and the 
Turbuhaler® showed significant (p>0.001) flow dependent dose emission property 
throughout the inhalation flow range of 10 to 60Lmin
-1
when tested using inhaled volumes 
of 2L and 4L. De Boer et al (1996) have attributed these differences in behaviour to 
differences in device-design and the type of powder formulation. The results of this study 
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are consistent with the previous in-vitro study by Palander et al (2000) which highlights 
that the Accuhaler and Easyhaler are less affected by changes in inhalation flows than the 
Turbuhaler. 
The effect of inhalation volume (which translates to inspiration time) on the emitted dose 
from the Accuhaler®, Easyhaler®, Clickhaler® and the Turbuhaler® is presented in 
Figures 4.6. Statistical comparison of the emitted dose from these inhalers between a 2L 
inhaled volume and a 4L inhaled volume at each inhalation flow is presented in Table 4.12. 
Overall, there was insignificant difference in the emitted dose between 2L and 4L 
inhalation volumes across the inhalation flow range of 10 to 60Lmin
-1
. The Accuhaler 
contains multiple doses with each dose factory-dispensed dose in a blister on a strip inside 
the device, while the Turbuhaler®, Clickhaler® and Easyhaler® are the reservoir-type of 
multidose inhalers. This finding is consistent with a previous study by De Boer et al (1996) 
who found that the effect of inspiration time (inhalation volume) on the dose emission 
from the Turbuhaler (reservoir) and the Diskhaler® (blister) over the same flow range was 
negligible for all four inspiration times (0.5, 1.5, 3.0 and 6 s) used. Although it was 
expected that a higher emitted dose may be obtained with a larger inhaled volume (because 
of the greater energy input), no significant difference was observed in this study. This may 
be attributed to particles being lifted from dose metering cup/strip and carried ex-
mouthpiece of an inhaler early in the simulated inhalation. Previously Everard et al (1997) 
have reported that dose emission from DPIs formulated with either a reservoir or blister 
occurs immediately at the start of the inhalation. Thus, for these types of DPIs energy 
impacted on the powder to overcome attractive forces between particles, or the particle and 
carrier, by a 2L volume may not be significantly different from that provided by a 4L 
inhaled volume. Hence, the effect of inhalation volume on the emitted dose is negligible 
highlighting the acceleration effect reported by Everard et al (1997). 
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The effect of the number of inhalations on the emitted dose from dose system of the 
Accuhaler®, Easyhaler®, Clickhaler® and the Turbuhaler® at different inhalation flows 
(10 to 60 Lmin
-1
) using the same inhalation volume is shown in Figures 4.7 and 4.8 (for 2L 
and 4 L inhalation volumes). The emitted dose from the four inhalers following two 
inhalations per metered dose is greater than that for one inhalation.  These differences in 
the emitted dose between one and two inhalations were different for each type of inhaler 
studied. The differences were confirmed by statistical comparison of the emitted dose 
between one and two inhalations at different inhalation flows (10 to 60 Lmin
-1
) using the 
same inhalation volume (Tables 4.13 and 4.14). The emitted dose from the Accuhaler was 
significantly (p>0.001) greater with two inhalations than one inhalation for each dose at 
inhalation flows below 30 Lmin
-1
. However, this trend was variable with the Turbuhaler. 
At the flow range of 30 to 60 Lmin
-1
 using a 4L inhaled volume, the emitted dose was 
significantly greater with two inhalations than one inhalation while for a 2L inhaled 
volume this trend occurred at the flow range of 10 to 30Lmin
-1
. On the other hand, the 
emitted dose from the Easyhaler® and the Clickhaler® was significantly (p<0.001) greater 
with two inhalations than one inhalation across the inhalation flow of 10 to 60 Lmin
-1.
 
4.5 Conclusion 
In conclusion, this study highlights that the Accuhaler, the Easyhaler, the Clickhaler, and 
the Turbuhaler all showed flow-dependent dose emission to a varying extent due different 
device-design and powder formulation.  
 Furthermore, the Accuhaler®, Easyhaler®, Clickhaler®, and the Turbuhaler® showed 
insignificant difference in the total emitted dose between a 2L inhalation volume and a 4L 
inhalation volume at different inhalation flows. This study shows that inhalation volume is 
not critical for these inhalers above a volume of 2L. Patients with either asthma or COPD 
have an average inhalation volume of 2L when they inhaled through a DPI (Hawskworth, 
et al. 2000). Since multidose inhaled products are for the use of these patients then it is 
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important to perform the in-vitro assessment of the inhaled products using the inhalation 
volume of 2L rather than 4L the recommended by the compendial method consistent with 
the US Food and Drug Administration (FDA 1998) guidelines.  
The Accuhaler®, Easyhaler®, Clickhaler® and the Turbuhaler® generally showed 
significantly greater total emitted dose after two inhalations than one inhalation per 
metered dose at inhalation flow less than 30 Lmin
-1
. This implies that patients with low 
inspiratory flows through these DPIs may benefit more from inhaling twice for each 
metered dose. At present the patient’s information leaflets for the studied inhalers instruct 
one inhalation per metered dose `as hard and fast as they can`.   
The fine particle dose (the portion of the inhaler output containing particles in the size 
range ≤ 5µm), and its aerodynamic particle size distribution determines the lung deposition 
and ultimately the clinical effects. Thus, the findings about the effects of the inhalation 
flow, the inhalation volume and the number of inhalations on the total emitted dose 
identified in this chapter need to be further evaluated by the measurement of aerodynamic 
dose emission characteristics of the Accuhaler, Easyhaler, Clickhaler and the Turbuhaler 
using the same inhalation criteria used  in this study. 
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5 In-vitro determination of aerodynamic dose emission characteristics 
of dry powder inhalers at different inhalation flows using a mixing 
inlet 
5.1 Introduction 
The fine particle dose (FPD) which is defined as that component of the emitted drug with 
an aerodynamic particle diameter of <5µm, comprises particles in the `respirable range` 
that have the greatest potential for lung deposition (Chrystyn, 2006). A study by Olsson et 
al. (1996) suggests that there is a correlation between lung deposition of salbutamol and 
the in-vitro fine particle dose obtained using a cascade Impactor. Other studies (Engel et al 
1992; Hirsch et al, 1997) have shown that the fine particle dose is related to lung 
deposition and ultimately the clinical effect, whilst in-vitro studies have reported (Palander, 
et al, 2000; Ross and Schultz 1996) that this dose is dependent on the speed of the 
inhalation used. 
The fine particle dose together with the aerodynamic particle size distribution 
characteristics of DPIs can be measured in-vitro using the Andersen Cascade Impactor 
(ACI). The methodology is described in the United State Pharmacopoeia (USP 2009), 
European Pharmacopoeia (EP 2007) and British Pharmacopoeia (BP 2008). Traditionally, 
the ACI has been designed for operation at a flow rate of 28.3 Lmin
-1
. Use of different 
flows will alter the cut-off diameter of each stage of the Impactor (Van Oort, 1995). To 
overcome this problem, modifications to the stages of the ACI have recently been 
introduced by replacing some stages. However, the stage replacements restrict the 
determination of dose emission characteristics to 28.3, 60 and 90 Lmin
-1
 but the inhalation 
profiles generated by patients through different inhalers do not result in fixed steady-state 
flows. It is, therefore, important to determine dose emission characteristics from an inhaler 
at a variety of flows to include those outside the fixed standard flows and thus be more 
consistent with the patient’s normal use of inhale products. A mixing inlet has been 
specially designed to provide a fixed flow (as for example 60 Lmin
-1
) through the impactor, 
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whilst permitting variable flows (below 60 Lmin
-1
) through the inhaler (Copley, 2007). 
Therefore no calculations are required to adjust the cut-off diameter of each stage.  
The studies in this chapter have been designed to identify the effect and influence of 
inhalation flow, inhalation volume and the number of inhalations for each dose on the fine 
particle dose and its particle size distribution characteristics. Four different DPIs namely 
the Accuhaler®, the Clickhaler®, the Easyhaler® and the Turbuhaler® have been used to 
identify the minimum criterion of the inhalation manoeuvre to deliver a dose into the lungs 
of patients. 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.1  (a) The ACI assembled with the mixing inlet side arm sealed (b) Inhalation 
flow set up with compressed air passed into the ACI via the mixing inlet valve  
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5.2 Method 
5.2.1 Instruments and inhaler devices 
Andersen MKII Cascade 
Impactor 
Copley Scientific Ltd, UK 
Critical flow controller 
model TPK 
Copley Scientific Ltd, UK 
Mixing inlet Copley Scientific Ltd, UK 
GF 50 filter Copley Scientific Ltd, UK 
GAST pump Brook Crompton, UK 
An electronic digital flow 
meter 
MKS Instrument, USA 
Parafilm M laboratory film Pechiney Plastic Packaging, USA 
Silicone fluid spray Releasil B silicone spray, Dow Corning Limited, Barry, 
Glamorgan, UK 
Inhaler devices: Ventolin®Accuhaler® [ACC] containing salbutamol sulphate 200 µg per 
dose (GlaxoSmithKline); Clickhaler® [CLICK] containing salbutamol sulphate 114 µg per 
dose; Easyhaler® [EASY] containing salbutamol sulphate 200 µg per dose (Orion Pharma, 
Finland); and 
Bricanyl® Turbuhaler® [TBH] containing terbutaline sulphate 500 µg per dose, (Astra 
Zeneca, UK). 
5.2.2 Procedure 
The ACI and its accessories (preseparator and induction port) were washed with 
methanol/water and dried at a room temperature. The collection plates were sprayed with 
silicone and allowed to dry prior to use. The ACI stages were assembled with 10ml of 
bamethane in distilled water (internal standard) in the preseparator and a GF50 (Copley 
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Scientific Ltd, UK) filter located in the final stage. The USP (2009) recommends the use of 
the pre-separator containing about 10ml of washing solution for DPIs to entrain large 
particles usually greater than 10µm. The Impactor was initially set up with the arm of the 
mixing inlet closed to set the airflow at 60 Lmin
-1
 so stages 0 and 7 were replaced by -1 
and -0. The inhalation time (discharge time) was set as described in chapter 4. Figure 5.1 
shows that the inhaler, enclosed in an airtight chamber, was attached to the induction port 
of the ACI. The inhaler was placed inside the chamber to enable the pressure drop to be 
monitored. The ACI was then connected to a vacuum pump via the critical flow controller 
(model TPK). The flow control valve was adjusted until a flow of 60 L/min was achieved 
(also sonic flow achieved P2/P3≤0.5). Then the side arm of the mixing inlet was opened 
and supplementary compressed air allowed through until a desired flow (say 10L/min) 
through the inhaler device was achieved, whilst maintaining the fixed flow of 60 Lmin
-1
 
through the impactor as shown in Figure 5.1. The inhaler was detached from the induction 
port and loaded before it was attached again to the port for discharge of the drug into the 
impactor by activating solenoid valve. Following the discharge, the inhaler device was 
flushed to waste at flow of 90 L min
-1
 to remove any remaining powder before proceeding 
to the next determination. The induction port, mixing inlet together with the preseparator, 
stage-plates and the filter were separately rinsed with standard aqueous bamethane solution 
(8000 µgL
-1
) according the washing volumes shown in Table 5.1. The amounts of active 
drug collected on the filter and deposited on the ACI stages were determined by the high 
liquid performance chromatography (HPLC) method described in chapter 3.This procedure 
was similarly carried out for each determination using two inhalations per metered dose, 
except that the TPK timer controlling the solenoid valve was activated twice to obtain two 
separate discharges for each loaded dose into the impactor at each inhalation flow.  
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Table  5.1 Washing volume for each stage of the ACI 
 
Stage 
Volume of washing (ml) 
 
10 L min
-1
 20 L min
-1
 30 L min
-1
 40 L min
-1
 60 L min
-1
 
Induction 
port 
25 25 50 50 50 
Preseparator 25 25 50 50 50 
-1 10 10 10 10 10 
-0 10 10 10 10 25 
1 10 10 25 25 50 
2 10 10 25 25 25 
3 10 10 25 25 25 
4 10 10 10 10 25 
5 5 5 10 10 25 
6 5 5 10 10 10 
Filter 5 5 10 10 10 
 
The aerodynamic dose emission characteristic of terbutaline sulphate from Bricanyl® 
Turbuhaler® and salbutamol sulphate from the Accuhaler®, Clickhaler® and Easyhaler® 
at inhalation flows of 10, 20, 30, 40, and 60 Lmin
-1
 following one and two inhalations per 
dose for a 2L inhaled volume and a 4L inhaled volume was determined. 
A total of five separate dose determinations (n=5);  two at the beginning, one in the middle 
and two drawn at the end of the lifetime of each type of inhaler, were performed and 
analysed for each type of inhaler. The dose numbers used was randomised. 
5.2.3 Data analysis 
A plot of the logarithm of the percentage less than a stated size on a probability scale 
against the logarithm of the effective cut-off diameter of the stage was constructed (United 
States Pharmacopeia 2005). Copley Inhaler Testing Data Analysis Software (CITDAS) 
was used to identify the aerodynamic characteristics of the emitted dose. The fine particle 
dose (FPD) was the amount with particles that correspond to a size less than 5µm. The fine 
particle fraction % (FPF) was the FPD expressed as a percentage of the total amount 
deposited into the throat and stages of the cascade impactor (this is the dose exiting the 
mouthpiece) as well as expressed as a percentage of the nominal dose (label claim). The 
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mass median aerodynamic diameter (MMAD) was the diameter corresponding to 50% 
undersize. The geometric standard deviation (GSD) was the square root for the size 
corresponding to 84.13% less than the stated size divided by the square root of the size for 
15.87% (United States Pharmacopeia 2005). Since the label claims of the studied inhalers 
differ, the total emitted dose (TED) and the fine particle dose (FPD) from each inhaler 
were respectively expressed as percentage nominal dose (label claim). 
5.2.4 Statistical analysis 
SPSS version 15.0 software (SPSS Inc., Chicago, USA) was used for the statistical 
analysis. A two-way analysis of variance (ANOVA) with the application of the General 
Linear Model Univariate was used to determine any significant differences in the fine 
particle dose from the four different inhalers at different flows. Also the statistical 
comparisons of the fine particle dose between two different inhalation volumes as well as 
between one and two inhalations for each metered dose at the same flows were made. The 
mean difference (95% confidence interval) was calculated and a probability value of 
(p<0.05) was considered being significant. 
5.3 Results 
The mean (SD) amount of drug deposited on each stage of the ACI, total emitted dose, fine 
particle dose, and the mass median aerodynamic diameter (MMAD) of drug particles  from 
each dry powder inhalers (DPIs) at varying inhalation flows (10-60) Lmin
-1
 following one 
and two inhalations using 2L and 4L inhaled volume respectively are shown in Tables 5.2 
to 5.17.  Figures 5.2 to 5.17 describe the amount of drug deposited on each stage of the 
ACI. 
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Table  5.2 Mean (SD) Dose emission of salbutamol from the Accuhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following one inhalation per dose using a 2L inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin
-1
) 
Stage 10 20 30 40 60 
Induction port 66.07(2.8) 41.89(12.3) 45.30(4.2) 41.92(2.2) 37.09(1.7) 
Preseparator 23.54(1.5) 35.77(6.1) 63.02(5.3) 70.61(5.7) 77.91(4.7) 
-1 1.11(0.9) 1.04(0.3) 2.65(0.4) 1.97(0.3) 2.30(1.2) 
0 1.11(0.6) 1.22(0.2) 2.62(0.8) 2.45(0.8) 2.74(1.53 
1 2.27(1.4) 2.74(0.2) 5.73(0.5) 5.90(0.5) 5.22(0.4) 
2 4.08(1.3) 5.44(0.5) 11.27(0.8) 11.15(0.8) 11.41(0.9) 
3 10.05(1.0) 15.61(1.1) 27.21(7.7) 29.11(4.3) 30.23(0.6) 
4 5.31(1.7) 10.36(3.9) 10.90(2.1) 15.85(0.6) 19.15(2.3) 
5 1.87(1.6) 2.44(3.1) 3.39(1.6) 4.29(0.8) 5.40(0.6) 
6 0.67(0.2) 0.66(0.6) 1.28(0.5) 2.52(1.3) 1.64(5.5) 
Filter 0.69(0.5) 2.59(0.2) 1.60(0.9) 2.38(0.3) 2.18(2.9) 
TED (µg) 116.76(7.0) 119.89(0.5) 174.96(15.2) 188.17(7.9) 195.28(2.5) 
TED (% nominal dose) 58.38(3.5) 60.12(6.9) 87.86(7.5) 93.03(4.0) 97.64(2.2) 
FPD (µg) 8.17(3.2) 23.17(3.5) 47.78(10.2) 61.36(4.7) 71.90(0.5) 
FPD (% Emitted dose) 6.86(2.3) 19.02(2.0) 27.17(3.6) 32.51(2.2) 36.82(0.1) 
FPD (% nominal dose) 4.08(1.6) 11.59(1.0) 23.89(0.1) 30.68(2.4) 35.95(1.1) 
MMAD (µm) 6.4(0.3) 4.3(0.1) 3.9(0.1) 3.1(0) 2.5(0.1) 
GSD 1.8(0.3) 1.7(0.1) 1.80(0.1) 1.7(0.1) 1.7(0.1) 
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Table  5.3 Mean (SD) Dose emission of salbutamol from the Accuhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following two inhalations per dose using a 2L inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin-1) 
Stage 10 20 30 40 60 
Induction port 55.16(7.6) 44.49(1.4) 41.20(2.0) 44.43(2.7) 47.19(2.3) 
Preseparator 26.94(1.0) 33.30(0.8) 67.15(3.1) 68.59(6.0) 68.86(2.4) 
-1 1.47(0.4) 1.530.3) 1.49(1.0) 1.36(0.8) 1.31(0.3) 
0 1.99(0.4) 1.45(0.2) 2.07(0.4) 2.46(1.3) 2.10(0.1) 
1 5.40(0.7) 2.12(0.5) 4.580.5) 5.07(0.7) 4.31(0.1) 
2 8.531.1) 5.17(0.5) 10.74(1.1) 11.46(0.9) 15.28(0.3) 
3 10.63(0.6) 16.67(0.6) 26.42(0.7) 28.70(0.6) 29.17(0.9) 
4 5.34(0.7) 10.07(0.3) 19.43(1.6) 15.39(0.6) 20.77(0.8) 
5 1.80(1.0) 3.32(0.5) 5.15(1.8) 5.12(0.5) 7.59(0.9) 
6 0.29(0.1) 1.73(0.5) 1.16(0.4) 1.90(0.6) 1.39(0.1) 
Filter 0.48(0.2) 1.80(0.4) 2.27(0.8) 1.05(0.4) 1.63(0.1) 
TED (µg) 118.04(7.1) 121.65(1.3) 181.67(3.1) 185.52(9.1) 199.49(1.9) 
TED (% nominal dose) 59.02(3.5) 60.83(0.7) 90.80(1.5) 92.76(4.6) 99.74(1.0) 
FPD (µg) 7.26(1.4) 28.90(0.7) 56.88(2.8) 59.74(1.4) 77.18(1.6) 
FPD (% Emitted dose) 6.17(1.2) 23.76(0.5) 31.12(1.1) 32.24(1.1) 38.69(0.5) 
FPD (% nominal dose) 3.63(0.7) 14.45(0.3) 28.44(1.4) 29.87(0.7) 38.59(0.8) 
MMAD (µm) 7.9(0.2) 4.2(0.1) 3.5(0.1) 3.2(0.1) 2.5(0) 
GSD 1.6(0) 1.7(0) 1.7(0.1) 1.6(0.1) 1.6(0) 
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Figure  5.2 Mean amounts (µg) of salbutamol from the Accuhaler® deposited on each stage 
of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 following 
one inhalation per dose using a 2L inhaled volume 
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Figure  5.3 Mean amounts (µg) of salbutamol from the Accuhaler® deposited on each stage 
of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
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Table  5.4 Mean (SD) Dose emission of salbutamol from the Accuhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following one inhalation per dose using a 4L inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin-1) 
Stage 10 20 30 40 60 
Induction port 46.85(3.2) 58.13(7.2) 39.78(8.9) 46.18(2.3) 44.29(1.7) 
Preseparator 23.73(5.2) 39.82(6.9) 65.68(5.6) 66.11(2.8) 70.20(2.0) 
-1 2.83(0.2) 1.86(1.0) 1.70(0.4) 1.55(0.5) 1.62(0.3) 
0 1.58(0.4) 2.74(1.2) 1.88(0.6) 2.41(1.0) 1.95(0.3) 
1 2.88(0.9) 5.08(2.5) 4.38(0.7) 5.39(1.4) 4.19(1.3) 
2 5.65(0.9) 7.84(1.5) 10.11(1.7) 10.75(2.7) 11.10(1.6) 
3 12.14(1.7) 17.19(0.9) 27.72(5.1) 29.45(2.5) 31.20(1.4) 
4 9.01(1.2) 9.88(0.3) 18.33(3.7) 18.76(1.2) 20.19(0.8) 
5 2.38(0.3) 3.27(0.6) 4.65(1.4) 4.80(0.7) 6.76(1.8) 
6 0.91(0.3) 1.95(0.2) 0.90(0.4) 1.74(0.4) 2.05(0.4) 
Filter 1.50(0.4) 2.44(0.5) 1.07(0.7) 1.800.9) 1.44(0.6) 
TED (µg) 109.47(8.4) 150.22(9.8) 176.22(23.7) 191.00(13.4) 194.99(5.3) 
TED (% nominal dose) 54.73(4.2) 75.00(5.1) 88.21(12.0) 95.32(6.7) 97.50(2.7) 
FPD (µg) 13.08(1.7) 29.82(3.2) 54.98(9.7) 63.59(5.1) 74.37(3.9) 
FPD (% Emitted dose) 11.97(1.5) 19.89(2.0) 31.18(2.9) 33.62(1.4) 38.24(1.6 
FPD (% nominal dose) 6.54(0.8) 14.91(1.6) 27.49(4.9) 31.80(2.6) 37.2(1.9) 
MMAD (µm) 6.30.2) 4.50.1) 3.5(0.1) 3.1(0.1) 2.4(0) 
GSD 2.0(0.1) 1.8(0.1) 1.7(0.1) 1.7(0.1) 1.6(0.1) 
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Table  5.5 Mean (SD) Dose emission of salbutamol from the Accuhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following two inhalations per dose using a 4L inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin-1) 
Stage 10 20 30 40 60 
Induction port 45.52(7.4) 62.95(5.4) 50.51(3.0) 42.92(1.1) 40.87(1.6) 
Preseparator 26.00(4.6) 43.23(3.0) 66.18(2.0) 70.02(4.2) 68.78(1.5) 
-1 2.45(1.4) 1.99(0.6) 2.08(0.5) 1.68(0.7) 1.54(0.3) 
0 1.56(0.7) 2.60(0.3) 2.42(0.7) 2.64(0.9) 2.22(0.2) 
1 2.97(1.2) 4.68(0.7) 2.28(0.4) 5.54(0.5) 5.49(0.3) 
2 5.61(0.5) 9.31(2.0) 9.30(1.0) 12.98(0.7) 15.84(0.4) 
3 13.43(1.8) 20.75(2.2) 27.20(0.7) 29.03(0.3) 29.56(0.3) 
4 8.59(2.0) 12.69(2.4) 16.81(1.2) 18.56(0.9) 25.47(0.8) 
5 2.61(0.8) 4.09(1.0) 5.12(0.6) 4.97(1.5) 9.71(0.4) 
6 0.70(0.3) 1.44(0.7) 1.17(0.5) 2.09(0.8) 2.08(0.4) 
Filter 1.33(0.5) 1.36(0.5) 1.12(2.3) 1.35(0.3) 1.34(0.2) 
TED (µg) 110.76(8.7) 165.10(14.5) 184.19(4.6) 191.76(6.4) 202.90(3.3) 
TED (% nominal dose) 55.38(4.4) 82.55(7.3) 92.10(2.3) 95.88(3.2) 101.45(1.7) 
FPD (µg) 12.60(2.0) 34.56(5.3) 53.51(1.5) 64.58(1.7) 86.15(0.8) 
FPD (% Emitted dose) 11.48(2.3) 19.90(2.7) 81.86(1.2) 33.70(1.1) 42.52(0.6) 
FPD (% nominal dose) 6.30(1.0) 17.28(2.6) 26.76(0.7) 32.29(0.8) 43.07(0.4) 
MMAD (µm) 6.0(0.4) 4.6(0.2) 3.5(0) 1.7(0.1) 2.4(0) 
GSD 1.9(0.2) 1.8(0) 1.62(0.1) 32.29(0.1) 1.7(0) 
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 Figure  5.4 Mean amounts (µg) of salbutamol from the Accuhaler® deposited on each 
stage of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 
following one inhalation per dose using a 4L inhaled volume 
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Figure  5.5 Mean amounts (µg) of salbutamol from the Accuhaler® deposited on each stage 
of the Andersen Cascade Impactor at different inhalation flow (10-60) Lmin
-1
 following 
two inhalations per dose using a 4L inhaled volume 
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Table  5.6 Mean (SD) Dose emission of salbutamol from the Easyhaler® using the ACI at different inhalation flows (10-60) Lmin
-
1
 following one inhalation per dose using a 2L inhaled volume (n=5). Amount expressed in (µg) unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin-1) 
Stage 10 20 30 40 60 
Induction port 52.43(8.6) 25.16(2.7) 33.61(3.4) 37.07(7.7) 20.82(1.0) 
Preseparator 13.13(2.8) 69.13(7.3) 74.71(3.4) 87.29(11.0) 118.11(4.9) 
-1 0.53(0.3) 0.86(1.0) 0.75(0.4) 0.71(0.4) 1.36(0.3) 
0 0.44(0.1) 0.92(0.8) 1.72(1.0) 0.95(0.6) 1.84(0.5) 
1 0.59(0.1) 1.74(1.4) 2.76(1.2) 2.43(0.7) 3.77(0.6) 
2 0.99(0.2) 5.57(2.5) 5.71(0.5) 6.55(0.9) 8.23(0.6) 
3 1.86(0.1) 13.60(4.2) 16.98(1.6) 20.21(1.1) 23.79(0.7) 
4 1.46(0.2) 10.38(1.5) 15.36(2.8) 17.83(1.1) 18.22(0.6) 
5 0.78(0.2) 1.92(0.8) 4.44(0.7) 5.60(0.9) 4.63(1.0) 
6 0.26(0.1) 0.68(0.5) 1.20(0.3) 0.96(0.6) 1.90(0.2) 
Filter 0.24(0.1) 0.60(0.4) 1.47(0.6) 2.62(1.9) 2.38(1.1) 
TED (µg) 72.72(9.5) 130.17(12.4) 158.72(7.2) 182.10(13.1) 205.01(6.4) 
TED (% nominal dose) 36.36(4.8) 64.89(6.2) 79.40(3.8) 91.00(6.5) 102.20(3.3) 
FPD (µg) 2.63(0.5) 23.49(2.3) 45.90(5.2) 54.58(3.3) 60.77(1.7) 
FPD (% Emitted dose) 3.69(0.2) 18.16(2.4) 28.91(2.2) 30.08(2.6) 29.66(1.0) 
FPD (% nominal dose) 1.30(0.9) 11.741.1) 22.9(2.6) 27.3(1.6) 30.4(0.8) 
MMAD (µm) 6.3(0.2) 4.2(0.3) 2.3(0.1) 2.2(0.1) 2.3(0.1) 
GSD 2.2(0.2) 1.6(0.3) 1.8(0.2) 1.6(0.1) 1.7(0) 
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Table  5.7 Mean (SD) Dose emission of salbutamol from the Easyhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following two inhalation per dose using a 2L  inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin-1) 
Stage 10 20 30 40 60 
Induction port 48.54(4.1) 45.25(4.0) 47.13(5.2) 45.80(11.0) 35.70(5.5) 
Preseparator 34.65(12.8) 59.59(4.2) 72.19(2.9) 72.77(3.8) 88.14(4.6) 
-1 1.22(0.2) 1.70(0.4) 1.14(0.2) 6.27(1.8) 2.47(1.1) 
0 2.02(0.3) 1.27(0.2) 1.49(0.6) 2.89(0.3) 2.99(0.8) 
1 2.96(0.4) 2.07(0.4) 2.65(0.4) 4.76(0.5) 4.51(0.5) 
2 5.33(0.4) 5.66(1.2) 5.24(0.4) 9.06(0.8) 8.60(0.6) 
3 6.35(0.4) 13.59(0.4) 18.43(0.4) 20.62(1.0) 24.31(1.3) 
4 4.21(0.5) 10.61(0.2) 15.67(0.9) 16.92(1.2) 19.17(0.7) 
5 1.52(1.3) 2.75(0.2) 4.50(0.2) 5.56(0.8) 4.85(0.1) 
6 0.35(0.1) 1.56(0.2) 1.46(0.2) 2.99(0.5) 2.28(0.1) 
Filter 0.36(0.1) 1.21(.8) 2.10(0.8) 3.39(0.8) 2.55(1.2) 
TED (µg) 107.51(16.4) 145.13(4.7) 172.01(8.0) 191.10(10.5) 195.56(1.3) 
TED (% nominal dose) 53.75(8.2) 72.56(2.3) 86.00(4.0) 95.55(5.3) 97.78(0.6) 
FPD (µg) 6.20(1.0) 25.87(1.6) 43.22(0.7) 54.33(1.1) 63.28(2.2) 
FPD (% Emitted dose) 5.78(0.5) 17.73(1.2) 25.16(0.9) 28.59(1.1) 32.36(1.1) 
FPD (% nominal dose) 3.10(0.5) 12.93(0.8) 21.61(0.4) 27.16(0.6) 31.6(0.2) 
MMAD (µm) 7.7(0.4) 4.2(0.1) 3.2(0.1) 3.0(0.1) 2.4(0.0) 
GSD 1.7(0.1) 1.8(0.0) 1.7(0.1) 2.1(0.1) 1.9(0.2) 
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Figure  5.6 Mean amounts (µg) of salbutamol from the Easyhaler® deposited on each stage 
of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 following 
one inhalation per dose using a 2L inhaled volume 
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Figure  5.7 Mean amounts (µg) of salbutamol from the Easyhaler deposited on each stage 
of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 following 
two inhalations per dose using a 2L inhaled volume 
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Table  5.8 Mean (SD) Dose emission of salbutamol from the Easyhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following one inhalation per dose using a 4L   inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin-1) 
Stage 10 20 30 40 60 
Induction port 63.88(7.7) 34.25(1.4) 26.23(2.8) 28.91(1.1) 19.82(1.9) 
Preseparator 2.10(0.8) 63.25(10.6) 88.96(5.9) 80.82(3.4) 107.67(2.3) 
-1 1.32(0.3) 2.37(0.2) 0.97(0.3) 0.87(0.4) 1.09(0.2) 
0 0.67(0.3) 2.15(0.6) 1.08(0.3) 1.60(0.6) 1.98(0.6) 
1 0.63(0.2) 2.69(0.5) 3.02(0.3) 3.32(0.7) 3.44(0.2) 
2 1.42(0.2) 6.10(1.1( 6.78(1.2) 7.11(1.0) 7.89(0.7) 
3 2.35(0.4) 16.06(1.5) 18.09(1.3) 21.51(2.4) 26.95(0.9) 
4 1.75(0.6) 10.99(1.6) 15.03(1.1 19.48(3.0) 20.74(0.9) 
5 0.96(0.4) 4.73(0.7) 4.15(0.5) 5.56(1.5) 5.63(0.5) 
6 0.46(0.2) 2.24(0.7) 1.28(1.6) 2.16(0.4) 1.91(0.2) 
Filter 0.43(0.2) 1.96(0.1) 3.04(0.4) 2.70(0.9) 2.29(0.7) 
TED (µg) 75.97(8.2) 146.78(14.1) 168.66(7.3) 174.04(8.4) 199.40(1.1) 
TED (% nominal dose) 37.99(4.1) 73.39(7.0) 84.26(3.6) 87.00(4.2) 101.20(2.5) 
FPD (µg) 3.46(0.9) 31.45(4.4) 49.52(2.3) 59.79(6.0) 66.73(2.4) 
FPD (% Emitted dose) 4.57(1.2) 21.43(0.8) 29.38(1.3) 34.30(2.0) 33.57(1.3) 
FPD (% nominal dose) 1.70(.0.5) 15.73(2.2) 24.8(1.2( 29.9(3.0) 33.4(1.2) 
MMAD (µm) 6.8(0.3) 4.2(0.1) 2.3(0.1( 2.2(0.1) 2.3(0.0) 
GSD 2.6(0.3) 1.9(0.1) 1.7(0.1) 1.7(0.1) 1.6(0.0) 
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Table  5.9 Mean (SD) Dose emission of salbutamol from the Easyhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following two inhalation per dose using a 4L   inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin-1) 
Stage 10 20 30 40 60 
Induction port 64.44(4.5) 26.55(2.4) 41.34(2.9) 36.76(6.9) 33.51(3.7) 
Preseparator 14.72(2.8) 69.21(2.0) 71.05(6.8) 85.00(9.9) 87.71(3.0) 
-1 0.70(0.4) 1.32(0.9) 6.64(2.2) 5.79(2.8) 2.04(0.2) 
0 0.93(0.7) 0.83(0.5) 3.26(0.5) 4.38(1.6) 5.56(0.5) 
1 1.53(0.1) 1.98(0.9) 4.22(0.2) 3.97(0.3) 1.30(0.3) 
2 2.64(0.2) 4.65(2.0) 6.90(0.4) 9.55(0.4) 9.48(0.5) 
3 5.18(0.4) 15.64(0.5) 18.83(0.7) 23.18(1.1 25.62(0.5) 
4 2.61(1.2) 12.77(1.2) 15.02(2.0) 19.16(1.2) 19.62(0.5) 
5 1.12(0.5) 3.65(0.4) 4.68(0.6) 4.34(1.2) 5.83(1.1) 
6 0.70(0.5) 1.01(0.4) 3.01(0.4) 2.20(0.7) 2.28(0.4) 
Filter 0.63(0.4) 1.13(0.3) 3.02(0.6) 3.02(0.7) 2.57(0.9) 
TED (µg) 95.19(8.3) 138.95(2.8) 178.01(4.8) 197.33(6.1) 195.52(3.0) 
TED (% nominal dose) 47.60(4.2) 69.60(1.4) 80.22(1.0) 98.67(3.1) 97.76(1.5) 
FPD (µg) 4.78(1.3) 40.14(1.2) 41.98(9.2) 57.95(0.7) 65.82(1.9) 
FPD (% Emitted dose) 4.97(1.0) 28.89(0.6) 21.52(10.0) 29.36(0.8) 33.67(1.0) 
FPD (% nominal dose) 2.40(0.7) 20.07(0.8) 20.99(4.6) 28.98(0.4) 32.9(0.9) 
MMAD (µm) 6.7(0.2) 4.2(0.2) 3.3(0.4) 3.1(0.2) 2.4(0.0) 
GSD 1.7(0.0) 1.9(0.1) 1.9(0.3) 2.2(0.3) 1.7(0.1) 
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Figure  5.8 Mean amounts (µg) of salbutamol from the Easyhaler® deposited on each stage 
of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 following 
one inhalation per dose using a 4L inhaled volume 
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Figure  5.9 Mean amounts (µg) of salbutamol from the Easyhaler® deposited on each stage 
of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 following 
two inhalations per dose using a 4L inhaled volume 
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Table  5.10 Mean (SD) Dose emission of salbutamol from the Clickhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following one inhalation per dose using a 2L  inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin-1) 
Stage 10 20 30 40 60 
Induction port 27.89(3.3) 20.15(2.9) 14.45(0.7) 13.80(1.3) 12.44(1.0) 
Preseparator 1.56(0.1) 18.98(3.3) 33.14(0.6) 34.57(1.1) 40.51(2.5) 
-1 0.22(0.1) 0.27(0.1) 0.67(0.4) 0.68(0.2) 1.10(0.1) 
0 0.32(0.2) 0.79(0.2) 1.05(0.2) 3.39(1.6) 1.96(0.2) 
1 0.56(0.2) 2.54(0.5) 3.96(0.4) 3.19(1.4) 5.72(0.3) 
2 0.94(0.2) 4.36(0.6) 7.91(0.6) 7.54(0.3) 9.41(0.9) 
3 1.91(0.9) 6.42(0.7) 12.38(0.8) 12.99(0.3) 17.72(0.9) 
4 1.71(0.7) 3.51(0.4) 6.57(0.4) 7.30(1.0) 9.45(0.4) 
5 0.85(0.2) 1.12(0.3) 2.25(0.7) 2.67(0.4) 2.86(0.8) 
6 0.45(0.2) 0.61(0.2) 1.15(0.1) 1.20(0.1) 1.93(0.5) 
Filter 0.78(0.1) 0.95(0.6) 2.02(0.7) 2.26(0.9) 1.00(0.6) 
TED (µg) 37.18(2.9) 59.69(3.6) 85.55(2.4) 89.59(2.3) 103.94(1.0) 
TED (% nominal dose) 32.61(2.6) 52.20(3.3) 75.05(2.1) 78.40(2.2) 91.18(0.9) 
FPD (µg) 3.70(0.9) 10.76(1.5) 26.71(1.3) 31.21(1.4) 44.40(1.5) 
FPD (% Emitted dose) 9.95(2.6) 18.03(2.6) 31.08(1.2) 34.84(0.8) 42.82(1.4) 
FPD (% nominal dose) 3.2(0.8) 9.44(1.3) 23.4(1.2( 27.4(1.3) 39.0(1.3) 
MMAD (µm) 5.2(0.5) 4.8(0.1) 3.80(0.2) 3.30(0.0) 2.7(0.1) 
GSD 2.1(0.4) 1.7(0.0) 1.7(0.0) 1.8(0.1) 1.8(0.1) 
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Table  5.11 Mean (SD) Dose emission of salbutamol from the Clickhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following two inhalations per dose using a 2L   inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD amount deposited on each stage (µg) 
  Inhalation flow (Lmin-1) 
Stage 10 20 30 40 60 
Induction port 15.30(2.3) 24.47(1.3) 35.21(1.6) 15.29(2.4) 12.51(1.7) 
Preseparator 7.72(2.3) 17.30(1.6) 13.12(0.8) 32.75(1.6) 36.71(6.3) 
-1 0.85(0.3) 1.63(0.7) 0.76(0.0) 1.21(0.7) 0.48(0.5) 
0 0.93(0.1) 1.48(0.1) 2.22(0.1) 2.11(1.1) 1.07(0.6) 
1 1.23(0.4) 2.66(0.2) 3.19(0.1) 4.34(0.2) 4.68(0.7) 
2 2.06(0.2) 4.38(0.4) 6.51(0.2) 8.04(0.5) 10.30(0.9) 
3 4.95(0.5) 6.98(0.7) 12.65(0.6) 13.90(0.7) 18.71(1.3) 
4 2.55(0.3) 3.95(0.3) 6.63(0.6) 7.26(0.7) 11.07(0.9) 
5 1.50(0.3) 1.22(0.2) 1.87(0.2) 2.98(0.8) 3.05(0.5) 
6 0.84(0.1) 0.92(0.1) 1.21(0.3) 1.83(0.4) 1.12(1.2) 
Filter 0.65(0.1) 0.72(0.1) 0.99(0.4) 2.19(0.6) 0.88(0.6) 
TED (µg) 38.59(4.0) 65.72(1.2) 84.19(1.9) 91.79(1.5) 100.59(7.4) 
TED (% nominal dose) 33.85(3.5) 57.65(1.0) 73.85(1.7) 80.52(1.3) 88.20(6.4) 
FPD (µg) 5.49(0.5) 15.26(0.8) 24.89(0.4) 33.26(1.9) 46.98(1.8) 
FPD (% Emitted dose) 14.46(1.9) 23.22(1.0) 29.52(0.9) 36.21(1.8) 46.71(3.0) 
FPD (% nominal dose) 4.8(0.5) 13.4(0.7) 21.8(0.4) 29.2(1.7) 41.2(1.5) 
MMAD (µm) 6.5(0.3) 4.8(0.1) 3.9(0.1) 3.3(0.1) 2.6(0.0) 
GSD 2.02(0.1) 1.9(0.1) 1.8(0.0) 1.8(0.0) 1.6(0.0) 
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Figure  5.10 Mean amounts (µg) of salbutamol from the Clickhaler® deposited on each 
stage of the Andersen Cascade Impactor at different inhalation flow (10-60) Lmin
-1
 
following one inhalation per dose using a 2L inhaled volume 
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Figure  5.11 Mean amounts (µg) of salbutamol from the Clickhaler® deposited on each 
stage of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 
following two inhalations per dose using a 2L inhaled volume 
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Table  5.12 Mean (SD) Dose emission of salbutamol from the Clickhaler® using the Andersen Cascade Impactor at different inhalation 
flows (10-60) Lmin
-1
 following one inhalation per dose using a  4L    inhaled volume (n=5). Amount expressed in (µg) unless stated  
  Mean (SD amount deposited on each stage (µg) 
  Inhalation flow (Lmin
-1
) 
Stage 10 20 30 40 60 
Induction port 9.08(2.0) 14.77(2.3) 13.98(0.7) 15.30(1.8) 14.51(2.3) 
Preseparator 2.26(0.7) 31.22(1.5) 38.78(1.3) 35.55(2.1) 38.71(1.9) 
-1 2.36(1.5) 0.48(0.1) 0.57(0.1) 0.84(0.2) 1.60(0.1) 
0 5.73(2.5) 1.01(0.1) 1.13(0.2) 1.84(0.4) 1.45(0.4) 
1 1.86(0.7) 3.99(0.6) 4.71(0.3) 5.30(0.5) 5.01(0.6) 
2 2.11(1.2) 7.54(0.4) 8.48(0.7) 9.16(0.5) 9.07(0.4) 
3 4.49(1.5) 12.16(0.9) 14.11(0.3) 17.03(0.9) 18.37(0.3) 
4 2.82(0.5) 6.51(0.6) 7.31(1.2) 8.41(0.4) 9.76(0.4) 
5 2.81(1.4) 1.52(0.4) 2.38(0.3) 2.54(0.3) 2.80(0.6) 
6 2.39(1.4) 1.01(0.2) 1.30(0.2) 1.05(0.5) 1.62(0.1) 
Filter 1.92(0.9) 2.55(0.6) 2.18(0.6) 1.53(0.7) 1.52(0.6) 
TED (µg) 37.74(6.5) 82.78(3.2) 94.93(3.8) 98.54(3.8) 104.20(4.6) 
TED (% nominal dose) 33.10(5.7) 72.20(3.1) 83.40(3.1) 87.80(5.4) 91.40(4.1) 
FPD (µg) 9.06(1.9) 20.28(1.0) 29.35(1.4) 36.44(2.1) 44.94(0.8) 
FPD (% Emitted dose) 24.15(3.9) 24.50(1.5) 30.92(0.8) 36.97(0.9) 42.88(2.0) 
FPD (% nominal dose) 8.0(1.7) 17.8(0.9) 25.7(1.2) 31.96(1.8) 39.4(0.7) 
MMAD (µm 7.6(1.3) 4.7(0.1) 3.8(0.0) 3.4(0.1) 2.7(0.0) 
GSD 2.5(0.3) 1.7(0.1) 1.7(0.0) 1.7(0.0) 1.8(0.1) 
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Table  5.13 Mean (SD) Dose emission of salbutamol from the Clickhaler® using the Andersen Cascade Impactor at different inhalation 
flows (10-60) Lmin
-1
 following two inhalations per dose using a  4L    inhaled volume (n=5). Amount expressed in (µg) unless stated  
  Mean (SD amount deposited on each stage (µg) 
  Inhalation flow (Lmin
-1
) 
Stage 10 20 30 40 60 
Induction port 14.31(1.4) 30.10(1.0) 38.01(1.2) 34.62(1.3) 13.35(2.9) 
Preseparator 6.99(2.1) 17.50(1.1( 14.58(0.3) 17.84(1.9) 37.17(5.0) 
-1 1.36(0.3) 1.14(0.5) 0.77(0.2) 1.75(0.8) 0.50(1.1) 
0 0.93(0.1) 2.03(0.7) 1.99(0.3) 1.38(0.1) 1.22(0.1) 
1 1.66(0.4) 4.46(0.3) 3.59(0.2) 4.58(0.9) 4.37(0.4) 
2 3.44(0.8) 7.09(0.3) 7.30(0.7) 9.82(0.7) 9.61(0.8) 
3 8.07(0.2) 13.53(0.4) 14.66(0.2) 17.15(0.3) 19.43(1.4) 
4 2.74(0.5) 6.83(0.4) 8.28(0.3) 9.21(0.5) 11.13(0.5) 
5 1.52(0.4) 2.26(0.4) 2.45(0.1) 2.99(0.6) 3.12(0.4) 
6 0.70(0.4) 1.77(0.5) 1.64(0.3) 1.53(0.4) 1.23(1.2) 
Filter 0.45(0.2) 2.00(0.2) 1.35(0.1) 1.39(0.4) 1.09(0.7) 
TED (µg) 42.05(5.2) 88.71(2.9) 94.62(1.5) 102.26(1.7) 102.22(3.7) 
TED (% nominal dose) 36.89(4.6) 77.82(2.6) 83.00(1.4) 89.70(1.5) 89.80(3.3) 
FPD (µg) 5.29(1.0) 22.52(1.1) 30.25(0.4) 38.66(1.0) 47.33(2.4) 
FPD (% Emitted dose) 12.48(1.2) 25.44(0.9) 31.84(0.6) 38.21(1.3) 46.37(0.9) 
FPD (% nominal dose) 4.6(0.9) 19.8(1.0) 26.5(0.3) 33.9(0.9) 41.5(2.1) 
MMAD (µm) 6.8(0.1) 4.7(0.1) 3.7(0.1) 3.4(0.1) 2.6(0.0) 
GSD 1.8(0.1) 1.8(0.1) 1.8(0.1) 1.7(0.0) 1.6(0.1) 
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Figure  5.12 Mean amounts (µg) of salbutamol from the Clickhaler® deposited on each 
stage of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 
following one inhalation per dose using a 4L inhaled volume 
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Figure  5.13 Mean amounts (µg) of salbutamol from the Clickhaler® deposited on each 
stage of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 
following two inhalations per dose using a 4L inhaled volume (n=5) 
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Table  5.14 Mean (SD) Dose emission of terbutaline from the Turbuhaler® using the ACI at different inhalation flows (10-60) 
Lmin
-1
 following one inhalation per dose using a 2L inhaled volume (n=5). Amount expressed in (µg) unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin
-1
) 
Stage 10 20 30 40 60 
Induction port 40.78(13.6) 145.13(20.3) 147.3(14.3) 145.5(5.3) 124.38(23.4) 
Preseparator 18.95(9.8) 76.4(12) 88.1(14.2) 74.08(8.2) 81.29(12.4) 
-1 2.19(1.7) 7.24(1.6) 7.44(3.4) 7.82(2.2) 7.74(3.0) 
0 7.30(2.6) 21.47(1.8) 22.2(2.1) 18.80(6.2) 16.34(7.0) 
1 10.52(2.6) 24.06(1.0) 26.3(3) 29.46(2.2) 31.61(6.4) 
2 13.50(3.4) 22.85(1.0) 27.67(3) 32.56(1.4) 38.30(8.4) 
3 16.34(3.2) 23.25(0.7) 35.19(3.1) 36.89(1.3) 46.47(7.6) 
4 9.61(1.5) 12.08(0.9) 13.65(1.3) 24.87(1.9) 26.91(9.5) 
5 4.95(1.0) 5.41(0.16) 5.6(1.1) 6.98(2.6) 9.55(4.3) 
6 2.41(0.4) 5.0(0.5) 4.31(0.4) 5.41(2.1) 4.77(1.9) 
Filter 0.88(0.5) 4.5(1.9) 6.14(1.5) 6.15(1.4) 2.87(1.7) 
TED (µg) 127.44(23.4) 347.22(28.2) 383.92(5.0) 388.54(2.9) 383.92(8.9) 
TED (%nominal dose) 25.49(4.7) 69.45(5.6) 76.2(0.8) 77.8(0.4) 76.23(0.8) 
FPD (µg) 17.30(2.0) 81.0(4.1) 101.34(5) 122.51(6.7) 167.78(19.9) 
FPD (% Emitted dose) 14.03(2.6) 23.4(1.7) 26.4(1.3 31.5(1.9) 44.18(9.6) 
FPD (%nominal dose) 3.46(0.4) 16.2(0.8) 20.27(1.0) 24.50(1.3) 33.56(4.0) 
MMAD 8.0(0.7) 4.0(0.1) 3.8(0.2) 3.5(0) 2.2(0.1) 
GSD 1.7(0.1) 1.7(0.1) 1.7(1.0) 1.7(0.1) 1.7(0.1) 
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Table  5.15 Mean (SD) Dose emission of terbutaline from the Turbuhaler® using the ACI at different inhalation flows (10-60) 
Lmin
-1
 following two inhalations per dose using a  2L inhaled volume (n=5). Amount expressed in (µg) unless stated  
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin
-1
) 
Stage 10 20 30 40 60 
Induction port 67.58(40) 108.89(3.4) 105.05(4.5) 109.42(8.7) 125.76(5.1) 
Preseparator 36.62(3.5) 46.41(6.2) 52.62(7.7) 44.387.7) 49.31(3.9) 
-1 6.20(3.1) 7.96(1.0) 11.34(3.4) 7.26(2.1) 6.48(1.3) 
0 14.02(2.4) 17.01(2.9) 12.93(2.8) 12.62(4.2) 13.18(2.3) 
1 20.50(3.5) 31.85(1.9) 31.69(0.9) 25.75(11.3) 39.23(4.4) 
2 23.87(5.5) 37.25(2.0) 40.52(2.3) 40.38(4.5) 49.03(5.6) 
3 28.55(5.3) 49.93(6.5) 57.35(2.5) 60.83(3.4) 69.62(1.7) 
4 17.97(5.7) 33.89(4.0) 38.87(1.7) 40.92(3.8) 48.50(3.3) 
5 8.66(3.4) 26.63(2.2) 20.26(1.3) 28.20(3.8) 26.00(9.4) 
6 4.08(1.5) 6.34(1.7) 6.57(1.0) 10.15(5.3) 8.19(2.1) 
Filter 2.09(0.8) 4.46(2.2) 6.23(12.4) 7.71(4.7) 7.83(5.7) 
TED (µg) 230.14(26.6) 370.62(1.7) 383.41(2.5) 392.29(7.5) 443.13(15.7) 
TED (% nominal dose) 46.03(5.3) 75.03(1.7) 76.68(4.5) 78.46(1.5) 88.63(3.1) 
FPD (µg) 32.00(9.6) 106.97(10.2) 138.60(1.5) 173.94(6.5) 223.47(10.6) 
FPD (% Emitted dose) 13.91(2.8) 28.59(8.4) 36.17(0.1) 44.89(2.6) 51.16(2.3) 
FPD (% nominal dose) 6.40(1.9) 21.39(1.7) 27.72(0.9) 34.79(1.3) 44.69(2.1) 
MMAD (µm) 8.3(0.7) 5.1(0.2) 4.1(0.1) 3.2(0.2) 2.8(0.2) 
GSD 1.7(0.1) 1.8(02) 1.8(0.1) 1.8(0.1) 1.8(0.1) 
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Figure  5.14 Mean amounts (µg) of terbutaline from the Turbuhaler® deposited on each 
stage of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin-1 
following one inhalation per dose using a 2L inhaled volume 
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Figure  5.15 Mean amounts (µg) of terbutaline from the Turbuhaler® deposited on each 
stage of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 
following two inhalations per dose using a 2L inhaled volume 
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Table  5.16 Mean (SD) Dose emission of terbutaline from the Turbuhaler® using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following one inhalation per dose using a 4L inhaled volume (n=5). Amount expressed in (µg) 
unless stated  
  Mean (SD amount deposited on each stage (µg) 
  Inhalation flow (Lmin-
1
) 
Stage 10 20 30 40 60 
Induction port 88.24(3.6) 133.24(17.9) 176.87(7.9) 147.98(15) 142.62(14.3) 
Preseparator 34.13(3.6) 74.83(20.3) 71.65(3.2) 96.01(21.9) 86.38(5.2) 
-1 4.89(1.0) 7.07(1.7) 7.08(4.4) 6.29(2.4) 7.09(1.9) 
0 9.63(1.0) 25.15(2.0) 21.98(2.0) 8.77(1.9) 19.15(3.6) 
1 10.40(0.7) 24.01(2.1) 24.87(0.7) 24.88(2.7) 35.58(3.8) 
2 12.60(1.0) 23.83(1.9) 24.26(1.6) 28.98(2.9) 43.21(2.6) 
3 16.54(1.0) 23.48(1.8) 26.33(2.1) 33.31(4.2) 57.94(4.4) 
4 12.671.1) 12.01(1.0) 13.20(1.8) 17.00(4.9) 27.56(5.4) 
5 7.97(0.6) 6.22(0.9) 4.45(1.4) 5.30(2.0) 14.23(4.8) 
6 5.26(0.5) 5.52(1.6) 4.77(2.1) 4.99(2.8) 3.92(1.0) 
Filter 1.68(0.2) 5.46(2.4( 4.43(1.2) 7.58(0.9) 2.26(1.7) 
TED (µg) 
TED (% nominal dose) 
203.99(5.2) 
40.80(1.0) 
340.80(38.7) 
68.22(7.6) 
380.18(11.1) 
76.00(2.3) 
381.08(28) 
76.27(5.7) 
437.79(26.3) 
87.56(5.3) 
FPD (µg) 26.561.3) 84.43(5.9) 117.15(4.1) 127.40(14.4) 194.84(10.6) 
FPD (% Emitted dose) 13.00(0.6) 24.99(5.9) 30.65(0.6) 33.59(4.6) 44.52(1.1) 
FPD (% nominal dose) 5.31(0.3) 16.89(1.2) 23.43(0.8) 25.48(2.9) 38.97(2.1) 
MMAD (µm) 7.4(0.2) 6.0(0.1) 2.7(0.1) 2.3(0.1) 2.3(0.1) 
GSD 2.1(0) 1.6(0.1) 1.68(0.1) 1.62(0.1) 1.7(0.1) 
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Table  5.17 Mean (SD) Dose emission of terbutaline from the Turbuhaler using the Andersen Cascade Impactor at different 
inhalation flows (10-60) Lmin
-1
 following two inhalations per dose  using a  4L inhaled volume (n=5). Amount expressed in (µg) 
unless stated 
  Mean (SD) amount deposited on each stage (µg) 
  Inhalation flow (Lmin-
1
) 
Stage 10 20 30 40 60 
Induction port 86.22(16.6) 98.81(7.2) 89.46(9.4) 95.76(3.9) 131.12(3.9) 
Preseparator 38.87(4.2) 30.39(4.7) 37.54(5.8) 32.13(2.1) 48.47(3.4) 
-1 8.15(1.8) 8.41(0.9) 8.91(1.4) 10.06(1.4) 7.85(2.4) 
0 13.07(1.2) 15.44(2.3) 15.88(3.0) 15.24(1.2) 18.99(3.1)) 
1 23.90(3.4) 33.06(3.7) 33.13(3.6) 34.62(1.1) 36.79(2.8) 
2 26.00(5.3) 42.28(1.5) 38.47(3.2) 45.15(1.1) 53.35((3.5) 
3 33.82(10.4) 63.74(2.4) 65.41(2.9) 66.45(1.7) 79.96(2.3) 
4 22.17(5.6) 39.90(3.1) 39.30(5.2) 42.76(1.1) 57.03(1.2) 
5 11.24(3.0) 23.08(3.1) 28.50(0.5) 27.89(2.3) 27.15(11.7) 
6 3.09(2.1) 9.23(2.3) 19.04(1.9) 19.30(3.1) 7.07(2.3) 
Filter 1.85(0.9) 9.76(2.3) 7.85(1.1) 10.18(9.81 5.64(1.2) 
TED (µg) 
TED (% nominal dose) 
268.40(39.4) 
53.68(7.9) 
 
374.10(6.9) 
74.82(1.4) 
383.50(11.3) 
76.70(2.3) 
 
399.53(1.8) 
79.91(4.5) 
 
473.41(11.7) 
94.68(2.3) 
FPD (µg) 39.95(10.2) 130.40(8.3) 169.18(8.3) 194.40(0.7) 239.14(15.3) 
FPD (% Emitted dose) 14.34(2.3) 34.59(2.0) 44.13(2.1) 48.66(0.1) 51.64(2.8) 
FPD (% nominal dose) 7.992.0) 26.08(1.7) 33.84(1.7) 38.88(0.9) 47.83(3.1) 
MMAD (µm) 7.8(0.8) 4.8(0.2) 3.7(0.2) 3.2(0.1) 2.8(0) 
GSD 1.8(0.1) 1.9(0) 1.94(0.1) 1.90(0) 1.9(0.1) 
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Figure  5.16 Mean amounts (µg) of terbutaline from the Turbuhaler® deposited on each 
stage of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 
following one inhalation per dose using a 4L inhaled volume 
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Figure  5.17 Mean amounts (µg) of terbutaline from the Turbuhaler® deposited on each 
stage of the Andersen Cascade Impactor at different inhalation flows (10-60) Lmin
-1
 
following two inhalations using a 4L inhaled volume 
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A summary of  the mean (SD) fine particle dose, expressed as % nominal dose, from the 
four dry powder inhalers at varying inhalation flows (10-60 Lmin
-1
) using 2L and 4L 
inhalation volumes following one and two inhalations per metered dose respectively is 
shown in Tables 5.18. Figures 5.18 to 5.21 describe the variation of the fine particle dose 
(FPD) from the Accuhaler®, the Easyhaler®, the Clickhaler® and Turbuhaler® with 
respect to the inhalation flow under the same inhalation volumes and the number of 
inhalations. The FPD increased with an increase of the inhalation flow, though this varied 
from device to device.  
Tables 5.19 and 5.20 show  the statistical comparison of the fine particle dose (% nominal 
dose) of the four different dry powder inhalers at varying inhalation flows (10-60) Lmin
-1 
using a 2L and a 4L inhaled volumes.  
A summary of the mean (SD) MMAD of the drug particles emitted from the four dry 
powder inhalers at varying inhalation flows (10-60 Lmin
-1
) using 2L and 4L inhalation 
volumes following one and two inhalations per metered dose respectively is shown in 
Tables 5.21. From the data presented in Table 5.21 the minimum inhalation flow at which 
the emitted fine particles with the MMAD of less than 5µm that have the greatest potential 
for lung deposition from the Accuhaler®, Easyhaler®, and Clickhaler® was about 
20Lmin
-1
, while that  from the Turbuhaler was about 30Lmin
-1
.     
Figures 5.22 to 5.25 describe the variation of the MMAD of the drug particles emitted 
from the inhalers with respect to the inhalation flow under the same inhalation volumes 
and the number of inhalations. Generally, the MMAD decreased with an increase of the 
inhalation flow. 
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Table  5.18 Mean (SD) fine particle dose, as % nominal dose from the four different dry powder inhalers following one and two inhalations per 
metered dose for 2L and 4L inhalation volumes   
  Mean (SD) fine particle dose (% nominal dose) following one inhalation 
Device Accuhaler Easyhaler Clickhaler Turbuhaler 
Inhalation volume 2L 4L 2L 4L 2L 4L 2L 4L 
Inhalation flow (Lmin-
1)                 
10 4.08(1.6) 6.54(0.8) 1.32(0.2) 1.73(0.4) 3.07(0.8) 7.95(1.7) 3.46(0.4) 5.31(0.3) 
20 11.59(1) 14.91(1.6) 11.74(1.1) 20.07(2.2) 9.44(1.3) 17.79(0.9) 16.2(0.8) 16.89(1.2) 
30 23.89(1.4) 26.76(0.) 22.9(2.6) 24.76(1.2) 21.83(0.4) 25.75(1.2) 20.27(1.0) 23.43.(0.8) 
40 29.87(0.8) 31.8(2.4) 27.29(1.6) 29.89(3) 27.38(1.3) 31.96(1.8) 24.50(1.3) 25.48(2.2.9) 
60 35.95(1.1) 37.19(1.9) 30.39(0.8) 33.37(1.2) 38.95(1.55) 39.42(2.1) 33.56(4.0) 38.97(2.1) 
  Mean (SD) fine particle dose (% nominal dose) following two inhalations 
Device Accuhaler Easyhaler Clickhaler Turbuhaler 
Inhalation volume 2L 4L 2L 4L 2L 4L 2L 4L 
Inhalation flow (Lmin-
1)                 
10 3.63(0.7) 6.30(1.0) 3.10(0.5) 2.39(0.7) 4.82(0.5) 4.64(0.9) 6.40(1.9) 7.99(2.0) 
20 14.45(0.3) 17.28(2.6) 12.93(0.8) 15.73(0.6) 13.39(0.7) 19.75(1) 21.39(1.7) 26.08(1.7) 
30 28.4(5.1) 27.49(4.9) 21.67(0.4) 27.19(0..6) 23.4(1.2) 26.54(0.) 27.72(0.9) 33.84(1.7) 
40 30.68(2.4) 32.29(0.8) 27.16(0.6) 28.98(0.4) 29.18(1.7) 33.91(0.9) 34.79(1.3) 38.88(0.9) 
60 38.59(0.8) 43.07(0.4) 31.6(1.1) 32.91(0.9) 41.21(1.3) 41.51(0.7) 44.69(2.1) 47.83(3.1) 
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Figure  5.18 Mean fine particle dose (% nominal dose) of salbutamol sulphate from the 
Accuhaler® at different inhalation flows (10-60) Lmin
-1
 (n=5) 
 
Figure  5.19 Mean fine particle dose (% nominal dose) of salbutamol sulphate from the 
Easyhaler® at different inhalation flow (10-60) Lmin
-1
 (n=5) 
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Figure  5.20 Mean fine particle dose (% nominal dose) of salbutamol sulphate from the 
Clickhaler® at different inhalation flow (10-60) Lmin
-1
 (n=5) 
 
Figure  5.21 Mean fine particle dose (% nominal dose) of salbutamol sulphate from the 
Turbuhaler® at different inhalation flow (10-60) Lmin
-1
 (n=5) 
 174
Table  5.19 Statistical comparison of the fine particle dose (% nominal dose) from the four different dry powder inhalers at different inhalation flows 
(10-60) Lmin
-1 
using a 2L inhaled volume  
Inhalation flow 
(Lmin
-1
) 
Mean difference (95 % confidence interval) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10 vs 20 -7.50***(-10.16, -4.85) 10.43***(-11.95, -8.90) -6.36***(-8.19, -4.53) -12.74***(-13.95, -11.53) 
10 vs 30 -24.35***(-31.93, -16.98) 21.64***(9-25.01, -18.27) -20.1***(-21.84, -18.17) -16.81***(-18.19, -15.43) 
10 vs 40 -23.59***(-29.92, -23.37) -25.97***(-27.88, -24.07) -24.32***(-26.15, -22.50) 21.04***(-22.79, -19.29) 
10 vs 60 -31.86***(-34.53, -29.19) -29.07**(30.29, -27.85) -38.14***(-40.47, -35.80) 30.09**(-34.98, 25.21) 
20 vs 30 -16.85***(-22.93, -10.77) 11.21***(-14.87, -7.54) -13.65***(-15.08, -11.82) 4.07**(-6.11, -2.03) 
20 vs 40 -19.09***(-22.52, -15.66) -15.54***(-18.92, -12.17) -17.97***(-20.61, -15.32) -8.30***(-9.46, -7.15) 
20 vs 60 -24.36***(-25.73, -22.99) 18.64***(-19.78, -17.50) -31.78***(-34.34, -29.23) 17.35***(-21.50, -13.21) 
30 vs 40 -2.24(-7.43, 2.94) 4.33***(-8.48, -0.19) -4.32***(-7.13, -1.51) -4.23**(-6.99, -1.47) 
30 vs 60 -7.51*(-12.55, -2.47) 7.43***(-10.41, -4.44) -18.13***(-20.88, -15.39) -13.29***(-19.27, -7.30) 
40 vs 60 -5.23*(-7.87, -2.65) 3.09**(-5.99, -0.20) -13.82**(-14.81, 12.83) -9.05***(-12.40, -5.70) 
The mean difference is significant *P<0.05; **P<0.01;   ***P<0.001  
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Table  5.20 Statistical comparison of the fine particle dose (% nominal dose) from the four different dry powder inhalers at different inhalation flow 
(10-60) Lmin
-1 
using a 4L inhaled volume  
Inhalation flow 
(Lmin
-1
) 
Mean difference ( 95% confidence interval) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10 vs 20 -8.37***(-9.82, -6.92)  -18.34***(-20.64, -16.04) -9.83***(-11.47, -8.14) -11.57*(-13.24, -9.89) 
10 vs30 -20.95***(-27.49, -14.41) -23.03***(-24.08, -21.97) -17.79***(-20.44, -15.33) -18.11*(-19.43, -16.78) 
10 vs 40 -25.26***(-28.32, -22.29) -28.16***(-32.01, -24.31) -24.01***(-27.44, -20.63) 20.16*(-23.64, -16.68) 
10 vs60 30.64***(-33.43, -27.86) -31.63***(-32.88, 30.38) -33.56***(-36.28, -30.83) 33.65*(-36.07, -31.23) 
20 vs 30 -12.58***(-19.62, -5.54) -4.69***(-7.09, -2.28) -7.98***(-10.23, -5.60) -6.54*(-7.61, -5.47) 
20 vs 40 -16.89**(-19.39, -14.38) 9.82***(-14.17, -5.46) -14.18***(-16.71, 11.66) -8.59*(-12.93, -4.25) 
20 vs 60 -22.27***(-25.36, -19.19) -5.13***(-9.18, -1.08) -6.22***(-8.26, -4.18) -22.08***(-24.36, -19.83) 
30 vs 40 -4.31(-12.03, 3.41) 13.29***(-15.38, -11.20) -23.73*(-25.11,-22.34) 2.05(-5.75, 1.64) 
30 vs 60 -9.70***(-17.34, -2.06) -8.60***(-10.65, -6.55) -15.77***(-17.96, -13.59)  -15.54*(-18.74, 12.38) 
40 vs 60 -5.39**(-7.72, -3.06) -3.47*(-8.11, 1.18) -9.55***(-12.10, -6.99) 13.48*(-16.88, -10.10) 
The mean difference is significant *P<0.05; **P<0.01;   ***P<0.001  
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Table  5.21 Mean (SD) mass median aerodynamic diameter (MMAD), in µm, for the four different dry powder inhalers following one and two 
inhalations per metered dose for a 2L and a 4L inhalation volumes  
  Mean (SD)  mass median aerodynamic diameter (MMAD) µm following one inhalation 
Device Accuhaler Easyhaler Clickhaler Turbuhaler 
Inhalation volume 2L 4L 2L 4L 2L 4L 2L 4L 
Inhalation flow (Lmin-1)                 
10 6.4(0.3) 6.4(0.3) 6.3(0.5) 6.7(0.3) 5.3(0.5) 7.6(1.3) 7.9(0.7) 7.4(0.2) 
20 4.3(0.) 4.5(0.3) 4.2(0.3) 2.3(0.4) 4.8(0.12) 4.7(0.1) 4.0(0.1) 4.(0.1) 
30 3.5(0.1) 3.5(0.1) 2.3(0.1) 2.3(0.1) 3.8(0.2) 3.8(0.1) 3.8(0.2) 2.7(0.1) 
40 3.1(0.1) 3.1(0.1) 2.2(0) 2.2(0.1) 3.3(0.1) 3.4(0.1) 3.5(0.1) 2.3(0.1) 
60 2.5(0) 2.4(0) 2.3(0.5) 2.3((0) 2.6(0.1) 2.6(0) 2.2(0.1) 2.3(0.1) 
 Mean (SD) mass median aerodynamic diameter (MMAD µm following two inhalations 
Device Accuhaler Easyhaler Clickhaler Turbuhaler 
Inhalation volume 2L 4L 2L 4L 2L 4L 2L 4L 
Inhalation flow (Lmin-1)                 
10 7.9(0.2) 6.0(1.0) 7.7(0.4) 6.7(0.2) 6.5(0.4) 6.8(0.1) 83(0.7) 7.8(0.8) 
20 4.2(0) 4.6(0.2) 4.2(0.2) 4.2(0.2) 4.8(0.1) 4.7(0.1) 5.1(0.2) 5.2) 
30 3.9(0.1) 3.5(0) 3.3(0.4) 3.3(0.4) 3.9(0.1) 3.7(0.1) 4.1(0.1) 3.7(0.2) 
40 3.2(0.1) 3.1(0.1) 3.0(0.1) 3.0(0.1) 3.3(0.1) 3.4(0.) 3.2(0.2) 3.2(0.1) 
60 2.5(0) 2.4(0) 2.4(0) 2.4(0) 2.7(0) 2.7(0) 2.8(0.2) 2.8(0) 
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Figure  5.22 Mass median aerodynamic diameter (MMAD in µm) of salbutamol particles 
from the Accuhaler® at different inhalation flows (10-60) Lmin
-1
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Figure  5.23 Mass median aerodynamic diameter (MMAD in µm) of salbutamol particles 
from the Easyhaler® at different inhalation flows (10-60) Lmin
-1
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Figure  5.24 Mass median aerodynamic diameter (MMAD in µm) of salbutamol particles 
from the Clickhaler® at different inhalation flows (10-60) Lmin
-1
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Figure  5.25 Mass median aerodynamic diameter (MMAD in µm) of terbutaline particles 
from the Turbuhaler® at different inhalation flows (10-60) Lmin
-1
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Figure 5.26 shows the fine particle dose at each inhalation flow with one inhalation per 
metered dose for a 2L and a 4L inhaled volumes while Table 5.22 presents the statistical 
comparison of the fine particle dose between the 2L inhaled volume and the 4L inhaled 
volume. This enabled the evaluation of the effect of the inhalation volume on the fine 
particle dose from the inhalers under the same inhalation flow.  
Figures 5.27 and 5.28 describe the differences in the fine particle dose from the 
Accuhaler®, Easyhaler®, Clickhaler® and Turbuhaler® between one inhalation and two 
inhalations at each inhalation flow for 2L and 4L inhaled volumes.  There are marginal 
differences in the fine particle dose emitted from the four inhalers. Tables 5.23 and 5.24 
show the statistical comparison of the fine particle dose (% nominal dose) from the four 
dry powder inhalers between one and two inhalations per metered dose at each inhalation 
flow using  2L and  4L inhaled volumes. This enabled the evaluation of the effect of the 
number of inhalations per metered dose on the fine particle dose from the studied inhalers. 
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Figure  5.26 Mean (SD) fine particle dose, as % nominal dose from the four different dry 
powder inhalers at different inhalation flows (10-60) Lmin
-1
 following one inhalation per 
metered dose for 2L and 4L inhalation volumes 
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Table  5.22 Statistical comparison of the fine particle dose (% nominal dose) from the four different dry powder inhalers between 2L and 4L inhaled 
volumes each inhalation flow  
Inhalation flow 
(Lmin
-1
) 
Mean difference (95 % confidence interval) 
(2L vs. 4L) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10 -2.46(-5.71, 0.17) -04.42(-1.24, -0.41) -4.88*(-7.79, -1.97) 1.85*(-2.35, 1.57) 
20 3.32*(-5.71, 0.93) -8.32*(10.09, -6.57) -8.35*)-10.78, -5.93) -0.68(-2.42, 1.05) 
30 0.95(-9.78, 11.68) 1.80(-5.46, 1.84) -2.66*(-3.39, -1.32) 3.16*(-5.38,-0.93) 
40 -1.11(-5.64, 3.41) -2.60(-6.66, 1.45) -4.56*(-7.67, -1.60) -0.98(0.54, 3.48) 
60 -1.24(-4.37, 1.96) -2.98*(-3.71, -2.24) -0.30(-2.07, 1.47) -5.41(-12.43, 1.60) 
*The mean difference is significant *(P<0.05); ** (P<0.01); *** (P<0.001)   
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Figure  5.27  Mean  (SD) fine particle dose, as % nominal dose, from the four different dry 
powder inhalers at different inhalation flows (10-60) Lmin
-1
 following one and two 
inhalations per metered dose for a 2L inhaled volume 
 
Figure  5.28  Mean  (SD) fine particle dose, as % nominal dose, from the four different dry 
powder inhalers at different inhalation flows (10-60) Lmin
-1
 following one and two 
inhalations per metered dose for a 4L inhaled volume  
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Table  5.23 Statistical comparison of the fine particle dose (% nominal dose) from the four different dry powder inhalers between one and two 
inhalations per metered dose at each inhalation flow using 2L inhaled volume 
Inhalation flow 
(Lmin
-1
) 
Mean difference (95 % confidence interval) 
(one vs. two inhalations) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10 0.23(-1.46, 1.93) -1.78*(-2.17, -1.39) -1.75*(-3.16, 0.33) -2.94*(-5.17, 0.70) 
20 2.86*(-4.49, -1.24) -1.19(-3.02, 0.64) -1.65(-4.01, 0.72) -5.10*(-7.82, -2.38) 
30 4.55(-2.80, 11.90) 1.34(-1.51, 4.21) 1.24(-0.4, 2.87) -7.45*(-8.90, -5.97) 
40 0.81(-2.09, 3.71) 1.28(-1.60, 1.86) 1.78(-4.55. 0.99) 10.29*(-11.91, -8.67) 
60 -2.65*(-3.76, -1.53) -1.25(-3.13, 0.62) 2.26*(1.36, 3.17) -11.13(-16.16, -.613) 
*The mean difference is significant *(P<0.05); ** (P<0.01); ***(P<0.001
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Table  5.24 Statistical comparison of the fine particle dose (% nominal dose) from the four different dry powder inhalers between one and two 
inhalations per metered dose at each inhalation flow using 4L inhaled volume 
Inhalation flow 
(Lmin
-1
) 
Mean difference (% 95 confidence interval) 
(one vs. two inhalations) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
10 0..25(-1.64, 2.13) 0.66(-1.46, 0.15) 3.31*(1.31, 5.31) -2.13(4.48, 0.23) 
20 -2.37(-6.02, 1.28) -4.35*(-6.89, -1.80) -1.97*(-3.40, 0.54) -9.20(-11.82, -6.54) 
30 -0.73(-4.98, 6.45) -2.46*(-4.07, 0.73) -0.79(-2.35, 0.75) 10.41*(-12.95, -7.86) 
40 0.49(-4.27, 3.29) 0.92(-3.09, 4.93) -1.95(-4.76, 0.87) -13.40*(-16.49, -10.30) 
60 -5.88*(-7.85, -3.92) 0.45(-1.99, 2.90) 2.09(0.21, 4.39) -8.86(-13.92, -3.80) 
*The mean difference is significant *(P<0.05); ** (P<0.01); *** (P<0.001 
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5.4 Discussion 
In-vitro characterisation of the aerosol is useful as a pre-clinical tool to predict the potential 
of the emitted dose to deposit into the lungs. In this study, the results indicated bimodal 
mass size distribution of the dose emitted from the Accuhaler®, Easyhaler®, Clickhaler® 
and the Turbuhaler® upon inhalation across the inhalation flow range of 10 to 60 Lmin
-1
. 
At each inhalation flow, over 50% of the mass contains large particles. These particles 
have an aerodynamic diameter greater than 5µm and are deposited by (inertial impaction) 
on the upper stages (induction port, mixing inlet, and preseparator) of the impactor (Hillery 
et al., 2001). These stages of the impactor morphologically correspond to the 
oropharyngeal region (Weibel 1963; Hickey 1992). Particles with an aerodynamic 
diameter smaller than 5µm were deposited on the lower stages and filter. The particle size 
distribution on the upper stages shows that deposition in the induction port decreased while 
that in the preseparator increased as the inhalation flow (hence turbulent energy for particle 
de-aggregation) increased for the four inhalers. Thus more proportion of the smaller 
particles penetrated into the lower stages of the impactor (Figures 5.2 to 5.17).  
Figures 5.18 to 5.21 show the influence of inhalation flow on the fine particle dose (FPD). 
The FPD (containing drug particles with an aerodynamic diameter ≤ 5µm) increased with 
an increase in the inhalation flow upon inhalation. An explanation for this observed trend 
can be found in the study reported by (Clark and Hollingworth 1993).The study  
highlighted that the turbulent energy inside a DPI is represented by a pressure change 
( P∆ ) that is generated inside the device during an inhalation. This pressure change is 
directly related to the DPI's internal resistance to airflow (R) and the inhalation flow (Q) 
and the relationship is described as: P∆ = QR. Since the turbulent energy required inside 
a DPI to transform the metered powder formulation into an emitted dose containing fine 
particles with the potential for lung deposition (a respirable dose) is a product of the 
inhalation flow and the inhaler’s internal resistance, then the faster the flow then the higher 
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will be the energy.  Therefore the higher energy results to greater de-aggregation of the 
metered powder formulation into a fine particle dose.  Hence, the better is the quality of the 
emitted dose for lung deposition. Figures 5.18 to 5.21 show the variability of the FPD from 
the four different inhalers with the inhalation flow. The change in the mean FPD (% 
nominal dose) with the inhalation flow from 10 to 60 Lmin
-1
 following one inhalation per 
metered dose are in the ranges of: 4.1 to 37.19, 1.4 to 33.4, 3.7 to 39.42 and 3.4 to 38.97 
for the salbutamol-containing Accuhaler®, Easyhaler®, and Clickhaler® and for the 
terbutaline Turbuhaler® respectively (Table 5.18). Similar data were respectively obtained 
for the inhalers following two inhalations (Table 5.18). Two inhalations per dose are 
therefore not required.  The Accuhaler® and Easyhaler® have lower range than the 
Clickhaler® and the Turbuhaler®. At an inhalation flow below 30 Lmin
-1
 FPD emitted  
from the and the Easyhaler® declined sharply, while the variation of FPD was relatively 
constant at the flow range of 30-60 Lmin
-1
 (Figure 5.18 and 5.19).  For the Clickhaler® 
and the Turbuhaler® the trends showed a pronounced variation on FPD an increase of the 
inhalation flow from 10 to 60 Lmin
-1
.  The difference in behaviour may be attributed to 
differences in formulations designs. Factors such as the internal structure of each device as 
well as the drug to excipient ratio may account for the varying resistance to inhalation flow, 
hence the amount of fine particle dose emitted from these inhalers.  
Statistical comparison of the differences in the FPD between inhalation flows presented in 
Tables 5.19 and 5.20 confirmed that the FPD significantly (p<0.001) increased with the 
increase in the inhalation flow. Overall, the results of this study have demonstrated the 
flow dependent dose emission property of the four studied inhalers, with the salbutamol 
Accuhaler® and Easyhaler® less affected compared with the salbutamol Clickhaler® and 
the terbutaline Turbuhaler. Also the finding is in agreement with the previous reported in-
vitro studies on the flow dependent FPD characteristics of salbutamol Accuhaler® greater 
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and Easyhale®r (Palander et al. 2000), terbutaline Turbuhaler (Malton  et al, 1996; Ross 
and Schulz, 1996).  
The mass median aerodynamic diameter (MMAD) provides an indication of size 
distribution of drug particles deposited in the lower stages of the impactor (and hence the 
likely drug deposition site in vivo). The results show that the MMAD decreased with an 
increase in the inhalation flow for the studied inhalers (Figures 5.22 to 5.25). The 
explanation of this trend can be found in the fact that the faster the inhalation flow through 
a DPI (hence energy), the greater is the  force inside the device to de-aggregate the drug-
carrier complex or pure pellets into fine particles with a reduced aerodynamic diameter 
thereby enhancing penetration to the lower  stages of the impactor. These lower stages are 
surrogates of the lower regions of the human respiratory system (Weibel 1963; Hickey 
1992).  
For each DPI, there will be a minimum inhalation flow (hence threshold energy) for the 
dose emission with sufficient potential for lung deposition when patients inhale fast as they 
can. This value may differ due to differences in the design-formulation combination. The 
data presented in Tables (5.2 to 5.17) show that the minimum inhalation flow for the dose 
emission (FPD) with sufficient potential for lung deposition for the Accuhaler®, 
Easyhaler® and Clickhaler® is 20 Lmin
-1
, while that for the Turbuhaler® is about 30 
Lmin
-1
.  Although the in-vitro data obtained should be viewed with caution as the data 
obtained from cascade impaction do not always reflect the clinical situation,  they can be 
used to guide clinical response (Barry and O`Callaghan, 2003). 
The inhalation flow through a DPI is affected by its intrinsic resistance. Studies have 
shown (Tarsin, et al, 2000) that the Accuhaler® has low resistance, whereas the 
Clickhaler®, Turbuhaler® and the Easyhaler® all have high resistance. Patients with 
COPD have been reported to have lower inhalation flows than adult asthmatics. Also the 
more severe the obstruction of the airways the lower were the inhalation flows through a 
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variety of inhalers (Tarsin et al. 2001). Thus, the efficacy of an inhaled product will be 
affected by the age and abilities of the patient who is asked to use it. 
Some asthmatic children and COPD patients were unable to generate the minimum 
inhalation flow of 30 Lmin
-1
 through a Turbuhaler® (Pedersen et al. 1990; Broeder et al. 
2003).  The finding about the terbutaline Turbuhaler® in this study implies that some 
patients with asthma//COPD may not be able generate a dose with the potential for lung 
deposition from the Turbuhaler® to achieve control. Thus, once their inhalation technique 
is identified with the aid of the In-Check Dial®, they should be given intensive training if 
they still prefer the Turbuhaler® or an alternative that suits their natural technique should 
be prescribed.  
The Accuhaler has low resistance to flow and thus less effort is required to achieve any 
given inspiratory flow. Conway et al. (1996) reported that the mean inspiratory flow of 55 
patients with asthma (aged 5 to 50) through the Accuhaler® was about 117Lmin
-1
. 
Therefore, the minimum inhalation flow of 20 Lmin
-1
 through the Accuhaler® to emit a 
dose with sufficient potential for lung deposition obtained in this study seems easily 
achievable. Hence, the force of inhalation may not be a critical factor when training 
patients to correctly use the Accuhaler®. Although the Easyhaler® has  high resistance, a 
study comparing the bronchodilating effect of salbutamol ( 100µg) delivered via 
Easyhaler® at low inspiratory flow (as low as 16 Lmin-1) showed that the Easyhaler® 
produced an equivalent improvement in lung function to a correctly used metered dose 
inhaler plus spacer (Koskela et al. 2000).  Similar clinical studies with asthmatic children 
using a Clickhaler® (intermediate resistance inhaler) at inspiratory flow of 15, 30 and 60 
Lmin
-1
 have demonstrated mean improvements in FEV1 of 0.44, 0.45, and 0.53 L 
respectively. The studies highlighted that clinical efficacy of the Clickhaler® is 
independent of inspiratory flows in the range of (15 – 60) Lmin
-1
 (Newhouse et al. 1999). 
In this study the minimum flow for potential lung deposition with the Easyhaler® and the 
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Clickhaler® has been identified to be 20 Lmin
-1
. Thus, the Easyhaler® and the 
Clickhaler® can be used with confidence in patients who may have difficulty in generating 
a high inspiratory flow such as children and the elderly.    
In order to test the effect of inhalation volume on the FPD generation from the DPIs, the 
data obtained from a 2L volume was compared with a 4L volume at each inhalation flow 
as shown in Figure 5.26.  The FPD (% nominal dose) at 2L and 4L emitted from the 
Accuhaler®, Easyhaler®, Clickhaler® and the Turbuhaler® were similar at inhalation 
flow range of 10 to 60 Lmin
-1
 (Table 5.18). In general, at each inhalation flow a higher 
FPD was emitted from the four inhalers with a 4L inhaled volume than a 2L. However, 
these differences were not statistically significant in most cases as shown in Table 5.22. 
Although it was expected that a higher FPD may be obtained with a larger inhaled volume 
(because of the greater energy input), no significant difference was observed in this study. 
Also interesting there were no differences in MMAD at each inhalation flow for a 2L 
inhaled volume compared with a 4L inhaled volume. Thus, particle distribution was not 
affected by inhalation volume with the four studied inhalers.  
The explanation to this observation can be found in the reported studies by De Boer et al, 
(1997) and Everard et al. (1997). These researchers highlighted that the device- 
formulation combination together with the rate of increase in the inhalation flow 
(acceleration rate) is a very important factor in the generation of the fine particle dose from 
a DPI. This acceleration rate correlates to the peak inhalation flow achieved by patients 
(Broeders et al. 2001). The steeper is the increase (exerts a greater air-impact on powder 
formulation), the more is the fine particle dose generated inside the DPI during an 
inhalation manoeuvre. However, the turbulent energy inside a DPI is a product of the 
patient’s inhalation flow and the resistance inside the inhaler. Therefore, the rate at which 
energy is applied to particles, and not just the total amount of energy, influences de-
aggregation to fine particles. They concluded that dose emission from DPIs formulated 
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with either a reservoir or blister occurs immediately at the start of the inhalation, that is a 
short and fast inspiration through a DPI gives an optimal fine particle output.   Therefore, 
for the Accuhaler (a multidose strip-type) and the multidose/reservoir-Easyhaler, 
Clickhaler and Turbuhaler at any given inhalation flow the energy impacted on the powder 
to overcome attractive forces between particles, or particle and carrier, by a 2L inhaled 
volume may not be significantly different from that provided by a 4L inhaled volume. 
Hence, the effect of inhalation volume on the emitted dose (fine particle dose) when 
patients inhale `as fast as they can` through the multidose DPIs (either a reservoir or a strip) 
is negligible. The finding about the effect of inhalation volume on the FPD from these 
multidose DPIs in this chapter concurred with that on the total emitted dose in chapter 4 
and similar previous in-vitro study using a Turbuhaler® (multidose/reservoir inhaler) and a 
Diskhaler® (multidose/strip inhaler) by the De Boer et al, (1997). 
 The effect of the number of inhalation on the fine particle dose (FPD) from the Accuhaler,  
Easyhaler®, Clickhaler® and the Turbuhaler® at different inhalation flows (10 to 60 
Lmin
-1
) using the same inhalation volume is shown in Figures 5.27 and 5.28 (for 2L and 4 
L inhalation volumes). In general, the (FPD) from the four studied inhalers is slightly 
greater with two inhalations than one inhalation at each inhalation for a 2L inhaled volume 
and a 4L inhaled volume respectively. However, these differences were not statistically 
significant (p<0.05) in most cases except for the Turbuhaler at low inhalation flow (range 
10-40 Lmin
-1
) using a 2L inhaled volume (Table 5.22). These may be considered as 
isolated cases that may not be of any clinical relevance. Overall, the influence of the 
number of inhalations on the fine particle dose hence lung deposition and ultimately 
clinical effects is negligible.  
5.5 Conclusion 
In conclusion, this study highlights that the Accuhaler, Easyhaler, Clickhaler, and the 
Turbuhaler all showed flow-dependent fine particle dose emission characteristics to a 
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varying extent. Also the study has identified that the minimum inhalation flow for the dose 
emission with sufficient potential for lung deposition when patients inhale as fast as they 
can for the Accuhaler, ® Easyhaler® and the Clickhaler® is about 20 Lmin
-1
 while that for 
the Turbuhaler® is about 30 Lmin
-1
. The finding, though in-vitro, relates to the reported 
clinical studies. These values together with the use of the In-Check dial provide insights 
into the choice of an inhaler that suits a patient’s natural technique for effective lung 
deposition.  
Furthermore, the four studied inhalers showed insignificant difference in the total fine 
particle dose between a 2L inhalation volume and a 4L inhalation volume at each 
inhalation flows. This study demonstrates that either a 2L or a 4L inhalation volume can be 
used for the in-vitro measurement of aerodynamic dose emission characteristics from 
multidose DPIs (either reservoir or strip-type). Since asthmatic patients have an average 
inhalation volume of about 2L when they inhaled through a DPI and they are the ultimate 
users of these inhalers, a 2L inhaled volume rather than the compendial recommended 4L 
inhaled volume should be considered for in-vitro tests.    
Although the Accuhaler®, Easyhaler®, Clickhaler® and the Turbuhaler® generally 
showed a significantly greater total emitted dose with two inhalations than one inhalation 
per metered dose across the inhalation flows (range 10-60 Lmin
-1
) as reported in chapter 4, 
there were no statistically significant differences in their fine particle dose between one 
and two inhalations. Since it is the fine particle dose that determines the lung deposition 
and ultimately the clinical effects, the finding in this study tends to support the 
continuation of the present manufacturers` instructions for patients to inhale once for each 
metered dose `as fast as they can`.  
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6 Ex- vivo determination of dose emission from dry powder inhalers 
(DPIs) at slow and fast inhalation flows using the In-Check
®
 Dial 
6.1 Introduction 
Lung deposition from an inhaler is dependent on the inhaler, its formulation and the 
inhalation technique used. Each inhaler due to its formulation and device-design requires a 
specific inhalation technique. For a DPI the inhalation manoeuvre should be fast from the 
start of the inhalation and sustained for as long as possible. Many patients experience 
problems using their devices correctly. Poor inhalation technique can markedly reduce the 
proportion of the drug that reaches the lungs. Studies suggested that 28-68% of patients 
with asthma have problems using their MDI or DPI sufficiently well to benefit from the 
dose (Raul, 2006). Overall, the issue of correct use is of critical importance in maintaining 
optimal asthma control as patients who misuse their inhalers tend to have less stable 
asthma than those who use their device correctly
 
(Giraud and Roche, 2002). 
The In-Check Dial® has been introduced to identify a patient’s inhalation flow through an 
inhaler and is useful to identify an inhaler to suit a patient’s natural technique. The 
mouthpiece has a dial that can be turned so that it is set to simulate the resistance of several 
commonly used inhaled products. This is achieved by altering the diameter of the 
inhalation orifice/hole such that the resistance is the same as that of the selected inhaler. 
The rate of inhalation is measured by reading the value on the meter. When the patient 
inhales through the In-Check Dial the reading identifies the inhalation rate that would be 
obtained when using the inhaler for which the meter has been set for. The In-Check Dial 
has been externally tested in-vitro by AEA Technology and found to provide similar 
resistance to the inhalation devices available. 
(http://www.clement.clarke.com/inspiratory/In-check). 
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Studies have highlighted the potential of the In-Check Dial to identify patient inhalation 
rates and thus inspiratory effort of all type of patients using different dry powder inhalers 
(Tarsin et al. 2000). Other studies have shown that DPIs operate effectively at peak 
inhalation flow >30Lmin
-1
 and that the optimum flow  for some DPIs in terms of the total 
emitted dose and the fine particle dose is >60Lmin
-1
 (Bisgaard et al. 1998; Nielsen et al. 
1998). Therefore, slow (30 Lmin
-1
) and fast (60 Lmin
-1
) inhalation flows have been chosen 
for this study because they are widely thought to be clinically relevant for patients with 
asthma (Chrystyn, 2006).  
The present study was designed to use an ex - vivo approach with the aid of the In-Check 
Dial® to determine the dose emission from a variety of multidose DPIs at slow and fast 
inhalation flows following one and two inhalations per metered dose. The DPIs used were 
the salbutamol Accuhaler®, Easyhaler® and Clickhaler® and the terbutaline Turbuhaler®. 
At present the instructions (manufacturer’s patient information leaflet) for using these 
multi-dose DPIs state only one inhalation per dose and patients should inhale as fast as 
they can. Since dose emission is dependent on inhalation flow, this study has included the 
ex-vivo dose emission after one and two inhalations per metered dose.  
6.2 Method 
Instrumentation and devices 
The In-Check Dial® (Clement Clarke International, Harlow UK) 
Pari electrostatic filter pad (Pari Gmbh, Starnberg, Germany) 
Filter holder (Copley Scientific, Nottingham, UK) 
Inhaler devices are: Ventolin® Accuhaler® (salbutamol sulphate 200 µg per label dose 
GlaxoSmithKline, UK); Asmasal® Clickhaler® (salbutamol sulphate 114 µg per label 
dose ULB, UK); Easyhaler® (salbutamol sulphate 200 µg per label dose);  Orion Pharma, 
Finland) and Bricanyl® Turbuhaler® (Labelled as nominal dose of terbutaline sulphate 
500 µg per dose Astra Zeneca, UK). 
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6.2.1 Procedure 
Twelve non-smoking healthy volunteers (six females) have been included in the study. The 
demographic data of the individuals that participated are as follows:   
Volunteer 
code 
Gender Age Height Weight FEV1 
1 Female 24.0 161.0 62.0 92.0 
2 Male 23.0 163.0 50.0 99.0 
3 Male 37.0 178.0 70.0 98.0 
4 Male 28.0 164.0 59.0 90.0 
5 Male 24.0 162.0 54.0 95.0 
6 Female 34.0 172.0 69.0 98.0 
7 Female 27.0 169.0 57.0 97.0 
8 Female 25.0 163.0 70.0 99.0 
9 Female 30.0 174.0 68.0 99.0 
10 Female 31.0 172.0 62.0 91.0 
11 Male 50.0 175.0 67.0 97.0 
12 Male 41.0 173.0 72.0 98.0 
Mean  31.2 168.8 65.6 96.1 
SD  3.6 5.1 12.7 3.7 
 
The local research ethics panel approval was obtained prior to this study and all volunteers 
gave signed informed consent. The twelve non-smoking healthy adult volunteers (six 
females) were trained to inhale through each dry powder inhaler (DPI) using slow 
(30Lmin
-1
) and fast (60Lmin
-1
) inhalation flows with the In-Check Dial® (Clement Clark, 
UK) set to correspond with the orifice/resistance of the inhalers under test. Then each 
volunteer inhaled at `the trained inhalation flows` through an active inhaler (according to 
the manufacturer’s instructions to patients).The mouthpiece of each inhaler was attached to 
a tightly-fitted mouthpiece adaptor. This contained a filter holder with a Pari® filter pad. 
This was therefore placed between the mouthpiece of the DPI and the volunteer's mouth as 
shown in Figure 6.1. The inhaled drug was entrained on the filter. On each occasion each 
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volunteer first inhaled once from a metered dose. The filter assembly was then replaced by 
a new one and the volunteer performed two inhalations from another metered dose. The 
filter assembly was dismantled: the mouthpiece, the filter-holder and the filter were rinsed 
with bamethane sulphate in distilled water (internal standard) for the HPLC quantitation of 
the emitted dose. Four separate determinations (n=4) were performed at each inhalation 
flow by each volunteer. 
.The DPIs used were the salbutamol Accuhaler, Clickhaler and Easyhaler and the 
terbutaline Turbuhaler.  
 
Figure  6.1 A schematic diagram of the ex-vivo determination of the emitted dose 
6.2.2 Analysis of data 
The emitted dose was calculated as µg per dose. Since the label claims of the studied 
inhalers differ, the emitted dose from each inhaler was expressed as a percentage of the 
nominal dose (label claim). 
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6.2.3 Statistical analysis 
SPSS version 15.0 software (SPSS Inc., Chicago, USA) was used for the statistical 
analysis. A two-way analysis of variance (ANOVA) with the application of the General 
Linear Model Univariate was used to determine any significant differences in the emitted 
dose from four different inhalers and the two inhalation flows. Also the statistical 
comparisons of the emitted dose between one and two inhalations for each metered dose 
under the same flows were made. The mean difference (95% confidence interval) was 
calculated and a probability value of (p<0.05) was considered being significant. 
6.3 Results 
The data presented in tables 6.1 to 6.4 describes the total emitted dose from each of the 
four inhalers at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) inhalation flows. A summary data on 
the mean (SD) total emitted dose (% nominal dose) from the four inhalers, following one 
inhalation per metered dose at 30Lmin
-1
and 60Lmin
-1
 inhalation flows from the Accuhaler, 
the Easyhaler, the Clickhaler and the Turbuhaler respectively were: 80.54(16.5) and 
93.10(16.1); 78.6(16.9) and 95.0(15.7); 57.4(12.3) and 73.7(12.7) and 58.7(23.0) and 
81.3(16.7). Similarly, the mean (SD) total emitted dose (% nominal dose) from the four 
inhalers, following two inhalations per metered dose were: 90.6(22) and 102(24.0); 
84.8(22.0) and 103(20.0); 67.1(19.1) and 81.7(23.5); and 67.9(18.5) and 91.4(21.8).These 
summaries are presented in Tables 6.5. Figures 6.2, to 6.5 described variation of the total 
emitted dose (%nominal dose) from each of the four inhalers with inhalation flows (30 and 
60) Lmin
-1
 following one and two inhalations. 
The statistical comparisons of the emitted dose (% nominal dose) from the four DPIs 
between inhalation flows and between one and two inhalations for each dose are presented 
in Tables 6.6 and 6.7. Figure 6.6 shows the comparison of the mean (SD) total emitted 
dose between one and two inhalations per metered dose at slow and fast (30 and 60 Lmin
-1
) 
inhalation flows for the Accuhaler, the Easyhaler, the Clickhaler and the Turbuhaler. 
 198
Table  6.1 Total emitted dose of salbutamol sulphate (% nominal dose) from the 
Accuhaler® following one and two inhalations at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) 
inhalation flows 
  Total emitted dose (% nominal dose) 
Inhalation flow  
(Lmin
-1
) slow (30) Fast ( 60 ) 
No. of inhalations one two one two 
Volunteer 
 1 88.9 102 97.3 113.1 
2 59.6 59.6 66.9 66.9 
3 53.1 58.8 58.7 58.7 
4 83.4 83.4 96.7 101.2 
5 92.6 101.5 108.4 122.6 
6 89.5 89.6 107 115.6 
7 72.7 73.8 86.4 86.4 
8 57.9 85 93.1 93.1 
9 87.3 97.9 97.9 110.5 
10 107.9 139.6 116 147.7 
11 92 105.5 97.1 107.5   
12 81.6 91 91.7 101 
Mean 80.5 90.6 93.1 102.03 
SD 16.5 21.9 16.3 24.0 
RSD 20.5 24.1 17.6 23.6 
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Figure  6.2 Total emitted dose of salbutamol sulphate (% nominal dose) from the 
Accuhaler® following one and two inhalations at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) 
inhalation flows 
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Table  6.2 Total emitted dose of salbutamol sulphate (%nominal dose) from the Easyhaler® 
following one and two inhalations at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) inhalation 
flows 
  Total emitted dose (% nominal dose) 
Inhalation flow  
(Lmin
-1
) slow (30) Fast ( 60 ) 
No. of inhalations one two one two 
Volunteer  
1 72 80.2 90.9 106.9 
2 60 60 74.6 74.6 
3 59.3 59.3 94.4 94.4 
4 70.4 78.5 84.2 84.2 
5 86.6 96.3 95.4 106.7 
6 67.9 69.3 88.2 102.1 
7 66.9 70.8 88.8 102 
8 77 77 78.6 91.2 
9 80.8 90.6 127.8 138.2 
10 119 138.8 121.7 143.5 
11 90.6 103.5 95.8 101.2 
12 92.7 92.7 99.2 102.8 
Mean 78.6 84.8 95.0 103.98 
SD 16.9 22.0 15.7 19.7 
RSD 21.5 25.9 16.5 19.0 
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Figure  6.3 Total emitted dose of salbutamol sulphate (% nominal dose) from the 
Easyhaler® following one and two inhalations at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) 
inhalation flows 
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Table  6.3 Total emitted dose of salbutamol sulphate (% nominal dose) from the 
Clickhaler® following one and two inhalations at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) 
inhalation flows 
  Total emitted dose (% nominal dose) 
Inhalation flow  
(Lmin
-1
) slow (30) Fast ( 60 ) 
No. of inhalations one two one two 
Volunteer 
 1 63.9 81.7 71.3 80.8 
2 25.9 25.9 51.9 60.9 
3 55 56.9 69.8 73.8 
4 49.3 49.3 71.5 71.5 
5 72.5 80.4 76.2 84.7 
6 66.4 74.1 81.5 84.5 
7 66.2 72.2 82 82 
8 61.14 61.14 64.2 64.2 
9 58.7 70.8 67.3 68.3 
10 51.4 94.9 105.2 150.4 
11 66.5 86 76 91 
12 51.5 51.5 68 68 
Mean 57.4 67.1 73.7 81.68 
SD 12.3 19.1 12.8 23.5 
RSD 21.4 28.5 17.3 28.8 
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Figure  6.4 Total emitted dose of salbutamol sulphate (% nominal dose) from the 
Clickhaler® following one and two inhalations at slow (30Lmin
-1
) and fast (60 Lmin
-1
) 
inhalation flows 
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Table  6.4 Total emitted dose of terbutaline sulphate (% nominal dose) from the 
Turbuhaler® following one and two inhalations at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) 
inhalation flows 
  Total emitted dose (% nominal dose) 
Inhalation flow  
(Lmin
-1
) slow (30) Fast ( 60 ) 
No. of inhalations one two one two 
Volunteer 
 1 56.9 62.1 90 97.9 
2 3.6 40.1 61.5 71.2 
3 43 46.8 76.98 88.88 
4 77 90.7 82.4 95.5 
5 53 59.4 60 66.8 
6 79.6 85.2 105.7 132 
7 69.8 69.8 80.3 80.3 
8 89.5 90.7 109 127.4 
9 49.5 53 56 60 
10 64.9 86.3 91.9 100.3 
11 75.3 81.4 81.9 89.6 
12 42.4 48.9 80.2 87 
Mean 58.7 61.9 81.3 91.4 
SD 23.0 18.5 16.7 21.8 
RSD 39.2 27.3 20.5 23.9 
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Figure  6.5 Total emitted dose of terbutaline sulphate (% nominal dose) from the 
Turbuhaler® following one and two inhalations at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) 
inhalation flows 
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Table  6.5 Mean (SD) total emitted dose (% nominal dose) from the four DPIs following one and two inhalations for each dose by the 12 volunteers 
 
Mean (SD) total emitted dose (% nominal dose) for one inhalation 
Inhalation flow (Lmin
-1
) Accuhaler Easyhaler Clickhaler Turbuhaler 
30 80.5(16.5) 65.3(23.1) 57.4(12.3) 58.71 
60 93.1(16.3) 78.6(35.4) 73.7(12.8) 81.3(16.7) 
Mean (SD) total emitted dose (% nominal dose) for two inhalations 
Inhalation flow (Lmin
-1
) Accuhaler Easyhaler Clickhaler Turbuhaler 
30 90.6(21.9) 84.8(26) 67.1(19.1) 67.1(18.5) 
60 102(24) 104(15.2) 81.6(23.5) 91.4(21.8) 
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Figure  6.6 Mean (SD) total emitted dose (% nominal dose) from the four DPIs following 
one and two inhalations at slow (30 Lmin
-1
) and fast (60 Lmin
-1
) inhalation flows by the 12 
volunteers 
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Table  6.6 Statistical comparisons of differences in emitted dose (% nominal dose) from the four DPIs between inhalation flows  
Mean difference (95% confidence interval) 
Following one inhalation 
Inhalation flow (Lmin
-1
) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
30 vs. 60 12.56***(-17.72, -7.39) 16.37**(-25.01, -7.72) -24.31**(-40.1, -8.54) 22.61**(-33.0, 12.19) 
Mean difference (95% confidence interval) 
Following two inhalations 
Inhalation flow (Lmin
-1
) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
30 vs. 60 -11.38***(-16.12, -6.64) -19.23***(-28.82, -9.64) 14.61*(-25.21, -4.00) -23.54***(-33.78, -13.29) 
Mean difference is significant *P<0.05 **P<0.01***P<0.001  
Table  6.7 Statistical comparisons of differences in emitted dose (% nominal dose) from the four DPIs between one and two inhalations  
 
Mean difference (95% confidence interval) 
one versus two inhalations 
Inhalation flow (Lmin
-1
) 
Accuhaler Easyhaler Clickhaler Turbuhaler 
30 -10.10**(-6.68,-3.51) -6.25**(-10.22, -2.27) -9.70*(-17.75,-.64) -6.41* 
(-10.10,-.72) 
60 -8.92**(-14.82,-3.02) -9.01***(-13.54, -4.48) -7.93(-16.02; .15) -10.08***(-14.44;-.72) 
Mean difference is significant *P<0.05 **P<0.01***P<0.001  
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6.4 Discussion  
Several in-vitro studies have shown that the inhalation flow has a significant influence on 
the dosage emission from dry powder inhalers (DPIs). For instance, in-vitro studies using 
the salbutamol Accuhaler®, Easyhaler® and Turbuhaler® (Palander et al, 2000), 
terbutaline Turbuhaler® (Malton et al, 1996; Ross and Schulzt, 1996) have highlighted 
flow dependent dose emission from these inhalers. Other in-vitro studies by Al-fadhl et at 
al., (2005) using the tiotropium Handihaler® (a single dose-capsule) and  De Boer et al 
(1997) using the drug Spinhaler® (Spincap) have highlighted that dose emission is 
influenced by inhalation flow and that two inhalations are required  for each dose to empty 
the capsule. Similarly the results of the in-vitro study presented in chapter 4 demonstrated 
flow dependent dose emissions from the Accuhaler®, Easyhaler®, Clickhaler® and 
Turbuhaler and that the total emitted dose from the inhalers is overall significantly greater 
(p≤0.05) with two inhalations than one inhalation per metered dose. Simulated flows at 
constant rates from a vacuum pump were used in these in-vitro studies which do not 
accurately represent an individual’s inhalation profile through each DPI. Patients inhale at 
varying flows through DPIs and their acceleration rates will differ. The inspiratory effort 
by the patient generates a pressure drop across the inhaler, which is proportional to the 
inhalation flow because the resistance of the inhaler is a constant variable (Clark and 
Hollingworth, 1993). 
An inhalation profile recorder (IPR) has been developed to capture profiles of pressure 
drop across the mouthpiece of the inhaler versus time when an individual inhales through 
the inhaler. The pressure profile can be converted into an inhalation flow profile when the 
resistance of the device is known (Clark and Hollingworth, 1993). Also individual 
inhalation rates through the currently marketed dry powder inhalers (DPIs) can be 
identified using the In-Check Dial. The results of   a study by Tarsin et al (2000) has 
highlighted that the peak inspiratory flows through the Accuhaler and the Turbuhaler 
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measured electronically (using an IPR) is as accurate as the peak inspiratory flows 
measured by the In-Check Dial. 
Furthermore, the reported ex-vivo studies on the  dose emission characteristics from the 
Accuhaler® and the Turbuhaler® using an IPR that recorded inhalation profiles from 
asthmatic children (Bisgard et al. 1998), COPD patients (Burnell et al. 2001) and asthmatic 
patients (Tarsin et al, 2006) with the Electronic Lung Device connected to a cascade 
impactor have highlighted flow dependent dose emission. 
The data obtained from the current ex-vivo dose emission study are in Tables 6.1 to 6.4. 
These and Figures 6.2 to 6.5 show that the total emitted dose (% nominal dose) from the 
Accuhaler, Easyhaler, Clickhaler and Turbuhaler increased with respect to the inhalation 
flow. The data in Table 6.5 show the mean (SD) total emitted dose (% nominal dose) of the 
four inhalers following one and two inhalations. Statistically the total emitted dose from 
the inhalers significantly (p ≤0.001) increased with the inhalation flow (Table 6.6). The 
results of this ex-vivo dose emission study demonstrate flow dependent dose emission 
similar to the results of the ex-vivo electronic lung studies cited above.  
Furthermore, Figure 6.6 shows that the mean (SD) total emitted dose (% nominal dose) 
from the Accuhaler®, Easyhaler®, Clickhaler® and Turbuhaler® was generally greater 
when using two inhalations than one inhalation per metered dose at each inhalation flow. 
Statistical comparison confirmed significant (p ≤0.001) differences in the total emitted 
dose from the inhalers between one and two inhalations per metered dose (Table 6.7) after 
one and two inhalations per dose. The results are similar with the results obtained in the in-
vitro study presented in chapter 4. The ex-vivo methodology in this study cannot be 
extended to measure fine particle dose from the four studied inhalers. 
6.5 Conclusion 
 Measurement of dose emission from dry powder inhalers by the in-vitro method at fixed 
flows does not accurately represent how individuals inhale through a device. The results 
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obtained using this method demonstrated the flow dependent dose emission of the four 
studied inhalers. The data obtained is consistent with the emitted dose from the Accuhaler 
and the Turbuhaler when the ex-vivo method using the Electronic Lung Device with 
recorded inhalations profiles from patients (Burnell et al, (2001); Tarsin et al., 2001). Thus, 
the total emitted dose obtained using this novel ex-vivo approach represented the emitted 
dose that an individual volunteer would have received when they inhaled through the 
Accuhaler®, Easyhaler®, Clickhaler® and Turbuhale®r.   
Furthermore, the results obtained using this ex-vivo study highlights that the total emitted 
dose from the inhalers is significantly (p ≤0.001) greater with two inhalations than one 
inhalation per metered dose, consistent with the results presented in chapter 4.     
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7 General discussion and conclusion 
7.1 General discussion 
 
The inhaled route of administration is a preferred route for local treatment of lung diseases, 
including asthma and chronic obstructive pulmonary disease. The success of inhaled 
therapy depends on the ability of an inhaler to emit an adequate aerosolised dose with 
particles in an optimal size range for deposition to the appropriate sites in the lung 
(Pauwels et al, 1998). This, in turn, depends on the patient’s inspiratory flow, inhaled 
volume and degree of airway obstruction (Martin et al. 1988; Stocks 1995). Thus, lung 
deposition from an inhaler is influenced by the inhalation technique used. Inhalers have 
different formulation designs that provide varying degrees of resistance to inhalation flow 
and require different inhalation techniques. All currently available dry powder inhalers 
(DPls) are passive devices which rely on turbulent energy, generated by the interaction 
between the patient's inspiratory flow and resistance within the device, to emit drug fine 
particles that have the potential lung deposition. The patient's inspiratory flow is 
proportional to the turbulent energy, the resistance within the device being a constant 
variable (Clark and Hollingsworth, 1993). Thus, DPIs will deliver a larger lung dose at a 
high inhalation flow than at a low flow (Newman et al. 1991; Borsgstrom 1994; Pitcairn et 
al. 1994).  Hence patient information leaflets for DPIs recommend the inhalation 
manoeuvre should be fast from the start of the inhalation, and sustained  for as long as 
possible. Studies have highlighted that some patients have problems achieving a fast rate 
during routine use with a DPI.  These studies have revealed that young children and those 
with severe obstruction are most likely to have problems using a fast inhalation flow 
(Peddersen et al. 1990; Broeder et al. 2003). Generally, during routine use patients will 
inhale through a variety of DPIs at varying inhalation flows and inhalation volumes. 
 This research programme has focused mainly on the use of the ex-vivo and in-vitro 
methods to identify the effect and influence of the inhalation flow, inhalation volume and 
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the number of inhalations per metered dose on the dose emission and aerodynamic dose 
emission characteristics of four different multidose dry powder inhalers (DPIs). The DPIs 
used were the salbutamol Accuhaler®, Easyhaler® and Clickhaler® as well as the 
terbutaline Turbuhaler®. 
The performance of an inhaled product is assessed in terms of its total emitted dose and the 
aerodynamic characteristics. These parameters can be quantified using high performance 
liquid chromatography (HPLC) methods. Thus, a modified HPLC method for the assay of 
salbutamol sulphate and terbutaline sulphate in aqueous samples has been validated 
according to the ICH guidelines (ICH 1994) (chapter 3). The results of the validation 
highlighted that the assays were precise, accurate and sensitive to determine the amounts of 
salbutamol sulphate and terbutaline sulphate in aqueous samples from the dose emitted 
from the inhalers. 
The total emitted dose from the Accuhaler®, Turbuhaler®, Clickhaler® and Easyhaler® 
has been evaluated with respect to inhalation flow, inhalation volume and the number of 
inhalations per metered dose (chapter 4).  
Several in-vitro studies have shown that the emitted dose from different DPIs varies with a 
change in the inhalation flow to a varying extent (de Boer et al. 1996; Malton et al. 1995; 
Palander et al, 2000; Tarsin et al, 2004).The results identified in  chapter (4) indicated that 
the total emitted dose (% nominal dose) from the Accuhaler®, Easyhaler®, Clickhaler® 
and Turbuhaler® increased with respect to the inhalation flow when tested using the same 
inhalation volume with one or two inhalations for each dose as shown in Figures 4.2 to 4.5. 
The extent of the variation was different for each type of device studied.  The data in 
Tables 4.10 and 4.11 shows that although the emitted dose increased upon increasing the 
inhalation flow, generally there was no statistically significant difference with the 
Accuhaler® and the Easyhaler® over the inhalation flow range of 30 - 60 Lmin
-1
. This is 
applied when inhaled volumes of 2L and 4L were used with the Accuhaler® and the 
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Easyhaler®. However, the flow dependent dose emission property of the Accuhaler® and 
the Easyhaler® was significant (p<0.05) at the inhalation flow range from 10 to 30 Lmin
-1   
for 2L and 4L inhaled volumes. The Clickhaler® and the Turbuhaler® showed significant 
(p<0.001)   flow dependent dose emission property throughout the inhalation flow range of 
10 to 60Lmin
-1 
when tested using 2L and 4L inhaled volumes. De Boer et al (1996) have 
attributed these differences in behaviour to differences in device-design and the type of 
powder formulation. The results of this study are consistent with the previous in-vitro 
study by Palander et al (2000) which highlights that the total emitted dose from the 
Accuhaler® and Easyhaler® are less affected by changes in inhalation flows than the 
Turbuhaler®. 
The data in Table 4.12 shows overall, there were marginal differences in the emitted dose 
between 2L and 4L inhalation volumes at each inhalation flow for the four studied inhalers. 
The Accuhaler contains multiple doses with each dose factory dispensed dose in a blister 
on a strip inside the device, while the Turbuhaler®, Clickhaler® and Easyhaler® are the 
reservoir-type of multidose inhalers. This finding is consistent with a previous study by De 
Boer et al (1996) who found that the effect of inspiration time (inhalation volume) on the 
dose emission from the Turbuhaler® (reservoir) and the Diskhaler® (blister) over the same 
flow range was negligible for all four inspiration times (0.5, 1.5, 3.0 and 6 s) used. 
Although it was expected that a higher emitted dose may be obtained with a larger inhaled 
volume (because of the greater energy input), no significant difference was observed in this 
study. This may be attributed to particles being lifted from dose metering cup/strip and 
carried ex-mouthpiece of an inhaler early in the simulated inhalation. Previously Everard et 
al (1997) have reported that dose emission from DPIs formulated with either a reservoir or 
blister occurs immediately at the start of the inhalation. Thus, for these types of DPIs 
energy impacted on the powder to overcome attractive forces between particles, or the 
particle and carrier, by a 2L volume may not be significantly different from that provided 
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by a 4L inhaled volume. Hence, the effect of inhalation volume on the emitted dose is 
negligible highlighting the acceleration effect reported by Everard et al (1997). 
The data describing statistical comparisons are in Tables 4.13 and 4.14. The emitted dose 
from the Accuhaler® was significantly (p<0.05) greater when using two inhalations than 
one inhalation for each dose at inhalation flows below 30 Lmin
-1
. However, this trend was 
variable with the Turbuhaler. At the flow range of 30 to 60 Lmin
-1
 using a 4L inhaled 
volume, the emitted dose was significantly (p<0.05) greater with two inhalations than one 
inhalation while for a 2L inhaled volume this trend occurred at the flow range of 10 to 30 
Lmin
-1
. On the other hand, the emitted dose from the Easyhaler and the Clickhaler was 
significantly (p<0.001) greater with two inhalations than one inhalation across the 
inhalation flow range of 10 to 60 Lmin
-1. 
The aerodynamic dose emission characteristics of the four inhalers, especially the fine 
particle dose (FPD) that determines the lung deposition has been similarly evaluated 
(Chapter 5). The variability of the FPD (% nominal dose) with the inhalation flow 
following one inhalation for 2L and 4L inhaled volumes is shown in Figures 5.18 to 5.21. 
Similar data were respectively obtained for the inhalers following two inhalations (Table 
5.18). Two inhalations per dose are therefore not required.  Statistical comparison of the 
differences in the FPD between inhalation flows presented in Tables 5.19 and 5.20 has 
confirmed that the FPD significantly (p<0.001) increased with the increase in the 
inhalation flow. Overall, the results of this study have demonstrated the flow dependent 
dose emission property of the four inhalers, with the salbutamol Accuhaler® and 
Easyhaler® less affected than the salbutamol Clickhaler® and the terbutaline Turbuhaler®. 
Also the finding is in agreement with the previous reported in-vitro studies on the flow 
dependent FPD characteristics of salbutamol Accuhaler® and Easyhaler® (Palander et al. 
2000) as well as the terbutaline Turbuhaler® (Malton  et al. 1996; Ross and Schulz, 1996).  
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The mass median aerodynamic diameter (MMAD) provides an indication of the size 
distribution of drug particles deposited in the lower stages of the impactor (and hence the 
likely drug deposition site in vivo). The results show that the MMAD decreased with an 
increase in the inhalation flow. This is due to de-aggregation of the drug-carrier complex 
or in the case of the Turbuhaler® the pure pellets into fine particles thereby enhancing 
penetration to the lower stages of the impactor (Figures 5.22 to 5.25).  
For each DPI, there will be a minimum inhalation flow (hence threshold energy) for dose 
emission containing particles with sufficient potential for lung deposition when patients 
inhale fast as they can. The data in Tables (5.2 to 5.17) show that the minimum inhalation 
flow for the Accuhaler®, Easyhaler® and Clickhaler® is 20Lmin
-1
, while that for the 
Turbuhaler is about 30Lmin
-1
.  However, this in-vitro data should be viewed with caution 
as the data obtained from cascade impaction does not always reflect the clinical situation,  
nevertheless the data can be used to guide clinical response (Barry and O`Callaghan 2003). 
The inhalation flow through a DPI is affected by its intrinsic resistance. Studies have 
shown (Tarsin, et al, 2000) that the Accuhaler has low resistance, whereas the Clickhaler®, 
Turbuhaler® and the Easyhaler® all have high resistance. Patients with COPD have been 
reported to have lower inhalation flows than adult asthmatics. Also the more severe the 
obstruction of the airways the lower were the inhalation flows through a variety of inhalers 
(Tarsin et al, 2001). Thus, the efficacy of an inhaled product will be affected by the age 
and abilities of the patient. 
Some asthmatic children and COPD patients were unable to generate the minimum 
inhalation flow of 30 Lmin
-1
 through a Turbuhaler® (Pedersen et al. 1990; Broeder et al. 
2003).  The finding about the terbutaline Turbuhaler in this study implies that some 
patients with asthma//COPD may not be able generate a dose containing many particles 
with the potential for lung deposition from the Turbuhaler to achieve control. Thus, once 
their inhalation technique is identified with the aid of the In-Check Dial®, they should be 
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given intensive training if they still prefer the Turbuhaler or an alternative inhaler that suits 
their natural technique should be prescribed.  
The Accuhaler® has low resistance to flow and thus less effort is required to achieve any 
given inspiratory flow. Clinical study (Conway et al. 1996) with asthmatic children and 
adults using the Accuhaler® has demonstrated that the minimum inhalation flow identified 
for the device is easily achievable. Hence, the force of inhalation may not be a critical 
factor when training patients to correctly use the Accuhaler. Although the Easyhaler® has  
a high resistance, a clinical study with asthmatic children using the device demonstrated 
that its clinical efficacy is not affected by low inspiratory flows (even as low as 16 Lmin
-1
) 
(Koskela et al. 2000). Similar clinical studies with asthmatic children using a Clickhaler 
(intermediate resistance inhaler) demonstrated that its clinical efficacy is independent of 
inspiratory flows in the range of 15 to 60 Lmin
-1
 (Newhouse et al. 1999). Thus, the 
Easyhaler® and the Clickhaler® can be used with confidence in patients who may have 
difficulty in generating a high inspiratory flow such as children and the elderly.    
The FPD (% nominal dose) emitted from the Accuhaler®, Easyhaler®, Clickhaler® and 
the Turbuhaler® are generally similar at each inhalation flow for 2L and 4L except for 
slight differences (Figure 5.26). However, these differences were not statistically 
significant in most cases as shown in Table 5.22, highlighting the effect of acceleration rate 
reported by Everard et al, (1997.  
Figures 5.27 and 5.28 have compared the fine particle dose (FPD) from the Clickhaler® 
and the Turbuhaler® at different inhalation flows with one and two inhalations per metered 
dose. There is no statistically significant difference (p<0.05) in most cases (Table 5.22). 
Overall, the influence of the number of inhalations on the fine particle dose hence lung 
deposition and ultimately clinical effects is negligible.  
The results of the present ex-vivo study using inhalation flow from adult volunteers with 
the use of the In-Check Dial® (Chapter 6) indicated that the total emitted dose increased 
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with the inhalation flow (Figures 6.2 to 6.3). Statistically the total emitted dose from the 
inhalers significantly (p ≤0.01) increased with the inhalation flow (Table 6.6) thereby 
demonstrating flow dependent dose emission of the four studied inhalers. These results are 
consistent with other ex-vivo studies using an inhalation flow profile recorder with the 
Electronic Lung Device ® (ELD). Thus, the total emitted dose obtained using the novel ex-
vivo approach represented the amount of drug an individual would have received when 
they inhaled through each of the four inhalers.    
7.2 Conclusion 
The total emitted dose and the fine particle dose (FPD) emitted from the Accuhaler®, 
Easyhaler®, Clickhaler®, and the Turbuhaler® were dependent on the inhalation 
manoeuvre to a varying extent. Also the minimum inhalation flow has been identified to 
generate a fine particle dose with the greatest potential for lung deposition when patients 
inhale as fast as they can for the four studied inhalers. These values together with the use 
of the In-Check Dial® provide insights into the choice of an inhaler that suits a patient’s 
natural technique for effective lung deposition.  
Furthermore, the total emitted dose and fine particle dose from the four DPIs were overall 
not affected by an inhalation volume above 2L irrespective of the inhalation flow used. 
Since asthmatic patients have an average inhalation volume of about 2L when they inhaled 
through a DPI and they are the ultimate users of these inhalers, 2L rather than 4L 
recommended by the compendial methods should be considered for the in-vitro 
measurement of the total emitted dose and fine particle dose from these types of inhalers.     
Although the four studied inhalers generally showed a significantly greater total emitted 
dose with two inhalations than one inhalation per metered dose as reported in chapter 4, 
overall there were no statistically significant differences in their fine particle dose between 
one and two inhalations per metered dose. Since it is the fine particle dose that is an 
indicator of lung deposition and ultimately the clinical effects, the finding in this study 
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tends to support the continuation of the present manufacturers` instructions for patients to 
inhale once for each metered dose `as fast as they can`. 
A novel ex-vivo approach for the determination of dose emission of the four different DPIs, 
using the adult volunteer inhalation flows measured by the use of the In-Check Dial®, has 
been identified. The results of the ex-vivo study using the four different inhalers have 
demonstrated flow dependent dose emission. Thus, the total emitted dose obtained using 
the novel ex-vivo approach represented the amount of drug an individual would have 
received when they inhaled through each of the four inhalers.  The ability of the volunteer 
to achieve high and low inhalation flow highlights the usefulness of the In-Check Dial® as 
a trusting aid. 
7.3 Future work  
The Thesis has shown that salbutamol delivered from an Accuhaler®, Clickhaler® and 
Easyhaler® as well as terbutaline from a Turbuhaler® all demonstrate flow dependent 
dose emission. These in-vitro results have shown that there is no difference between an 
inhalation volume of 2 and 4 L and that there was no need to make two inhalations from 
each dose.  There is a greater difference between one and two inhalations in the results of 
the ex-vivo study.  The latter use humans to generate the inhalation profile through an 
inhaler, whereas the in-vitro methods use a vacuum pump.  When using the vacuum pump 
the acceleration of flow for a set peak inhalation flow will be the same but this will vary 
amongst humans. Recently work (at the University) has shown that formoterol formulated 
in a Turbuhaler® and an Easyhaler® does show a difference between 2 and 4 L inhalations. 
In the absence of this affect in this Thesis then drug : excipient ratio may be an issue.  Also 
other recent clinical work is showing that many patients inhale with volumes down to 
300ml with low inhalation flows.  
Future work should be extended to: 
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1. Professor Chrystyn’s research team is internationally recognised for their 
urinary pharmacokinetic methods to identify the relative lung and systemic 
bioavailability of salbutamol and terbutaline following an inhalation.  The ex-
vivo method could be repeated to include these samples. This was not studied in 
this thesis due to the lack of time.  This study should be completed and will 
allow a comparison between the total dose emissions by in-vitro methods in 
chapter 4 to be compared to those using the ex-vivo method in Chapter 6 and to 
the in-vivo urinary pharmacokinetic methods.  The ex-vivo and in-vivo studies 
should include inhalations using a slow and fast acceleration to attain the fast 
and slow peak inhalation flows that were used in the Thesis.  All this work 
would expand the knowledge about in-vitro, ex-vivo and in-vivo correlations 
and provide some preliminary evidence about the influence of acceleration rates 
through DPI. 
2. If the affect of inhalation flow and volume is dependent on the drug : excipient 
ratio then specially prepared formulations of salbutamol and terbutaline could 
be made. For example formulations of salbutamol 25, 50 and 100µg per dose 
and terbutaline 50 and 100µg per dose. This would be easily achieved using the 
Clickhaler® and the Easyhaler®.  Special formulations in an Accuhaler and a 
Turbuhaler would have to be prepared by the manufacturer of these products. 
Nevertheless repeating the work in this thesis with the specially prepared low 
dose formulations in the Clickhaler® and the Turbuhaler® would provide the 
necessary evidence whether it is formulation that is a deciding factor for the 
effect of inhalation flow and volume. 
3. Since many patients inhale with volumes below 2L then the same in-vitro 
studies as those in this thesis using flows from 20 -60 l/min with inhalation 
volumes of 500ml and 1L should be carried out.  Also with formulations 
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prepared according to point 2 immediately above should be carried out with 
these smaller volumes. 
4. Rather than use a vacuum pump the use of replaying inhalation profiles into the 
supplementary arm of the mixing inlet should be investigated.  When the 
supplementary air into the mixing inlet is the same as that drawn through the 
ACI then replaying an inhalation profile into the supplementary air would result 
in the profile being drawn through the DPI. This would require a significant 
investment of equipment and setup as well as validation. 
5. From the results in this Thesis it can be stated that the minimum flow through 
the Accuhaler®, Clickhaler® and Easyhaler® is 20 L/min and 30 L/min 
through a Turbuhaler®.  The studies mentioned above would consolidate these 
claims.  These could then be validated in clinical studies using patients inhaling 
at different flows and volumes. The focus would be low flows and small 
volumes. 
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